In Vitro Evolution of Antibody Affinity using Libraries with Insertions and Deletions by Skamaki, Kalliopi
 1 
 
In Vitro Evolution of Antibody Affinity 




Kalliopi Skamaki  
Wolfson College  
University of Cambridge  
 
Supervisors: 
Dr. Florian Hollfelder 
Dr. Ralph Minter 
 




















This dissertation is the result of my own work and includes nothing which is the outcome of 
work done in collaboration except where specifically indicated.   
 
This dissertation has not been submitted, and is not currently being submitted, for any other 



















Firstly, I would like to extend my sincerest gratitude to both my supervisors Dr. Florian 
Hollfelder and Dr. Ralph Minter, who gave me great support and scientific guidance 
throughout the course of my PhD. I am really grateful for all the help and guidance I received 
from you both which led to a thoroughly enjoyable PhD experience.  
Special thanks to Dr. Stephane Emond who developed the method that allowed me to start 
my PhD study and all his help. I thank all past and present Hollfelder group members who I 
had the pleasure of meeting the last four years.  
From Medimmune, where I implemented large part of my research, a huge thank you to Dr. 
Andrew Buchanan and his team for hosting me, especially Dr. Matthieu Chodorge for all his 
advice and help with of my project. It was great help for me to be a member of your friendly 
and knowledgeable team.   
Many people in Medimmune who took time out of their busy work schedules to impart their 
experimental knowledge. Thanks to John Andrews for his help with my screening. Ben Kemp 
and the protein expression team for producing my antibodies, especially Jenifer Spooner. 
Gareth Rees for his substantial help with my affinity measurements. Bojana Popovic, Jason 
Breed, Daniel Cannon and Mariana Rangel Pereira for their efforts on crystallography. The 
DNA chemistry team for their help with sequencing. Other people from Medimmune, 
Sridharan Sudharsan, Andrew Barnard, Alan Sandercock and from the Biochemistry 
Department, Kathrine Stott.  
 
Furthermore, I thank Wolfson College for creating such a friendly environment that made my 
life in Cambridge enjoyable. 
 
 5 
I never forget the people who gave me great opportunities to learn before I started my PhD. 
Dr. Andreas Roussis from the National and Kapodistrian University of Athens. Dr. Hans de 
Haard and Dr. Peter Ulrich from the company argenx.  
 
Last but not least, I would like to thank my Mother, my Father, all my beloved family and 
close friends who supported me in all my pursuits.  
 
Finally, I would like to dedicate this thesis to all the people who believed in me and 



















BCR             B-cell antigen receptor 
bnAbs          Broadly neutralizing monoclonal antibodies 
CSR             Class switch recombination 
CDRs           Complementarity determining regions 
DSF              Differential scanning fluorimetry 
Epitopes      Antigenic determinants 
ep-PCR        Error-prone PCR 
Fab               Fragment antigen binding  
Fc                 Fragment crystallizable  
FWR            Framework regions 
FACS           Fluorescence activated cell sorting 
GCV            Gene conversion 
HCAbs        Heavy chain antibodies 
HVLs           Hypervariable loops 
Ig                  Immunoglobulin   
Indels           Insertions and deletions 
KD                         Equilibrium dissociation constant 
mAbs           Monoclonal antibodies 
Paratope     Antigen combining site 
scFv             Single-chain variable fragment 
VH                Variable heavy chain domain 




In Nature, antibodies are capable of recognizing a huge variety of different molecular 
structures on the surface of antigens. The primary factor that defines the structural diversity 
of the antibody antigen combining site is the length variation of the complementarity 
determining region (CDR) loops. Following antigen stimulation, further diversification 
through the process called somatic hypermutation (SHM) leads to antibodies with improved 
affinity and specificity. Sequence diversification by SHM is mainly achieved by introduction 
of point substitutions and a small percentage of insertions/deletions (indels). Although the 
percentage of indels in affinity matured antibodies is low, probably due to the low rate 
incorporation of in-frame indels throughout the course of the SHM diversification process, it 
is likely that the antibody fold can accommodate higher diversity of affinity-enhancing 
indels. By in vitro evolution, other researchers have sampled either only restricted diversity 
of indels or extended diversity of insertions only in specific positions chosen based on 
structural information and natural length variation. The aim of this thesis was to study the 
impact of random and high diversity indels on antibody affinity by in vitro evolution.  
New approaches for construction of libraries with in-frame amino acid indels were applied to 
enable sampling of indels of different lengths across the entire antibody variable domains. I 
followed two different approaches for construction of indel libraries. Firstly, a recently 
developed random approach allowed the construction of libraries with random insertions and 
deletions. Secondly, a semi-random approach was developed to build libraries with different 
lengths of insertions that could be widely applied in future in vitro antibody affinity 
maturation campaigns. Libraries constructed by either of these approaches yielded variants 
with insertions with improved affinity.  
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Overall, this thesis demonstrates that insertions besides offering alternative routes to affinity 
maturation can also be combined with point substitutions to take advantage of additive effects 
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1. Introduction    
 
 
The objective of this thesis is on the development of new approaches for construction of 
libraries with amino acid insertions and deletions (indels) as a tool for antibody affinity 
maturation by in vitro evolution and also in helping improve our understanding of protein 
evolution. This chapter offers an overview of relevant topics for the experimental results 

















1.1. Diversity of the antibody repertoire in Nature  
Antibodies, often referred to as immonoglobulins (Ig), are proteins generated throughout the 
course of the immune response to recognize a huge variety of different molecular structures 
(antigenic determinants) on the surface of antigens (foreign material) via their antigen 
combining sites. The antigen is eliminated either by inactivation through antibody binding, 
eg. "neutralizing" a virus by preventing viral entry into host cells, or by employment of other 
molecules (effector molecules) which trigger antigen destruction, eg. antibody-dependent 
cellular cytotoxicity (ADCC) by NK cells and phagocytosis by host immune cells.  
The structure of the antibody molecule consists of four polypeptide chains, two identical 
heavy (H) chains (µ, α, γ, δ, ε) and two identical light (L) chains (κ, λ), which form two 
identical Fab (fragment antigen binding) units and one Fc (fragment crystallizable) unit 
(Figure 1), which are linked by a flexible hinge region. The Fab arms are involved in binding 
to antigen while the Fc binds to effector molecules. The Fab arm is composed of a variable 
fragment (Fv) composed of the variable heavy (VH) and light (VL) domains and a constant 
fragment composed of the heavy (CH1) and light (CL) domains. The specificity of the 
antibody is determined by the variability of the Fv, which is conferred by short sequences in 
the variable domains that sow extreme variation, the hypervariable regions (HV) (three in 
each variable domain), often referred to as complementarity determining regions (CDRs). 
The constant Fc region is involved in binding to effector molecules, inducing functions such 
as complement-dependent cytotoxicity (CDC), complement dependent cell-mediated 
cytotoxicity (CDCC) and antibody-dependent cellular cytotoxicity (ADCC). These occur by 
engagement of the Fc region with Fcγ receptors which are expressed on different immune 
cells (e.g. natural killer cells, mast cells, macrophages and neutrophils) resulting into lysis of 
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target cells. The Fc also binds to the neonatal Fc receptor (FcRn) resulting IgG serum 
recycling (Cohen-Solal, 2004). Fc regions differ between different antibody classes (IgG, 
IgM, IgA, IgD and IgE), leading to triggering of different effector functions.   
 
Structure of the human IgG molecule  
Each domain of an IgG molecule folds into a common pattern, the "immunoglobulin fold" 
(Figure 1), which consists of two stacked β-sheets which are further stabilized by a 
disulphide bond. These highly conserved β-strands are joined by more diverse loops with 
little secondary structure. The VH/VL and CH1/CL domain pairing is driven by hydrophobic 
interactions, while CH1 and CL are linked by a disulphide bond. The variable domains are 
composed of four conserved framework regions (FWR) and hypervariable regions (HV) (T. 
T. Wu & Kabat, 1970; Kabat & Wu, 1971), the six CDR regions encode structurally variable 
loops, the hypervariable loops VL CDR1, CDR2 and CDR3 and the VH CDR1, CDR2 and 
CDR3 (Figure 1). The CDR loops form the antigen combining site, a single continuous 
binding surface at the tip of the Fab fragment (Padlan, 1994). The main role of the FWR 
regions is structural support to the CDR loops but can also affect the conformations of the 
CDR loops either directly or indirectly by affecting the VH–VL interface (Foote & Winter, 
1992; Abhinandan & Martin, 2010). The Fc of the IgG is composed of the CH3 domains that 







Figure 1. (Above) the IgG molecule and (below) the "immunoglobulin fold", the VH domain (left) 
and the CH1 domain (right). The CDRs, CDR1 and CDR2 and CDR3 are shown in yellow, orange 






1.1.1. Primary antibody repertoire  
Soluble high affinity antigen-specific antibodies which are produced by plasma cells are the 
final products of B-cell differentiation (Figure 2). The repertoire of B-cell antigen receptors 
(BCRs), which is the membrane-bound form of the antibody, is initially expressed on the 
surface of B-cells that have never been exposed to antigen (naïve B-cells). Stimulation of a 
B-cell by antigen is followed by B-cell proliferation, a process called clonal expansion, that 
leads to further maturation of antibody affinity and specificity by somatic hypermutation 
(SHM) and finally generation of specific memory B-cells and plasma cells.  
 
 
Figure 2. B-cell differentiation and Ig diversification. B cell development starts in the bone marrow 
where the BCR is expressed as IgM. Mature B cells expressing IgM and IgD migrate from the bone 
marrow into the blood and the secondary lymphoid organs. Stimulation by antigen causes further 
maturation of BCR affinity and specificity through the process of somatic hypermutation in the 
germinal centre (GC) in secondary lymphoid organs and production of memory B-cells and plasma 




1.1.1.1. Genetic diversity  
Humans and mice 
The BCR variable (V) heavy and light chain domain repertoires are encoded by rearranged 
genes that are produced by somatic recombination of multiple gene segments (V(D)J gene 
segments) which compose the heavy, κ and λ light chain loci. The constant (C) domains are 
encoded by individual exons which can be combined with different rearranged V-region 
exons to produce different Ig isotypes. Each V-gene segment contains the coding sequence of 
the FWRs 1-3 and the N-terminus sequence of the CDR3, while the J gene segments encode 
the C-terminus sequence of the CDR3 and the FWR4. The V-domains of the light chains are 
encoded by VJ rearrangement while those of the heavy chains additionally contain DH 
segments between the VH and JH segments (VDJ) which encode the middle part of the VH 
CDR3 (Figure 3).  
 
 
Figure 3. Combinatorial diversity of the VH-gene derives from VDJ somatic recombination of diverse 
VH, DH and JH gene segments, which encode the regions FWRs 1-3 to N-terminus CDR3, middle 
CDR3 and C-terminus CDR3 to FWR4, respectively.  
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The diversity generated by the process of V(D)J recombination is referred to as combinatorial 
diversity (Figures 3 and 4). The H-chain locus is composed of 80 VH segments grouped into 
7 families of which 40 are functional, 27 DH and 6 JH segments. Combination of these 
segments can produce around 104 different heavy chain combinations (H. W. Schroeder, 
2006). The light chain loci can produce much less, only around 300 combinations. The κ 
locus contains 75Vκ and 5Jκ, the Vκ segments belong to 6 different gene families but only 30 
of them are known to be functional. The λ locus contains up to 36 functional Vλ segments 
divided into 3 families and 4 Jλ genes. Strong biases in the usage of specific gene segments 
and higher frequency of recombination events between certain gene segment have been 
shown by sanger (Brezinschek, Foster, Dörner, Brezinschek, & Lipsky, 1998; de Wildt, Hoet, 
van Venrooij, Tomlinson, & Winter, 1999) and next generation (Ig-seq) (Arnaout et al., 
2011) sequencing of human naive and memory B cells. For example, 50% of the rearranged 
genes are composed of only five of the VH segments (Glanville et al., 2009). Variation of the 
Ig loci between individuals leads to unique repertoires between individuals (Boyd et al., 
2010; Kidd et al., 2012), with differences mostly found in the VH CDR3, while light chain 




Figure 4. Organization of the V-gene loci. The heavy (Ig H) and light (Ig κ and Ig λ) chain loci are 
comprised of V, (D) and J gene segments (H. W. J. Schroeder & Cavacini, 2010).  
 
 
The process of somatic recombination also creates diversity by introduction of random 
lengths of nucleotides deletions or insertions (N and P) at the junctions of the joined gene 
segments, the so called junctional diversity. The recombination is performed by RAG 
recombinases guided by recombination signal sequences (RRS) on the borders of gene 
segments (Schatz & Ji, 2011). A double-stranded break induced by RAG recombinase 
cleavage causes the formation of hairpins ends. During the repairing process of the DNA 
breaks there is loss or gain of nucleotides at the coding ends of the gene segments (junctions). 
The nucleotide insertions are caused either while filling the gaps of palindromic sequences 
(P-nucleotides) or by non-template addition of nucleotides (N-nucleotides) by the enzyme 
terminal deoxynucleotidyl transferase (TdT) (Alt & Baltimore, 1982).  
The VH CDR3 is the most diverse region in length and sequence determining the antibody 
specificity (Xu & Davis, 2000). Although there are around 104 different VDJ combinations, 
the large diversity of the VH CDR3 is generated by the junctional diversity (Figure 5), that 
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could theoretically generate more than 1 x 107 heavy chain variants (H. W. Schroeder, 2006). 
Whereas the theoretical VH CDR3 diversity that can be generated by the random process of 
somatic recombination is huge, the actual VH CDR3 diversity is restricted by factors like the 
amino acid preferences, charge, length and hydrophobicity of the VH CDR3 loop (Georgiou 
et al., 2014).   
 
 
Figure 5. Generation of diversity in the VH CDR3. Starting from diverse VDJ rearranged genes the 
diversity is further amplified by introduction of length variation at the junctions of the gene segments 
(left panel). The antigen-binding site that is formed mainly by the VH CDR3 (red) (right panel) forms 
the most diverse part of the antigen combining site enabling huge number of antigen specificities 
Adapted from (H. W. Schroeder, 2006).  
 
Overall, the primary antibody repertoire is defined by the diversity of antibody gene 
segments, combinatorial diversity by somatic recombination and junctional diversity. Adding 
the random combination of L and H chains can result a repertoire of more than 1013 different 
antibody variants in humans (Schroeder, 2006). Accurate estimation of the actual antibody 
repertoire diversity by high throughput sequencing (Ig-seq) is technically challenging 
because of limitations of the sequencing technologies (Khan et al., 2016), eg. sequencing 
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errors, the huge number of B-cells (more than 1 x 109 in human peripheral blood) and the fact 
that only 2% of the total B-cells reside in the peripheral blood (Georgiou et al., 2014).    
  
Other species  
Different mechanisms of diversification of the primary antibody repertoire exist in other 
species. Chickens, unlike humans and mice, do not contain multiple VH, DH and JH gene 
segments but a single V-gene. Diversity is generated by recombination using multiple VH-
region pseudogenes (~ 50) by a process called gene conversion (Figure 6) and further 
insertions in the DH-region (Parvari et al., 1988). Interestingly, this process is performed by 
the enzyme activation-induced deaminase (AID) which in other species executes the process 
of somatic hypermutation (SHM) (Arakawa, 2002). Huge genetic diversity of the CDRs is 
generated by multiple gene conversion events (L. Wu et al., 2012).  
Additionally to a small classical repertoire, cows possess an unusually long VH CDR3 
repertoire that is encoded by a single VH (VH BUL), DH2 and JH combination and can exceed 
the length of sixty amino acids (F. Wang et al., 2013). The diversity of these antibodies is 
concentrated in the "knob" mini-domain, by diversification of the disulphide patterns using 




Figure 6. Different mechanisms of genetic diversity generation in chickens and cows. (a) Chickens 
use gene conversion to produce diverse V-genes from a single VDJ combination, while (b) cows 
diversify the region encoding a mini-domain ("knob") by diversification of the cysteine pattern of a 
single rearranged gene through SHM. Adapted from (de los Rios, Criscitiello, & Smider, 2015). 
 
 
1.1.1.2. Structural diversity 
Humans and mice 
The structural diversity of the antigen combining site (paratope), which is formed by the 
CDR loops (Figure 7), is accountable for binding to a large diversity of antigenic 
determinants (epitopes). The topography of the antigen-binding site differs between 
antibodies binding different sizes of antigens. Binding surfaces that recognize proteins are 
flat, those that bind peptides form a groove, while hapten binding surfaces use a deep binding 
site with contact residues buried in the VH:VL interface (Almagro, 2004, Raghunathan et al., 
2012).  
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Despite the great diversity of the hypervariable regions, all the CDR loops except from the 
VH CDR3 fold into a limited number of main chain conformations, the so called "canonical 
structures" (Chothia & Lesk, 1987; Al-Lazikani, Lesk, & Chothia, 1997). Recently, 
comprehensive analysis of a large number of available antigen-antibody complexes redefined 
the length variation and the diversity of conformations of the hypervariable loops (North, 
Lehmann, & Dunbrack, 2011). 83% of the non-VH CDR3 loop conformations of known 
genetic source (mouse, human, camel or Llama) can be predicted based on the length of the 
loop and some conserved residues. Analysis of CDR conformations with 28 different lengths 
(non-VH CDR3) from mouse, human, camel and Llama identified 72 different loop 
conformations (clusters) (North, Lehmann, & Dunbrack, 2011), as some CDR lengths can 
have multiple conformations.  
In human and mouse, the large variety of VL CDR1 loop lengths (10-17 residues) forming a 
variety of different conformations seems to be correlated with the type of antigen. Short (6–8 
residues) loops recognize proteins, while long (11–13 residues) loops peptides and haptens 
(Collis, Brouwer, & Martin, 2003). The lengths of the other loops are not related to the type 
of antigen. VL CDR2 is the most conserved, with either 8 or 12 residues adopting always the 
same conformation. The VL CDR3 is quite diverse with 7-13 residues, but in 85% of 
antibodies it is comprised of 9 amino acids. 70% of the κ-chain VL CDR3 has a single 
canonical structure, while the λ-chain VL CDR3 adopts a wide range of lengths and 
conformations, of which only a low percentage can be classified as canonical (Chailyan, 
Marcatili, Cirillo, & Tramontano, 2011). VH CDR1 is composed of 12-16 residues, with 
strong bias toward a 13-residue loop (92%), dominated by a single conformation. The VH 
CDR2 adopts diverse conformations, composed of 8-12 residues with more common 9- and 
10-residue loops.  
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The VH CDR3 is the most diverse loop, with high length variation (5-26 amino acids), but 
most commonly (86%) composed of 7 and 16 residues. The basis of the loop usually adopts 
specific conformations (Shirai, Kidera, & Nakamura, 1996; Morea, Tramontano, Rustici, 
Chothia, & Lesk, 1998), but the huge diversity in length and amino acid composition in this 
loop does not allow the prediction of its overall conformation.  
 
 
Figure 7. The CDR loops conformations define the antigen-binding site topography (adapted from 
Finlay & Almagro, 2012).  
 
Taken together, all CDR loops (except from the VH CDR2) can have considerably different 
lengths, with some of them varying more than others. The loop length is recognised as the 
primary factor that defines the topography of the combining site (Al-Lazikani, Lesk, & 
Chothia, 1997; North, Lehmann, & Dunbrack, 2011), as different CDR lengths can form 
pockets, grooves or fill in the space to form a flat antibody surface (Vargas-Madrazo, 1995). 
The combinations of canonical loop structures composing an antigen-binding site are limited 
(Lara-Ochoa, Almagro, Vargas-Madrazo, & Conrad, 1996). The VH CDR3 loop mainly 
defines the topography of the antigen-binding site (Vargas-Madrazo, 1995). A short VH 
CDR3 loop can form a cavity to bind peptides, while a long VH CDR3 loop can from a 
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finger-like structure that protrude in cavities, like anti-HIV antibodies that penetrate the 
recessed CD4-binding site of gp120 (Saphire, 2001).    
 
Other species  
While the immunoglobulin structure is highly conserved in vertebrates (with exception the 
jawless fish), some species have evolved immunoglobulins with structurally diverse features 
(Figure 8) (de los Rios, Criscitiello, and Smider 2015). In human and mice, the diversity 
occurs in all six CDRs, with most variability focused on the CDR3s (Xu & Davis, 2000). 
Additionally to the classical IgG molecule, the antibody repertoires of sharks (R. L. Stanfield, 
2004), camels (Desmyter, Spinelli, Roussel, & Cambillau, 2015) and cows (F. Wang et al., 
2013) produce antibodies with unique structural characteristics.  
Camels generate antibodies that lack the heavy chain CH1 domain and light chains, referred 
to as heavy chain antibodies (HCAbs) (Hamers-Casterman et al. 1993). On the course of 
adaptation from conventional IgG molecules, HCAbs have evolved some unusual 
characteristics to compensate for the loss of 3 VL CDRs, like a long VH CDR3 loop that 
enable them to interact with epitopes that cannot be accessed by conventional antibodies, eg. 
enzyme active sites (Flajnik, Deschacht, & Muyldermans, 2011).  
Cow antibodies possess unusually long CDR H3 regions with lengths that could exceed the 
sixty amino acids (F. Wang et al., 2013). The binding site of these antibodies is formed by a 
"knob" domain placed at the tip of a b-ribbon "stalk" that protrudes far from the traditional 
antibody paratope site. The diversity of these antibodies is generated by diversification of the 
disulphide patterns of the "knob" domain. The functional advantage of these antibodies 
remain unknown, as the types of antigen that are recognised by these antibodies have not 
been studied yet (Robyn L Stanfield, Wilson, & Smider, 2016). These examples demonstrate 
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novel structural characteristics that evolved from conventional antibodies to expand the 
typical repertoire diversity.  
 
 
Figure 8. Evolution of immunoglobulins (Ig) with structurally unusual characteristics in different 
species. Sharks and camelids convergently evolved heavy chain antibodies without light chains. 
Camelids often have long VH CDR3 with disulphide bonds. Cows have evolved some antibodies with 
ultralong VH CDR3. The binding site of the antibodies is formed by a disulphide-rich mini-domain 
("knob") which protrudes far from the typical antibody binding site. Diversity of the knob is generated 
by diversification of the disulphide patterns. (Right) The diverse structures are shown. Adapted from 








1.1.2.  Secondary antibody repertoire  
Somatic hypermutation (SHM)           
The primary BCR repertoire expressed on the surface of B-cells is capable of recognizing an 
infinite number of antigenic determinants with low affinity. Encounter of B-cells to their 
cognate antigen induces a series of events that lead to BCR affinity maturation and finally B-
cell differentiation into memory B-cells and plasma cells that produce soluble antibodies. 
Low affinity B-cells undergo clonal expansion, somatic hypermutation (SHM) and selection 
of clones that express BCR variants with higher affinity in the germinal centres (GC) (Figure 
9), which are specialized structures in secondary lymphoid organs (e.g., spleen, lymph 
nodes), (McHeyzer-Williams, Okitsu, Wang, & McHeyzer-Williams, 2011). SHM involves 
iterative rounds of diversification of the rearranged V-gene and affinity-based selection of B-
cell clones by competition for binding to the antigen that leads to slow elimination of low 
affinity variants and survival of the higher affinity variants (Tas et al., 2016). Class switch 
recombination (CSR) that allows the switch from IgM to IgG, IgA, or IgE also occurs in the 
GC.  
There is a biological limit in antibody affinity maturation by SHM, as antibodies with KD 
values below a certain threshold do not have further selective advantage (T. R. Poulsen, 
Meijer, Jensen, Nielsen, & Andersen, 2007; Tine Rugh Poulsen, Jensen, Haurum, & 
Andersen, 2011). Theoretical analysis of the limits of antibody affinity for any antigen has 
predicted that the lowest possible KD value is around ≈10-10 M ( ≈105 – 106 M-1s-1/ ≈10-4 s-1) 
(Foote & Eisent, 1995). The maximum on-rate constant (105 – 106 M-1s-1) is restricted by the 
diffusion coefficients of the antibody and antigen molecules, while the factor limiting the off-
rate (≈10-4 s-1) is the BCR internalization after binding to an antigen. Studies of the on- and 
off-rates of vaccinated individuals indicate that the limit is KD of ≈10-9 M, as boost 
vaccination induced only a small degree of further V-gene sequence diversification without 
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further increase in affinity (Tine Rugh Poulsen, Jensen, Haurum, & Andersen, 2011). 
Experimental data on the correlation between the B-cell antigen presentation and the affinity 
of the BCR-antigen interaction is in agreement with B-cells responding to the antigen only 
when the affinity of the interaction is between KD values of 10-6 M to 10-10 M (Batista & 




Figure 9. Affinity maturation of B-cells by SHM occurs in the GCs. GCs are divided in two regions 
known as dark zone (DZ) and light zone (LZ) (Victora & Nussenzweig, 2012). Clonal expansion and 
SHM occurs in the DZ, while the highest affinity B-cells are selected in the LZ, where the antigen is 
presented by follicular dendritic cells (FDCs). The clones that bind to the antigen then present it to T 
follicular helper (Tfh) cells which direct them to the DZ, while B-cells that cannot compete for 
binding to the antigen do not enter the DZ. The selected B-cells undergo more rounds of proliferation 
and SHM. Adapted from (Oropallo & Cerutti, 2014).  
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1.1.2.1. Genetic diversity  
Point substitutions  
Sequence diversification by SHM is achieved mainly by introduction of point mutations, but 
also insertions and deletions (indels). High mutation rate in the V-genes is induced by high 
transcription levels of the corresponding genes (Bachl, Carlson, Gray-Schopfer, Dessing, & 
Olsson, 2001). Hypermutation targets the rearranged V-region and a part of the 3’-intron but 
not the constant region (1-2kb downstream the transcription start site). Somatic point 
mutations are not introduced in a stochastic manner, but high frequency of mutations 
accumulate in hotspot positions across the V-genes. The hotspot motif of SHM is the 
sequence DGYW (D=A/G/T; Y=C/T, W=A/T) (Rogozin & Diaz, 2004).  
Activation-induced cytidine deaminase (AID) is the enzyme responsible for SHM (Revy et 
al., 2000) and class switch recombination (CSR). The same enzyme is implicated in 
homologous recombination of V-genes during gene conversion (Arakawa, 2002). While AID 
is expressed mainly in B-cells while subjected to SHM, overexpression of this enzyme in 
other cell lines generates high frequency of mutations (Yoshikawa, 2002; Bowers et al., 
2011). The process starts by cytidine deamination on single-stranded DNA (ssDNA) (Pham, 
Bransteitter, Petruska, & Goodman, 2003; Shen, Ratnam, & Storb, 2005) that results in dU-
dG mismatch. The mismatch can lead to different mutational outcomes generating mutations 
with a bias to transitions over transversions (Figure 10) (Neuberger, Harris, Di Noia, & 
Petersen-Mahrt, 2003). These mutations are generated by pathways that normally repair such 







Figure 10. Possible mutational outcomes of cytidine deamination by AID. Phase 1a: If DNA 
replication occurs, the dU-dG mismatch will become either dC-dG or dT-dA (because A will be 
added opposite to U), resulting C>T and G>A transition mutations. Phase 1b: if an uracil-DNA 
glycosylase (UNG) removes dU, all mutations (dA, dT, dC or dG) can result by DNA synthesis 
opposite to the empty site, resulting in both transition and transversion mutations. Phase 2: dA-dT 
mutations also occur during SHM, by the mismatch repair (MMR) which generates dA-dT mutations 
near the dC-dU lesion. Gene conversion in other organisms (chicken or rabbit) starts when the dU-dG 
mismatch results in recombination with one of the Ig V pseudogenes.  
 
SHM targets preferentially the CDRs than the FWRs of the V-genes  according to study of V-
genes with frameshifts, consequently rearranged genes that were subjected to somatic 
hypermutation but were not selected based on affinity (Dörner et al., 1997), but the reason 
why the same DGYW motifs are targeted more frequently in CDRs is a subject of 
investigation (Dörner et al., 1997; Wei et al., 2015; Yeap et al., 2015). SHM targets 
predominantly Ig V-genes, while the DGYW motifs are only partially more enriched in V-
genes than in the rest of the genome, indicating that the presence of hotspot motifs is not the 
only factor determining AID targeting sequences (Di Noia & Neuberger, 2007). Additionally, 
non-Ig genes controlled by Ig promoters can undergo as high SHM frequencies as the CDRs 
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of V-genes at positions containing AID motifs (Yélamos et al., 1995). These observations 
have led to the conclusion that local sequences in CDRs have evolved to direct SHMs 
preferentially in CDRs than FWRs (Yeap et al., 2015).   
 
Indels  
Additionally to point substitutions, the mechanism of SHM introduces a low percentage of 
in-frame indels. Sequencing analysis of rearranged VH-genes amplified from DNA of naïve 
and GC single sorted B-cells by flow cytometry (Klein et al., 1998, Goossens et al., 1998) has 
shown that VH-genes of GC B-cells, which have been subjected to SHM but not necessarily 
selected for improved affinity, but not naive B-cells contain around 4% in-frame and 43% 
out-of-frame indels, indicating that the highest percentage of indels introduced by SHM are 
out-of-frame. In 28 out-of-frame VH-genes they found 20 indels and 319 point mutations, 
thus only a low percentage (6%) of all mutations were indels, suggesting that the percentage 
of indels introduced through SHM is very low compared to that of point substitutions. 
Frequent occurrence of deletions due to SHM was observed in positions with high SHM 
frequency (Yeap et al., 2015).  
Analysis of in-frame indels in V-genes of B-cells that have been subjected to selection by in 
vivo (de Wildt, van Venrooij, Winter, Hoet, & Tomlinson, 1999) or in vitro (Bowers et al., 
2014) SHM indicate that indel sequences are related to adjacent sequences. This is because 
insertions occur by duplication of adjacent sequences while deletions by removal of repeated 
sequences. This observation suggests that indels could be created according to the DNA 
misalignment model (Figure 11) (de Wildt, van Venrooij, Winter, Hoet, & Tomlinson; 
1999). The higher percentage of repeats in CDRs compared to FWRs in germline V-gene 
segments is likely to indicate hotspots for indels (de Wildt, van Venrooij, Winter, Hoet, & 
Tomlinson, 1999).  
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In the same study, it has been proposed that most indels share the same hotspots with point 
mutations as indel duplications or deletions involve AGY motifs (de Wildt et al., 1999). A 
high percentage of point substitutions that accumulate following the occurence of the 
insertion that further diversify the inserted sequence has been proposed to be linked either 
with a shared mechanism of generating indels and point substitutions (de Wildt et al., 1999) 
or with optimization of the binding paratope during affinity maturation (Bowers et al., 2014).  
 
 
Figure 11. (a) Deletions and (b) insertions could be generated based on the DNA misalignment 
model. A repeated sequence (in bold) creates a loop because of misalignment. Subsequent extension 
of the DNA as if it was normally aligned leads to a deletion or an insertion depending on which DNA 
strand forms the loop. Adapted from (de Wildt et al., 1999).  
 
 
Affinity matured antibodies  
Affinity matured V-genes contain on average 15-20 mutations across the entire variable 
sequences with an average 18.0 ± 8.1, 9.7 ± 5.4, and 7.7 ± 4.0 mutations for VH, κ and λ VL 
genes, respectively (Tomlinson et al., 1996; Tiller et al., 2007). The percentage of point 
mutations and indels in V-genes of antibodies that have been selected by SHM has been 
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determined by sequencing the V-genes from a total of 365 IgG+ B-cells derived from 
peripheral blood (de Wildt, van Venrooij, et al., 1999; de Wildt, Hoet, van Venrooij, 
Tomlinson, & Winter, 1999).  
In addition to high percentage of point substitutions (10.9% and 7.6% in the VH and VL, 
respectively), affinity matured antibodies also contained indels in 6.5% of the antibodies 
analyzed (24/365) (de Wildt, van Venrooij, et al., 1999). Similar percentage of in-frame 
indels (≈1.9% insertions and ≈2% deletions) has been estimated by high throughput 
sequencing of IgM and IgG memory B-cells isolated by flow cytometry (Briney, Willis, & 
Crowe, 2012) and in B-cells from patients with rheumatoid arthritis (≈1.4% indels) (Reason 
& Zhou, 2006). Overall, it has been estimated that only a low percentage, 1.4 – 6.5% of 
affinity matured antibodies contain indels. The percentage of indels in affinity matured 
antibodies could be underestimated, because indels in the VH CDR3 and at the end of the VL 
CDR3 cannot be identified due to length variation that is introduced at these positions 
(junctions) during the initial V(D)J rearrangement. The CDR3 loops can tolerate high length 
variation, thus it is possible that further length diversification through SHM could contribute 
to antibody affinity maturation. All these studies agree that the location of indels is mainly in 
or in close proximity to the CDRs.  
 
Extensively affinity matured antibodies  
Most antibodies that have undergone SHM contain 15-20 mutations (Tiller et al., 2007), 
except from potent broadly neutralizing monoclonal antibodies (bnAbs) to type 1 
immunodeficiency virus (HIV-1) that accumulate 40-110 mutations (F. Klein et al., 2013). 
bnAbs develop only in some patients 2–3 years after infection (Mikell et al., 2011) and 
contain higher percentage of somatic mutations in comparison to other antibodies isolated 
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from the same patients (Scheid et al., 2009; Xiao et al., 2009). These mutations are essential 
for neutralization potency and breadth (Scheid et al., 2009; Xiao et al., 2009).    
The reason why such a large number of mutations is required for broad neutralization activity 
has been studied using the VRC01 class bnAbs, which neutralize HIV-1 by binding to the 
CD4 site of the gp120 envelop (Kwong & Mascola, 2012). All these antibodies use the same 
VH segment (VH1-2*02) and contain mutations in up to 32% rearranged VH-gene. Only a 
fraction of all these mutations in mature bnAbs is required for broad neutralization activity 
(Zhou et al., 2010; Burton & Mascola, 2015). Recent study has revealed that some mutations 
critical for neutralization activity have low intrinsic mutation potential, supporting the idea 
that extensive mutagenesis and selection by SHM needs to occur to achieve targeting of these 
residues (Hwang et al., 2017).  
Αnalysis of HIV-1 bnAbs estimated that high percentage of the reported bnAbs contain indels 
(≈40%) acquired during SHM with lengths ranging from 1 to 11 amino acids (Kepler et al., 
2014). 27 unique in-frame indels were identified in 56 HIV-1 bnAbs (108 V-genes), thus 
25% of the total bnAb V-genes contain indels. The unusually high frequency of indels in 
bnAbs is due to high levels of SHM which leads not only to accumulation of high percentage 
of point mutations but also to other more substantial sequence modifications, like indels.  
An essential role of insertions in neutralization activity has been demonstrated in some cases. 
Measurements of the neutralization activity of members of the anti-CD4 bnAb clonal lineage 
CH31 before and after the occurrence of a 9-amino acid insertion in the CDR1 loop has 
revealed that broad neutralization activity was acquired only after the occurrence of the 
insertion (Kepler et al., 2014). Additionally, removal of the FWR3 insertion of another anti-
CD4 bnAb (3BNC60) abolished the neutralization activity (Klein et al., 2013). Taken 
together, high percentage of insertions in bnAbs that occur by extensive SHM seem to have a 
functional role in broad neutralization activity.  
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1.1.2.2. Structural basis of affinity maturation 
Point substitutions  
After selection of antibodies with an antigen-binding topography that confers relatively low 
affinity, further structural diversification is introduced by SHM. Somatic mutations can be 
found across the entire V-genes, with the highest percentage of mutations at the antigen 
combining site, but also on the surface of the variable domains and the VH: VL interface 
(Clark, Ganesan, Papp, & van Vlijmen, 2006). SHM does not change residues that form 
direct contacts with the antigen, but residues adjacent to those residues. While the diversity in 
the primary repertoire is concentrated in the centre of the combining site, mutations 
introduced by SHM are located in the periphery of the binding site (Tomlinson et al., 1996), 
indicating that the diversity generated by SHM is complementary to that of the primary 
repertoire diversity.  
Analysis of crystal structures of antibody-antigen complexes has shown that SHM improves 
the shape and molecular complementarity (additional inter-molecular hydrogen bonds, van 
der Waals contacts) of the antigen combining site to the epitope (Cauerhff, Goldbaum, & 
Braden, 2004). Additionally to improving the shape complementarity, improved binding has 
been shown to be achieved by increasing the buried interface with antigen, which is the result 
of subtle structural rearrangements in the periphery of the interface with antigen (Sundberg et 
al., 2000; Li, Li, Yang, Smith-Gill, & Mariuzza, 2003).  
In addition, increased binding can be attributed to changes in the entropic cost of complex 
formation. Starting from an antibody that can adopt several combining site conformations 
(flexible), affinity maturation stabilises the conformation that is beneficial for binding, which 
is a conformation with smaller conformational change upon binding (paratope 




Analysis of the sites of indels on structures of bnAb-antigen complexes has shown that these 
are preferentially located close to the antigen-binding site, indicating that indels probably 
improve interactions with the antigen (Kepler et al., 2014). Co-crystal structure of NIH45-46 
with gp120, a clonal variant of the anti-CD4 bnAb VRC01 with a four-residue insertion in 
the VH CDR3, has shown that the insertion extends the VH CDR3 loop introducing new 
contacts with the antigen, which result an extended buried interface area with the gp120 and 
enhanced neutralization (X. Wu et al., 2011). Superimposition of the crystal structure of 
3BNC60, a clonal variant of NIH45-46 with an insertion in the FWR3, with the co-crystal 
structure of NIH45-46 with gp120 suggested that the insertion might enhance binding by 
interacting with a loop region in the gp120 that was truncated from the initial construct (F. 
Klein et al., 2013). The role of an insertion on broad neutralization was well illustrated on the 
complex structure of 8ANC195 with gp120 (Scharf et al., 2014). The insertion in the FWR3 
was shown to extend the epitope surface allowing interaction with a pocket on gp120 surface 
that conferred broad neutralization activity. Taken together, the mechanism by which 
insertions seem to confer broad neutralization activity is by extending the antigen-binding 
site surface allowing targeting of new surface epitopes on gp120.   
 
1.2. Technologies for discovery of therapeutic monoclonal antibodies  
Monoclonal antibodies (mAbs), known for recognizing a single epitope with high affinity and 
exquisite specificity, are widely used as therapeutics for cancer, autoimmune and infectious 
diseases, transplantation and other medical conditions (Chan & Carter, 2010; Weiner, 2015). 
The first great innovation that allowed rapid development of the therapeutic antibody 
technology was the invention of hybridoma technology, which is still widely used to produce 
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mouse monoclonal antibodies with defined specificity (Köhler & Milstein, 1975). Before 
clinical use, the immunogenicity of antibodies derived from animal sources is reduced by the 
process of "humanization", which is usually performed by grafting the CDRs of a mouse 
antibody into human V-genes (P. T. Jones, Dear, Foote, Neuberger, & Winter, 1986). 
Development of technologies for generation of fully human antibodies allowed the wide use 
of mAbs as therapeutics of human disease (Lonberg, 2008).   
Therapeutic antibodies exert their effect by different mechanisms (Chan & Carter, 2010) 
including binding to a ligand or their cognate receptor to either block their interaction and 
consequently prevent receptor activation and function (e.g., infliximab, adalimumab) or 
downregulate the expression of the receptor (e.g., efalizumab, omalizumab). Another 
important mechanism of action of therapeutic antibodies is the target cell lysis by induction 
of effector functions (like ADCC, ADCP and CDC) through the interaction of the Fc region 
with cellular receptors (Melis et al., 2015). More recently, two immune checkpoint inhibitors, 
the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and the programmed death 1 (PD-1) were 
targeted to render tumor immunogenic in order to fight cancer through the patient’s immune 
system (Couzin-Frankel, 2013).    
 
Engineered antibody fragments  
Genetic engineering allows the production of diverse antibody fragments, like fragments 
lacking the Fc region, with reduced size or with two different binding sites (bi-specifics). 
Most therapeutic applications require the Fc fragment of the IgG to increase the FcRn-
mediated recycling for extended antibody half-life and to recruit effector functions, but there 
are some applications where the Fc fragment is not required. For example, presence of the Fc 
can induce massive cytokine release and associated toxic effects (Holliger & Hudson, 2005). 
Reduced size could have several benefits including improved pharmacokinetics for tissue 
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penetration (Holliger & Hudson, 2005) and bi-specific formats (more than 60) offer the 
possibility to either interact with two different disease targets or redirect T-cells to kill tumor 
cells (Spiess, Zhai, & Carter, 2015).  
The most commonly used antibody fragments are the fragment antigen-binding (Fab) and the 
single-chain fragment variable (scFv). The Fab fragment (50kDa) has one-third of the size of 
an IgG molecule (150kDa) and is one of the formats that are being explored for therapeutic 
applications, in fact these are the most successful fragments accounting for 49% of the 
fragments that have entered clinical development with three FDA approved fragments 
(Nelson, 2010). The single-chain variable fragment (scFv) is composed of the variable 
domains of the heavy and light chain linked by a flexible linker (Skerra & Pluckthun, 1988). 
The scFvs represent a large percentage (40%) of candidates in clinical development (Nelson, 
2010).  
 
1.2.1. Isolation of antibodies with defined specificity 
The discovery of therapeutic antibodies with defined specificity against a wide variety of 
target proteins is generally possible due to the development of appropriate technologies. The 
classical hybridoma technology has some restrictions, like inability to produce antibodies 
against antigens that are toxic to the animal and conserved across species (non-immunogenic) 
(Dufner, Jermutus, & Minter, 2006). Additionally, although KD values lower than 100 pM 
have been reported (Rathanaswami et al., 2005), there is an affinity ceiling in the KD values 
that can be achieved by the BCR affinity maturation process in vivo.  
A key technology that allows isolation of specific antibodies from large libraries of functional 
antibodies is phage display (Smith, 1985), which was adapted to display "fully human" 
antibody repertoires for selection in vitro (McCafferty, Griffiths, Winter, & Chiswell, 1990). 
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The past decades these technologies were exploited to generate human antibodies with high 
affinity and specificity (Hoogenboom, 2005). The first mAb that derived from phage 
displayed antibody libraries was Adalimumab (Humira), an anti-TNF antibody for the 
treatment of rheumatoid arthritis discovered by Cambridge Antibody Technology (Brekke & 
Sandlie, 2003).   
 
1.2.1.1. Construction of antibody libraries  
Libraries displaying fully human antibody fragments (Fab or scFv) on phage have been 
constructed by cloning the V-genes of the total B-cell repertoire by RT-PCR (Marks et al., 
1991), the so called naïve libraries, which have been used to isolate antibodies with affinities 
down to the sub-nanomolar range (Winter, Griffiths, Hawkins, & Hoogenboom, 1994; 
Vaughan et al., 1996; P Holliger & Hoogenboom, 1998). Synthetic libraries are usually made 
starting by a restricted number of antibody germline genes, eg. one VH-gene (Griffiths et al., 
1994; Viti, Nilsson, Demartis, Huber, & Neri, 2000) or 49 VH-genes (Hoogenboom & 
Winter, 1992), by diversification of small number of VH or VL CDR3 residues. The fully 
synthetic human combinatorial antibody libraries (HuCAL) were developed in an effort to 
mimic the diversity of the human repertoire. The library design was based on 7 VH and 7 VL-
germline genes that represent each gene family, so starting from 49 VH:VL gene combinations 
diversity was introduced in the CDR3s by mimicking the natural diversity, including length 
diversity (Knappik et al., 2000). All these synthetic libraries have been used successfully for 
isolation of antibodies to haptens, proteins and peptides.   
 
1.2.1.2. Selection of specific antibodies  
From antibody libraries that typically contain around 109-1010 members, antibodies that bind 
specifically to the desired antigen are isolated by in vitro selection. Selection is possible 
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because each phage particle displaying a specific antibody carries the gene encoding it, which 
can be recovered after selection of the antibody for binding to the desired antigen.  
 
Phage display  
This link between the phenotype and the genotype is achieved by displaying an antibody 
fragment (Fab or scFv) on the surface of filamentous bacteriophage by fusion to the phage 
coat protein pIII. The filamentous bacteriophage M13, a single-stranded DNA virus, is the 
most commonly used phage for display, because it can infect E. coli containing the F-pilus 
without causing cell lysis. The pIII phusion protein (pIII-scFv) is encoded by the phagemid, a 
plasmid with a phage origin of replication and an antibiotic resistance gene (Winter, Griffiths, 
Hawkins, & Hoogenboom, 1994). A phagemid can be replicated as a plasmid, and also be 
packaged as single stranded DNA in viral particles when it is "rescued" by a helper phage 
which provides the proteins necessary for particle assembly.  
 
Biopanning 
The selection process called "biopanning" involves iterative rounds of production of phage 
particles displaying the scFv library in E. coli, incubation of the library with the target 
antigen, washing to remove the variants that do not bind, elution of the particles that bind the 




Figure 12. Schematic representation of the biopanning process demonstrated with the phage display 
method. In phage display, the link between the genotype and phenotype is created by producing phage 
particles that contain the gene encoding the scFv variants and the scFv fused to the pIII minor coat 
protein. The phage library is used for selection for binding to the target antigen and particles 
expressing scFv variants that bind the target remain bound to the antigen after washing. The genotype 
of the selected variants is recovered by phage elution and E.coli infection. This process is repeated a 
number of times to enrich a pool of antigen-binding scFv variants. Adapted from (Weisser & Hall, 
2009). (Weisser & Hall, 2009) 
 
 
1.2.2. In vitro antibody affinity maturation  
Discovery of a therapeutic antibody candidate for a disease target is usually followed by 
improving antibody affinity in vitro. The highest possible affinity for the antigen is desirable 
to achieve high efficacy even at low concentrations, reduced dosing and cost of the therapy 
(Dufner et al., 2006). In some cases the best affinity is not clear, for example when targeting 
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a solid tumor a high affinity mAb may be retained at the periphery of the tumour which could 
result in reduced tumor penetration (Adams et al., 2001; Weiner & Carter, 2005).  
The process of directed evolution of antibody affinity may include iterative rounds of genetic 
diversification and selection or/and screening for improved variants. Construction of libraries 
with variants of the selected parent antibody is followed by identification of improved 
variants by selection strategies similar to those described above. Very high affinities, in the 
low picomolar (Schier et al., 1996; Razai et al., 2005) or even in the fentomolar (E. T. Boder, 
Midelfort, & Wittrup, 2000) range can be achieved.   
 
1.2.2.1. Strategies for library construction  
Point substitutions  
Different strategies have been applied to build libraries with variants of the parent antibody 
with diversity at random or targeted positions. Random approaches, like error-prone 
polymerase chain reaction (ep-PCR) (Neylon, 2004) and DNA recombination (Stemmer, 
1994), introduce diversity at random positions of the entire V-gene, while focused 
approaches, like CDR walking mutagenesis (W. P. Yang et al., 1995) and rational design, 
introduce diversity at restricted number of specific positions.  
In Nature, diversity is introduced mainly in specific regions, the CDRs, indicating that 
sufficient beneficial mutations can be found in these regions (Tomlinson et al., 1996). 
Focused in vitro affinity maturation strategies, mimicking the process in Nature, introduce 
variation only in the CDRs. By saturation mutagenesis (with all possible amino acids at the 
position) it is impossible to diversify all six CDRs in one library, as each of them is on 
average nine residues long and each library (with 109-1010 variants) can only contain all 
possible combinations of six to seven residues. Thus, the challenge of focused approaches is 
to identify which CDR positions to target.  
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One approach that is commonly used to overcome this limitation is called CDR walking,  
which involves targeted mutagenesis of CDR regions and selection that can be performed in 
parallel or sequential (Barbas et al., 1994; W. P. Yang et al., 1995). The parallel approach 
involves randomization of different CDRs in different libraries, parallel affinity-based 
selections and subsequent combination of the most beneficial mutations from different CDRs 
in one library. In the same study, the outcome of the parallel approach was compared to that 
of a sequential approach, which was conducted by randomization of one CDR and selection 
followed by picking the best variant to be the template for randomization of another CDR. 
The results of the parallel approach were unpredictable, as beneficial mutations in different 
CDRs did not always have an additive effect on affinity, but a high improvement (420-fold) 
was achieved. Whereas using the sequential approach improved variants with small 
improvements (4-fold) were obtained consistently in each walk with the highest 
improvements (8-fold) obtained by the VH CDR3 walk, that seems to be most rapid route to 
obtain affinity gains.  
Since both the VH and VL CDR3 regions are the most diverse CDRs in Nature, with the VH 
CDR3 focusing by far the highest diversity (Xu & Davis, 2000), a strategy of targeting only 
these regions was followed to increase the affinity (Schier et al., 1996). By sequential 
targeting of the VL CDR3 and then the VH CDR3, an improvement of more than three orders 
of magnitude was achieved. Due to the fact that the CDR walking approaches are time 
consuming, a large number projects have focused on randomization of the VH CDR3, which 
is more likely to yield affinity improvements.  
Random mutations across the entire V-gene can be introduced by gene amplification by ep-
PCR using low-fidelity DNA polymerases. Comparison of libraries containing different 
number of mutations per scFv gene (2, 4 or 22 mutations) for improved affinity has shown 
that all these libraries yielded variants with improved affinity, but the greatest affinities 
 47 
derived from the libraries with the moderate and high mutation rate (Daugherty, Chen, 
Iverson, & Georgiou, 2000). Interestingly, a high percentage of variants were still functional 
in the libraries with the high mutation frequency and the majority of beneficial mutations 
were located in residues distant from the binding site.  
The effect of DNA recombination on antibody affinity have been assessed by comparing the 
outcome of selection for libraries with error-prone PCR with and without a recombination 
step. The outcome of selection of the recombined library was a population with higher 
percentage of improved variants including the variant with the highest affinity, indicating that 
combinatorial library strategies allow sampling of larger sequence space than ep-PCR.  
A semi-rational approach, using ribosome display combined with ep-PCR mutagenesis 
between rounds of selection has been used to identify position (hotspots) that could improve 
affinity across the entire scFv of an antibody specific for IL-13 (BAK1) (Thom et al., 2006). 
Identification of mutational hotspots was followed by construction of libraries targeting these 
positions with the full diversity of amino acid substitutions. These libraries also contained 
combinations of beneficial mutations in different CDRs to take advantage of additive effects 
on affinity. The majority of beneficial point substitutions was not found in the CDR3s but in 
the VL CDR1, underlining the importance of targeting all CDRs to find mutations that confer 
affinity improvements. Also, the majority of mutation hotspots (84%) were located in the 
CDRs, which is in agreement with preferential selection of CDR mutations in human 
antibodies in Nature.  
A disadvantage of the ep-PCR approaches is that these are biased towards conservative 
substitutions because more than one mutations per codon are rarely introduced, thus sampling 
of all amino acids in each position is impossible. More recently, a more systematic approach 
was implemented to study the impact of each mutation across the entire V-gene in affinity, by 
construction of a single-site saturated mutagenesis library (Koenig et al., 2017). Positions that 
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enhanced affinity were identified by determining the frequency of each mutation in the 
library before and after selection by deep sequencing. A variant with improved affinity and 
stability was identified, with mutation out of the CDRs in a framework position far from the 
antigen combining site. The fact that the same mutation constitutes one of SHM hotspots in 
Nature underlines the possibility of finding beneficial mutations throughout the V-region.  
 
Indels  
The design of antibody libraries aiming at in vitro affinity maturation rarely includes indels. 
The only platform used for development of therapeutic antibodies that incorporates low 
percentage of indels during the affinity maturation process is mammalian surface display 
(Bowers et al., 2011), by using the enzyme AID in vitro to generate diversity in the V-gene in 
mammalian cells, mimicking the process of SHM in vivo. The rate of in-frame indels 
occurring by in vitro SHM (≈ 0.05-0.1%) is 10-fold lower than the in vivo SHM rate (Bowers 
et al., 2014). Such a low rate of indels introduced by in vitro SHM, arising only by local 
sequence duplication, shows that this approach samples an even lower diversity of indels than 
in vivo SHM.  
 
In some cases antibody libraries generated by classic methods of site-directed mutagenesis 
yielded antibodies with improvements attributed to in-frame indels (Finch et al., 2011). These 
modifications were not intentionally incorporated but probably occurred by mispriming 
during mutagenesis. Variants of a human anti-IL-6 antibody with enhanced affinity contained 
either deletion in the VL CDR3 or insertion in the VH CDR3. The authors proposed that this 
may be an additional important strategy to engineer antibody affinity (Finch et al., 2011).   
Libraries with length variation in the VH CDR2 of an anti-hapten antibody were constructed 
using a method called insertional mutagenesis. The design of libraries with randomized 
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insertions of different lengths was based on a model structure of the parent antibody 57-2 
complexed with 17β-estradiol combined with the observation of natural length variation at 
the specific position. Libraries with length of insertions up to 4 amino acids on the tip of a b-
turn like VH CDR2 loop were designed with the aim of creating novel contacts with the 
hapten. Several improved variants were identified, with the highest affinity mutant carrying 
12-fold higher affinity than the parent (Lamminmäki et al., 1999). This method was also 
successfully used to design libraries with insertions in the VL CDR3 based on structural 
information with aim changing the specificity of an anti-hapten antibody (Krykbaev, Tsantili, 
Jeffrey, & Margolies, 2002).  
 
1.2.2.2. Affinity selections  
The advent of phage display (McCafferty et al., 1990) was followed by development of more 
display systems (Weisser & Hall, 2009) that provide linkage of the genetic information 
(genotype) with the encoded protein (phenotype). While phage display is the most popular 
method for the isolation of specific antibodies, for maturation of antibody affinity other 
display technologies are widely used as well (Lipovsek & Plückthun, 2004; Hoogenboom, 
2005; Fukuda et al., 2006; Zahnd, Amstutz, & Plückthun, 2007; Bradbury, Sidhu, Dübel, & 
Mccafferty, 2011).  
 
Other display technologies 
Other display technologies that have been used for selection include cell-free formats, like  
ribosome (Jozef Hanes, Jermutus, Weber-Bornhauser, Bosshard, & Plckthun, 1998), mRNA 
(Josephson, Ricardo, & Szostak, 2014), CIS (Odegrip et al., 2004) display and methods that 
involve in vitro compartmentalisation in water-in-oil emulsion droplets, like bead surface 
display (BeSD) (Mankowska et al., 2016) and SNAP display (Houlihan, Gatti-Lafranconi, 
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Kaltenbach, Lowe, & Hollfelder, 2014). Moreover, bacterial (Georgiou et al., 1997), yeast 
(Eric T. Boder & Wittrup, 1997) or mammalian (Bowers et al., 2011) cells expressing 
antibodies on their surface are not commonly used for selection, but for screening by FACS 
(Figure 13).  
 
 
Figure 13. Different display formats for scFv affinity maturation by in vitro evolution. (A) Phage 
display, (B) Ribosome display, (C) Cell surface display. Adapted from (Weisser & Hall, 2009). 
 
One important restriction of the selection process by phage display is the limitation of the 
library size, that is restricted by the transformation efficiency of cells which is typically ≈109 
cfu/μg DNA (Dufner et al., 2006). Even lower number of variants can be sampled by cell 
surface display systems, as these are limited by the number of cells that can be sorted by 
FACS (practically ≈106-107) (Feldhaus et al., 2003). In vitro expression systems remove this 
restriction and give access to greater sequence space, as the input of selection is a DNA 
library that is amplified by PCR, consequently, the library size is not limited by the 
transformation efficiency of cells, thus allowing libraries theoretically greater than 1013 to be 
explored (Barrick, Takahashi, Ren, Xia, & Roberts, 2001). Another complication of phage 
 51 
display is that expression takes place into bacterial cells, thus variants are enriched not only 
by selection, but also for rapid growth in the bacterial host or even toxicity (Plückthun, 
Schaffitzel, Hanes, & Jermutus, 2000). Furthermore, in vitro methods allow selection 
conditions to be controlled by including detergents and competitors, in addition to extreme 
pH, temperature and ionic strength since cell viability does not need to be maintained.  
 
Ribosome display  
Ribosome display was first developed in 1994 (Mattheakis, Bhattt, & Dower, 1994)  with the 
display of synthetic peptides on ribosomes and subsequently was further adapted for display 
of scFvs (J Hanes & Plückthun, 1997). The link between genotype and phenotype is realized 
during in vitro translation, by formation of a complex of the translated scFv linked to the 
ribosome and the mRNA encoding it. The complex remains stable in cold environment (4 °C) 
and high concentrations of magnesium ions, which can be used for affinity selections via 
panning to isolate library members with improved affinity for the target protein. After 
selection, the mRNA pool encoding selected variants is recovered by RT-PCR.  
Ribosome display has been proven a powerful technology for in vitro antibody affinity 
maturation. A DNA amplification step by PCR is performed after each round of in vitro 
selection, thus using error-prone DNA polymerases between the rounds of selection have 
enabled accumulation of multiple beneficial mutations hat conferred affinities up to ≈ 81 pM 
(J Hanes, Schaffitzel, Knappik, & Plückthun, 2000; Thom et al., 2006). Furthermore, ep-PCR 
has been combined with recombination between rounds of in vitro selection to generate the 
highest affinity peptide binding mAb to date (KD=1 pM) (Luginbühl et al., 2006).  
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Stringency during affinity-based selections  
The conditions of affinity-based selections must be designed in order to enrich for the highest 
affinity variants instead of variants with affinity similar to the parent or improved expression 
in E.coli (Zahnd, Sarkar, & Plückthun, 2010). One strategy to achieve enrichment of 
improved variants is performing equilibrium selections, by panning with an antigen 
concentration below the KD and reducing the concentration by 10-fold after each selection 
round  (Hawkins, Russell, & Winter, 1992; Groves & Nickson, 2012). Another methodology 
is carrying out off-rate selections, by panning using an excess of competing unlabelled 
antigen to isolate variants with slower off-rates, which will remain bound to the biotinylated 
antigen captured on streptavidin beads (Hawkins, Russell, & Winter, 1992; Jermutus, 
Honegger, Schwesinger, Hanes, & Plückthun, 2001).     
 
1.2.3. In vitro evolution of other proteins 
Strategies for construction of libraries with indels  
Despite the technical difficulties in construction of libraries containing length variation of 
diverse sequence composition, some protein engineering studies have given insight into the 
structural and functional effects of indels in proteins other than antibodies. These libraries 
contained in-frame indels which were constructed either by random (Arpino, Reddington, 
Halliwell, Rizkallah, & Jones, 2014; Liu, Wei, Dong, Xu, & Liu, 2015) or by targeted 
mutagenesis approaches (Afriat-jurnou, Jackson, & Taw, 2012). Methods that have been 
developed for construction of libraries with indels are further analysed in the introduction of 
Chapter III of this thesis.  
The essential role of loop length variation in the emergence of new functions was 
demonstrated by reconstruction of the pathway of evolution of PTE phosphotriesterase 
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activity, which catalyses the hydrolysis of synthetic substrates, from PTE-like lactonases 
(PLLs), that exhibit promiscuous phosphotriesterase activity (Afriat-jurnou et al., 2012). 
Based on structural and phylogenetic analyses a 7-amino acid deletion combined with an 
epistatic substitution enabled the emergence of HSLase activity while retaining PTE’s 
paraoxonase activity.  
More recently developed methods of transposon-mediated mutagenesis (D. Jones, 2005) have 
been used for construction of libraries with in-frame amino acid deletions across the entire 
GFP gene (Arpino et al., 2014; Liu et al., 2015). One of these studies showed that the 
enhanced green fluorescent protein (eGFP) can tolerate amino acid deletions  mainly in loops 
(Arpino et al., 2014). Furthermore, this study revealed that deletion mutations more often 
occur in helices than in strands, except from positions towards the strand termni. 
Furthermore, a deletion in the N-terminal 310 helix conferred improved eGFP fluorescence, 
which enhanced the fluorescence not by affecting the brightness but by optimization of the 
folding efficiency, therefore increasing the production of functional eGFP in the cells. 
Another similar study on the UV-optimized GFP variant (GFPUV) examined the idea that 
decreased fluorescence of GFPUV mutants with deletions could be the result of compromised 
efficiency of the protein folding and therefore they rescued these variants by introducing 
mutations that enhanced folding (Liu et al., 2015).   
These studies are in agreement with the idea that indels could be a key step in the evolution 
of new functions (Tóth-Petróczy & Tawfik, 2013), with substitutions in close proximity to 
the indels compensating or enabling the functional effect of indels (Leushkin, Bazykin, & 





1.3. Interaction between mutations during affinity maturation  
1.3.1. Fitness landscapes and evolutionary trajectories  
In order to understand the enormous breadth of protein sequence and function that could be 
sampled by natural and directed evolution, fitness landscapes in protein sequence space have 
been used to visualise evolutionary trajectories as a movement through related sequences 
(Maynard Smith, 1970; Wright, 1930). Protein sequence space shows all the possible 
combinations of amino acids of a protein of certain length so that neighbouring points 
represent genotypes which differ by one amino acid mutation. The large number of 
theoretical possibilities makes the protein sequence space multi-dimensional. For a protein 
with 100 amino acids sequence space would be represented with 100 dimensions. For 
simplicity, sequence space is condensed into two axes (Figure 14).  
Fitness can represent specific properties, such as protein binding affinity or catalytic activity. 
Flat areas indicate proteins with low fitness while peaks represent desired proteins with high 
fitness. Thus adaptive evolution can be conceptualized as a walk from a lower to an optimal 
phenotype across the landscape (Maynard Smith, 1970). In directed evolution, selection or 
screening methods can explore only a small proportion of a fitness landscape with the aim of 
isolating phenotypes with higher fitness peaks for a biophysical property such as affinity or 










Figure 14. Graphical representation of a fitness landscape. Sequence space is represented by two 
axes. Height represents protein fitness (vertical axis). The transition from blue to green to yellow to 
red indicates an increase in fitness. Most of the sequences in the landscape are non-functional (blue) 
while rare fitness optima are represented in the peaks. If all mutations are additive, the fitness peaks 
appear smooth while if epistasis occurs between mutations, a rugged landscape with multiple peaks 
separated by valleys of genotypes with low fitness is observed. Adapted from (de Visser & Krug, 
2014).  
 
Experimental studies have generated sequence function maps by using libraries of protein 
binders coupled to yeast display and high throughput sequencing. Sequence enrichment in the 
selected versus initial library has been used to assess the fitness (binding) of adaptive 
mutations on the structure of a protein (Whitehead, Baker, & Fleishman, 2013). Deep 
mutational scanning represents a powerful method for identifying proteins with high fitness 
and also enabling experimental investigation of fitness landscape topologies. Another 
example of mapping a fitness landscape has explored the space of all possible sequences (424 
sequences) for short RNAs (24 nt length) by in vitro selection for binding to GTP (Jiménez, 
Xulvi-brunet, Campbell, Turk-macleod, & Chen, 2013).  
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The main constraints that are known to shape the fitness landscape of a protein include 1) 
epistatic interactions observed between mutations and 2) the protein stability threshold  
(Bershtein, Segal, Bekerman, Tokuriki, & Tawfik, 2006).  
 
1.3.2. Epistatic interactions  
Epistasis is the non-additive phenotypic effect of the combination of individual mutations, 
meaning that the effect of each mutation on function depends on the genetic background on 
which it occurs (Phillips, 2008). For instance, a beneficial mutation may exert its effect only 
in the presence of another permissive mutation (Gong, Suchard, & Bloom, 2013). 
Conversely, a mutation may be beneficial only in the absence of another restrictive mutation 
(B. C. Dickinson, Leconte, Allen, Esvelt, & Liu, 2013). Epistatic effects can be synergistic, 
diminishing, antagonistic, aggravating, ameliorating, buffering, compensatory, and 
reinforcing. Synergistic is when the effect of the combination is beyond that expected from 
the individual effects, which could mean extra good or extra bad. Positive epistasis means 
that the phenotype is higher than expected, while negative means lower than expected 
(Phillips, 2008). Epistatic mutations have been shown in both natural (Ortlund, Bridgham, 
Redinbo, & Thornton, 2007) and experimental evolution (Bershtein et al., 2006), indicating 
that the effect of combining mutations is unpredictable.   
Similarly, not consistent additivity has been observed in in vitro evolution experiments, as 
combining individual beneficial mutations in different CDRs in a parallel CDR walking 
approach resulted in unpredictable outcomes (Barbas et al., 1994; W. P. Yang et al., 1995). 
Measurements of the affinities of intermediate mutants of an in vivo affinity maturation 
pathway has shown that the effect of individual mutations on binding was either positive or 
neutral, with a high degree of synergy between mutations (P. L. Yang & Schultz, 1999). In 
other cases, the effect of combining individual somatic mutations was either additive (Ulrich 
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et al., 1997; England, Nageotte, Renard, Page, & Bedouelle, 1999) or non-interactive 
(Romesberg, 1998).  
 
1.3.3. Trade-offs between affinity and stability  
Natural evolution not only results in proteins with improved activity, but it also maintains 
soluble, thermodynamically stable proteins (Tokuriki & Tawfik, 2009; Soskine & Tawfik, 
2010). In parallel, antibodies need to maintain high thermodynamic stability and reduced 
aggregation tendency to be considered as therapeutic candidates because these properties 
could affect manufacturing, storage and serum half-life (Carter & Merchant, 1997). Often 
mutations that enhance a protein function have a negative effect on stability, indicating a 
trade-off between function and stability (X. Wang, Minasov, & Shoichet, 2002; Gong et al., 
2013). To overcome this effect compensatory mutations have been shown to restore the 
compromised stability (Tokuriki, Stricher, Serrano, & Tawfik, 2008). Additionally to 
mutations that improve affinity, compensatory mutations that preserve thermodynamic 
stability have been shown to accumulate during in vivo ( Sun et al., 2013; F. Wang, Sen, et 
al., 2013, retracted recently; Sen et al., 2017) and in vitro (Julian, Li, Garde, Wilen, & 










1.4. Objectives of this thesis  
1.4.1. Affinity maturation of a scFv by in vitro continuous evolution 
The Chapter II of this thesis describes efforts to develop a continuous evolution for in vitro 
evolution of protein binding. Using a continuous evolution set-up sequence space can be 
explored in a different way, raising the possibility of fundamentally altering the strategy of 
combinatorial methods. Normally we conduct very stringent selections that yield very few 
hits that are then re-randomised. However, this is very different from the way Nature evolves 
biomolecules.  The near-neutral theory of natural evolution (Ohta, 1992) suggests that only a 
fraction of differences between homologous genes lead to improvements in fitness. The 
remaining majority of observed polymorphisms are the result of genetic drift exploring 
neutral networks of functionally equivalent genes. Such genetic drift that leads to cryptic 
variation (neutral to current function) has been suggested to be beneficial to subsequent 
adaptive evolution (Davies EK, 1999; Masel, 2006; Wagner, 2011). The conditions of the 
continuous evolution “lagoon’ in which competition occurs can be manipulated, so that either 
regimes of neutral or more stringent adaptive evolution are favoured. For example, will the 
phylogeny of selected clones be more diverse (in contrast to the severe bottlenecking that a 
stepwise process implies) and will the broader sampling of sequence space accelerate 
evolution leading to ultimately better binders?  
In this way scFvs relationship between the whole protein sequence and high affinity could be 
explored for the first time. This objective could be achieved by using continuous in vitro 
evolution. Continuous in vitro evolution of binding proteins had not been described in the 
beginning of this PhD study (January 2014), but the development of a continuous in vitro 
evolution system (PACE) by Esvelt and Carlson (2011 and 2014) suggested a practical way 
of conducting such experiments. Based on the PACE system we tried to a develop a system 
of continuous evolution of protein binding properties. As it was shown by Esvelt such a 
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system would allow large protein populations to evolve over hundreds of rounds of evolution 
in short time. As the number of rounds performed and the size of population are determinants 
of in vitro evolution experiments, the mutants that could be sampled by PACE are 
significantly higher than for any other conventional in vitro evolution approach, so the 
improvements in the desired property that could be achieved by PACE are expected to be 
unprecedented.  
 
1.4.2. Affinity maturation of an entire scFv using libraries with insertions and deletions  
In Nature, many steps of the diversification of the primary antibody repertoire include 
variation of the length of the CDR loops, which can have considerably different lengths with 
some of them varying more than others, indicating that these can tolerate significant length 
modification. The loop length is recognised as the primary factor that defines the structural 
diversity of the antigen combining site.  
Following antigen stimulation, further diversification through SHM includes mainly point 
substitutions and a small percentage of indels. SHM has been shown to introduce subtle 
changes in the already defined topology of the combining site, thus the percentage of indels 
could be low because SHM does not introduce major structural changes that would result 
from an indel. Alternatively, it is likely that the antibody fold can accommodate higher 
diversity of indels that improve affinity than that observed in Nature, as SHM does not 
sample random but only biased diversity with a biological limit in the level of affinity that 
can be achieved, which is sufficient for a biologically competent affinity maturation process. 
This notion is supported by the fact that the mechanism of SHM has been shown to introduce 
only a very low percentage of in-frame indels, thus not permitting sampling of high diversity 
of indel variants. Only anti-HIV bnAbs, which have been subjected to extensive affinity 
maturation, acquire a higher percentage of indels with a functional role in neutralization.  
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Consequently, it would be interesting to study the impact of random high diversity indels on 
antibody affinity by in vitro evolution, as it is likely that more indels with beneficial effect on 
affinity could be found and the structural basis of their function could be elucidated. Other 
researchers have identified indels that improved antibody affinity, but their methods did not 
allow them sampling of high diversity indels at random positions. Mammalian surface 
display introduces only low diversity of indels due to the small library size and the low rate 
of incorporation of in-frame indels by this method (Bowers et al., 2014). Other researchers 
have studied long full diversity insertions by insertional mutagenesis, but the insertions were 
not random, as the design was based on structural information and natural variation 
(Lamminmäki et al., 1999).  
This thesis focuses on the development of new approaches for construction of libraries with 
in-frame indels that would enable sampling of different lengths of high diversity indels at 
random positions across the entire antibody variable regions. Chapter III describes the 
application of a random approach that allowed the construction of libraries with random 
insertions and deletions. Chapter IV describes the development of a semi-random approach 
to build libraries with different lengths of insertions that could be widely applied in future in 
vitro antibody affinity maturation campaigns. Libraries constructed by either of these 
approaches were subjected to affinity-based selections using appropriate display methods and 









2. Continuous In Vitro Evolution of 























2.1.1. In vitro Continuous Evolution  
The greatest limitation of in vitro evolution is each cycle of diversification and selection is 
cumbersome and require significant time and effort by a skilled researcher. A process of 
continuous in vitro protein evolution, which would allow protein populations to evolve 
autonomously by continuous rounds of mutation and selection without the interference of the 
researcher would allow evolution of large protein populations over hundreds of cycles of 
evolution, circumventing the limitations in the number of mutants that can be screened by 
traditional in vitro evolution experiments.  
In theory, a process of continuous evolution could be a cell culture growing under conditions 
of selection pressure, where variants of a gene which encode the protein of interest are 
selected because they confer survival of the cell. For example, a pool of β-lactamase gene 
variants, that allows growth of bacterial ells growing in medium containing ampicillin. Such 
a process though would not allow the selection of functional genes, because genomic 
mutations could permit growth of non-functional genes. Furthermore, the rate of error by 
cellular replication is not sufficient for generation of large number of mutants.  
 
2.1.2. Filamentous phage  
The filamentous phage M13 is a bacteriophage which infects gram-negative bacteria by 
attaching to receptors on a projection found on the bacterial surface, the F-pili (Mar, & 
Herbert, 2014). Filamentous phage M13 possesses some characteristics that render it suitable 
for continuous evolution. Because of its rapid phage cycle compared to E. coli cells, it is 
possible to sustain a phage culture while providing fresh E. coli cells. M13 is non-lytic and it 
does not kill the host cell, but phage particles are continually released and the sole impact on 
the cells is that it slows down the cell growth rate (Hoffmann-Berling & Mazé, 1964). 
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Furthermore, release of the first progeny phage particles starts about 10-15 minutes after 
infection.   
The most known phage coat protein because of its common use in phage display, is pIII, 
which constitutes the only phage coat protein essential for infectivity (Russel & Model, 
1989). Phage protein pIII is expressed on the cell inner membrane before incorporation into 
phage particles. Mature pIII is comprised of three domains, the N1, N2 and CT, which are 
separated by two glycine-rich linkers. The N-terminal N1 and N2 domains consist of 68 and 
132 amino acids, respectively, while the C-terminal (CT) membrane-anchoring domain 149 
amino acids. The G1 linker which connect the N1 and N2 domain is shorter than (18 amino-
acids) compared to the G2 linker (39 amino-acids). The CT domain adhere to the phage 
particle, while the N1 and N2 domains are displayed on the surface of the phage (Holliger, 
Riechmann, & Williams, 1999a). 
 
2.1.3. Filamentous phage infection mechanism  
Three to five copies of pIII are attached to the phage surface, but a single copy is sufficient 
for infectivity (Russel & Model, 1989). Filamentous phages infect E. coli cells in a process 
involving two steps (Figure 15). The initial step involves binding of the N2 domain to the F-
pilus. Once the phage particle is attached to the cell, the pilus retraction allows the N1 
domain to approach and interact with the TolA-C receptor (Riechmann & Holliger, 1997; 
(Holliger, Riechmann, & Williams, 1999). It has been shown that the N1 domain forms a 
complex with the N2 domain (Lubkowski, Hennecke, Plückthun, & Wlodawer, 1999), which 
hides the N1 binding site from the TolA-C until the N2 domain binding to the F-pilus and 






Figure 15. A) Schematic representation of the M13 phage infection process. Starting by interaction of 
the N2 domain of pIII (blue) with the F-pilus, the intramolecular association between two N1 and N2 
domains is disrupted and the N1 domain binding site is accessible for interaction with the TolA-C 
receptor. Figure adapted from (Marvin D.A. 2014) B) N1-N2 domain structure. Figure adapted from 
(Holliger P, 1999).   
 
2.1.4. Continuous culture of filamentous phage 
Researchers have performed continuous culture of filamentous phage (Husimi, Nishigaki, 
Kinoshita, & Tanaka, 1982) by adding new host cells to a culture of filamentous phage 
growing in a vessel called cellstat”.  The dilution rate was adjusted in way that prevented 
phage wash out from the “cellstat”, but did not allow cell division. The purpose of his studies 
was to compare the fitness of different phage strains, by measuring how quickly the fittest 
strain took over the “cellstat”. Filamentous phage infect only E. coli cells that contain the F-
pilus on their surface, which is expressed only when the cells are in the log-phase, which 
depends on the cell density of the cell culture. In order to create a source of host cells 
growing at constantly at the log-phase, he constructed a device called the turbidostat where 
the growth phase was kept constant by observing the cell density and regulating the media 
flow in the turbidostat.  
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2.1.5. A system for the continuous directed evolution of biomolecules (PACE)  
Using a continuous phage culture based on the “cellstat” (Husimi et al., 1982), Esvelt et al. 
(Nature, 2011) constructed the “lagoon” (Figure 16). While increasing the cellular 
mutagenesis rate, the mutagenesis in the lagoon is restricted to the gene of interest. This was 
achieved by inserting the gene of interest in the phage genome. The phage population is 
propagating in the lagoon, while fresh host cells are constantly transferred to the lagoon, thus 
the mutations to the host cells would have minimal impact on the selection of gene variants 
with mutations. As mentioned above, filamentous phage infectivity depends entirely on the 
presence of one phage coat protein, the pIII. To selectively enrich the gene mutants with the 
desired activity they linked the function of interest with the pIII expression, which allows 
filamentous phage selective propagation. Additionally, the phage titer rises with increasing 
pIII expression levels, so the pIII infective phage titer could be linked with the activity levels 





Figure 16. In PACE the phage population is propagating in the lagoon. The host cells are kept in a 
constant growth phase (mid-log phase) in a separate vessel, where the cell density is measured by a 
turbidity meter. From this vessel fresh host cells are transferred to the lagoon. Adapted from (Esvelt, 




The proof of concept study of the phage assisted continuous evolution system (PACE) 
described the evolution of T7 RNA polymerase variants capable of transcribing DNA 
downstream the T3 promoter (Esvelt et al., 2011). T7 RNA polymerase is highly specific for 
the T7 promoter and T7 RNA polymerase variants recognizing the T3 promoter has not been 
reported before. Starting from less than 3% activity levels on the T3 promoter, T7 RNAP 
evolution by PACE resulted in variants exhibiting more than 200-fold improvement in 8 days 
of continuous evolution after around 200 rounds of evolution.   
Linkage of the function of interest, the T7 RNA polymerase binding to the T3 promoter, was 
achieved by deleting gene III from the phage genome and replacing it with the T7 RNA 
polymerase gene (Figure 17). The gene III was cloned into an accessory plasmid (AP) under 
the control of the T7 promoter, so that pIII expression and therefore the phage infectivity 
depends on the activity of the T7 RNA polymerase variant on the phage genome. When the 
evolving gene mutant encodes an active T7 RNA polymerase variant, pIII is expressed and 
infective phage particles are released. The progeny phage produced from a cell infected with 
a phage containing an inactive T7 RNA polymerase variant do not induce pIII expression and 
are not rendered infective. Additionally, the infective phage titer production varies according 
to the activity levels of the T7 RNA polymerase mutant, which defines the pIII expression 
levels. Thus in the lagoon only recombinant phage encoding active enzyme variants are 
infective and propagate. Furthermore, phages containing variants with the highest activity 
levels will infect more host cells. The evolving population for the T7 RNAP evolution 
experiments was  around 1010 phages (Bryan C Dickinson, Leconte, Allen, Esvelt, & Liu, 
2013).  
In the lagoon, T7 RNAP gene variation was introduced by using host cells containing a 
mutagenesis plasmid (MP), which encodes a DNA polymerase dominant negative 
proofreading subunit (Figure 17). Expression of this subunit leads to decreased fidelity of the 
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DNA polymerase. For a 1000 base pairs evolving gene, the mutagenesis rate was estimated to 




Figure 17. Schematic representation of the PACE system (Esvelt et al., 2011). In the lagoon, there is 
a linkage of selective replication of T7 RNAP gene variants recognizing the T3 promoter with 
selective phage propagation. This is achieved by replacing the gene III on the phage genome with the 
T7 RNAP coding sequence. The gene III is cloned into an accessory plasmid (AP) under the control 
of the T3 promoter (PT3). T7 RNAP gene variation in the lagoon is introduced by the mutagenesis 
plasmid (MP), which encodes a DNA polymerase dominant negative proofreading subunit. The host 
cell strain contains both the AP and the MP. When a phage encoding a functional T7 RNAP variant 
infects a host cell, it recognizes the T3 promoter and induces the expression of pIII. Consequently, the 
phages particles that are released from this cell are infective and the functional T7 RNAP variants 
keep replicating in the lagoon. In contrast, a phage encoding an inactive T7 RNAP does not recognize 
the T3 promoter and non-infective phage particles are produced from this cell. Continuous inflow and 





2.1.6. Selectively Infective Phage (SIP) technology  
Selectively infective phage (SIP) technology was developed in 1994 (Dueñas & Borrebaeck, 
1994) with aim the selections of binding proteins from libraries of variants of a gene by 
linking binding to phage infectivity. SIP was further explored and evaluated by other 
researchers (Krebber, Spada, Desplancq, & Plückthun, 1995; Krebber et al., 1997; Jung, 
Arndt, Müller, & Plückthun, 1999), but never reached routine use in antibody selections.  
SIP is based on the phage coat protein pIII which is essential for phage infectivity. The three 
domains of pIII (N1, N2 and CT) are joined by two linkers (G1 and G2). The attribute that 
makes pIII suitable for SIP is the fact that phage infectivity is dependent on the presence of 
the N-terminal domain (N1). Phages expressing only the CT-N2 domain or CT domain are 
not infective, but the infectivity is restored when the N1 or N1-N2 is associated with the CT-
N2 or CT domain, respectively, by a non-covalent interaction. Thus, an interaction of a scFv 
with its cognate ligand could trigger phage infectivity. In the most common SIP format, the 
N1-N2 domains are deleted from the phage genome and fused to the peptide ligand of the 
scFv, while the scFv coding sequence is cloned into the phage genome so that it can be 
expressed as a CT- scFv fusion protein on the phage surface. The scFv variants exhibiting 
high affinity and specificity for the peptide ligand, interact with the N1-N2-ligand fusion 
protein, which leads to reconstitution of the pIII protein and consequently to a selectively 
infective phage (Figure 18). The coding sequences of scFv mutants that survive the selection 
are recovered because the phage genome confers resistance to an antibiotic marker and 




Figure 18. pIII is comprised of the domains N1, N2 and CT joined by flexible linkers (G1 and G2). 
The N1 domain confers phage infectivity. Phages containing only the CT domain on their surface are 
non-infective, even when the N1-N2 domain is present. A phage displaying an scFv-CT fusion is 
rendered infective only if the scFv (red shape) binds to its cognate peptide ligand (green shape). The 
phages that contain N1-N2-ligand fusion bound on the scFv are called “selectively infective phages”. 
Adapted from (Krebber et al., 1995) 
 
  
2.1.7. In vitro and in vivo SIP technologies 
There are two different types of SIP: in vivo and in vitro SIP. For in vitro SIP, the phage 
displaying the binding protein fusion (CT-ScFv) and the N1-N2-ligand fusion are separately 
produced and purified and then mixed to yield infective phages (Figure 19) (Krebber et al., 
1997; Pedrazzi, Schwesinger, Honegger, Krebber, & Plückthun, 1997; Cèbe & Geiser, 2000). 
In in vivo SIP, both the ligand and the scFv fusion proteins are encoded on the phage 
genome. Appropriate leader sequence drive N1-N2-ligand expression to the bacterial 
periplasm, while the CT-scFv remains anchored to the bacterial inner membrane. When an 
interaction occurs in the bacterial periplasm the phage incorporate reconstituted CT-
ScFv:N1-N2-ligand protein, which renders it infective (Figure 19) (Krebber et al., 1995; 
Spada, Honegger, & Plückthun, 1998). In vivo and in vitro SIP has been studied extensively 
as they could represent fast selection methods for identification of high affinity binding 
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proteins. But there are some limitations in the application of both in vitro SIP and in vivo SIP 
technologies (Jung, Arndt, Müller, & Plückthun, 1999).  
There are two published studies referring to affinity selections by in vivo SIP (Krebber et al., 
1995; Spada, Honegger, & Plückthun, 1998). Krebber in 1995 cloned the CT-scFv coding 
sequence of an anti-hemagglutinin (HA) peptide scFv (KD  2×10-8M) on the phage genome. 
Both the scFv-CT and the N1-N2-HA fusion proteins were encoded on filamentous fd phage 
genome. After overnight phage production, around 1010 selectively infective phages were 
used to infect E. coli cells. The infectivity was quantified by counting the number of colonies 
after infection: 228 colonies were observed, suggesting that 228 phages out of 1010 were 
infective. Thus the efficiency of the method in this study was very low (2.2×108-fold lower 
infectivity than that of the wild-type phage), although it was successfully used for selection of 
binding proteins in vivo (Spada,  Honegger, & Plückthun, 1998).  
 
 
Figure 19. Schematic representation of in vitro and in vivo SIP technology (Krebber et al., 1997). In 
in vivo SIP both the ScFv-CT and the N1-N2-peptide ligand (Ag) fusion protein are cloned in the 
phage genome. In in vitro SIP, only the ScFv-CT fusion protein is cloned in the phage genome. The 
N1-N2-Ag fusion protein and phages particles displaying the scFv are produced separately and then 
mixed in vitro. PM, bacterial periplasm 
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The efficiency of in vitro SIP was higher than that of in vivo SIP (Krebber et al., 1997). When 
beta-lactamase (31 kDa) was inserted between the N1 and N2 domains (phage-CT-N2-Bla-
N1) the infectivity was 104-fold lower than that of the wild-type phage, showing that the Bla 
insertion caused steric hindrance, probably because of the disruption of the inter-domain 
interaction between the N1 and N2 domains. The same result (104-fold lower infectivity) was 
obtained when an anti-fluorescein scFv with KD of 3×10-10 M was fused to the CT-N2 
domain while the antigen (fluorescein) was conjugated to the N1 domain, to form a 
selectively infective phage (phage-CT-N2-ScFv: fluorescein-N1). The fact that both a 
covalent and a non-covalent interaction resulted in the same infectivity suggests that 
selectively infective phages can be infective. Consequently, this is not a factor that restricts 
the efficiency of in vitro or in vivo SIP technology. The efficiency of other factors, as steric 
hindrance of the scFv insertion and production of selectively infective phages could be the 
factors resulting in so low infectivity. 
 
2.1.8. Affinity maturation of a scFv by in vitro continuous evolution 
Using a continuous evolution set-up sequence space can be explored in a different way, 
raising the possibility of fundamentally altering the strategy of combinatorial methods. 
Normally we conduct very stringent selections that yield very few hits that are then re-
randomised. However, this is very different from the way Nature evolves biomolecules.  The 
near-neutral theory of natural evolution (Ohta, 1992) suggests that only a fraction of 
differences between homologous genes lead to improvements in fitness. The remaining 
majority of observed polymorphisms are the result of genetic drift exploring neutral networks 
of functionally equivalent genes. Such genetic drift that leads to cryptic variation (neutral to 
current function) has been suggested to be beneficial to subsequent adaptive evolution 
(Davies EK, 1999; Masel, 2006; Wagner, 2011). The conditions of the continuous evolution 
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“lagoon’ in which competition occurs can be manipulated, so that either regimes of neutral or 
more stringent adaptive evolution are favoured. For example, will the phylogeny of selected 
clones be more diverse (in contrast to the severe bottlenecking that a stepwise process 
implies) and will the broader sampling of sequence space accelerate evolution leading to 
ultimately better binders?  
In this way scFvs relationship between the whole protein sequence and high affinity could be 
explored for the first time. This objective could be achieved by using continuous in vitro 
evolution. Continuous in vitro evolution of binding proteins has not been described so far, but 
the development of a continuous in vitro evolution system (PACE) by Esvelt and Carlson 
(2011 and 2014) suggested a practical way of conducting such experiments. Based on the 
PACE system we would like to use this method for continuous evolution of protein binding 
properties. As it was shown by Esvelt such a system would allow large protein populations to 
evolve over hundreds of rounds of evolution in short time. As the number of rounds 
performed and the size of population are determinants of in vitro evolution experiments, the 
mutants that could be sampled by PACE are significantly higher than for any other 
conventional in vitro evolution approach, so the improvements in the desired property that 







2.2. Results and Discussion 
2.2.1.  Using SIP technology to link protein affinity to infective phage production in 
PACE 
To develop a PACE process for continuous evolution of the affinity of protein binders to their 
cognate ligands, SIP technology was used to link the affinity to the production of infectious 
progeny. The chosen protein binder was a scFv fused to the CT domain of the pIII protein, by 
cloning the coding sequence of the CT-protein binder fusion into the genome of a phage M13 
strain lacking gene III. To couple pIII protein reconstitution to the desired function, the 
coding sequence of the N1-N2-peptide ligand fusion could be cloned into an accessory 
plasmid (AP) which would be present in the host cells. Only phages with variants of the 
protein binder with high affinity to their cognate peptide ligand would be able to induce 
sufficient pIII reconstitution, propagate and persist in the lagoon (Figure 20). 
 
A possible implication is that high pIII expression before phage infection leads to inhibition 
of phage infectivity (Carlson, Badran, Guggiana-Nilo, & Liu, 2014a). Particularly, when the 
half N-terminal domain (residues 1-198) of pIII is expressed the infection is inhibited. 
Expression of the N1-N1-ligand fusion protein under the control of the lac promoter would 
probably lead to high background expression and decreased infection due to inhibition of 
infection by the N1-N2-ligand fusion protein. To deal with this problem in PACE evolution 
experiments for pIII expression, Carlson and the others used a promoter, the Ppsp promoter, 
which is induced only after infection of the host cell by the phage. This promoter could be 
used for N1-N2-ligand peptide expression in SIP and successful propagation of selectively 




Figure 20. PACE format for affinity maturation by continuous evolution based on SIP technology. In 
the lagoon, the linkage of selective replication of scFv variants binding the desired ligand peptide is 
achieved by replacing the gene III on the phage genome with the scFv-CT coding sequence. The N1-
N2-ligand coding sequence is cloned into an accessory plasmid (AP) under the control of the Ppsp 
promoter (phage shock promoter), which is induced only after phage infection.  
 
 
2.2.2. Factors that determine the efficiency of in vivo SIP  
As mentioned above, the efficiency of in vivo SIP for selections of scFv variants with high 
affinity was shown to be very low (Krebber C, 1995; Spada S, 1998). For the scFv 17/9 with 
KD of 2×10-8 M, 228 selectively infective phages were produced out of 1010 input phages (1 
infective phage out of 108 input phages). To apply this method for PACE, all the input phages 
of a protein binder with KD as high as 2×10-8 M should be selectively infective. Otherwise, 
the selectively infective phage population would start to drop in the lagoon and the phage 
encoding the parent protein would not propagate. There are multiple factors that determined 
the efficiency of in vivo SIP in previous experiments that could be improved and proposed 
solutions are analyzed in the paragraphs below. 
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Different scFv variants of a phage library may present different levels of expression and 
degradation of the scFv-pIII protein fusion. scFv expression and degradation levels of the 
scFv-CT fusion when expressed in E. coli periplasm could be factors that impact the levels of 
scFv display on the phage particles and the percentage of phage that contain intact scFv 
fusion protein. Therefore, if the parent scFv 17/9  presents high levels of degradation 
(O’connell, Becerril, Roy-Burman, Daws, & Marks, 2002), an alternative binder with better 
expression and degradation profile could improve the efficiency of in vivo SIP. DARPins 
could be an alternative to scFvs as these are expected to have higher expressed levels in the 
E. coli periplasm and probably lower degradation levels of the DARPin-CT fusion protein. 
Consequently, DARPins are expected to have better phage surface display levels and could 
be the protein scaffold chosen for display in our continuous evolution experiments.  
O'Connell (2002) observed that the scFvs display levels on phage particles was higher when a 
phage instead of a phagemid library was used (O'Connell D, 2002). The authors propose that 
this could be partially because of the use of the natural gene III phage promoter (PgIII), 
which would probably lead to lower but well-regulated scFv fusion expression. Increased 
expression of the scFv expected from the Plac promoter may lead to lower than higher phage 
surface expression (due to toxicity to E. coli). The lac promoter was used to drive the 
expression of the scFv-CT fusion protein for in vivo SIP (Krebber C, 1995; Spada S, 1998). 
Alternatively, the natural gene III phage promoter (Pg III) couls be tested for better scFv-CT 
phage surface display levels.  
During selectively infective phage production the phages were produced overnight at 25°C. Is 
the N1-N2-HA fusion protein expected be bound to the phage-scFv after overnight 
incubation? This is unlikely, as even for an scFv of Koff in the range of 10-4 s-1, the residence 
time to the ligand binding site is around 2 hours. In order to reduce the incubation time, a 
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protocol for phage production with shorter incubation times at higher temperatures could be 
examined. 
When an antibiotic resistance marker gene is inserted into the phage genome, the levels of 
phage replication are lower than that of the wild-type phage. Different antibiotic resistance 
markers have different impact on phage propagation (Krebber et al., 1995). For in vivo SIP, 
chloramphenicol was used as it was found to have the lower impact on the phage titer, but 
there was still 100-fold decrease in the phage titer. When kanamycin was used the phage titer 
presented a 104-fold decrease, even higher than that of chloramphenicol. In PACE 
experiments, the improved phage vector that was used for evolution of the T7 RNAP had no 
antibiotic resistance marker (Esvelt et al., 2011). Use of antibiotic resistance markers may 
have had an impact on the selectively infective phage production, but it is necessary for the 
infectivity assay by which the selectively infective phage titer determination is performed. As 
an alternative a plaque assay instead of an infectivity assay for infective phage titer 
determination could be explored.   
When beta-lactamase (31kDa) was inserted between the N2 and CT domains there was a 
100-fold decrease in infectivity of the N1-N2-Bla-CT phage compare to the wild type phage 
(N1-N2-CT). The efficiency of in vitro SIP was shown to decrease when larger size protein 
binders were used (Cèbe & Geiser, 2000). This is a problem that could be addressed by 
applying an in vitro evolution approach to adapt the function of N1-N2 domains of the N1-




2.2.3.  Experimental efforts to improve in vivo SIP for PACE  
The first experimental step was to reproduce the in vivo SIP experiment using the scFv-ligand 
pair that has been used before by Krebber (1995) while introducing some of the changes 
according to the observations that were analyzed above (section 2.2.1).  
 
2.2.3.1. Construction of vectors for SIP  
For the N1-N2-ligand fusion protein expression in the E. coli periplasm the vector pUC-N1-
N2-MCS (Figure 21) was constructed. The N1-N2 coding sequence is followed by an MCS 
(multi-cloning site) for cloning of the peptide ligand coding sequence. The N1-N2 amino acid 
sequence that was chosen to be fused to the ligand peptide is shown in the Figure 22 
(Holliger, Riechmann, & Williams, 1999). On the pUC-N1-N2-MCS, the transcription of the 
N1-N2-ligand fusion is under the control of the lac promoter and the lac operator and the 
localization of the fusion protein is directed by the signal peptide (pelB) that directs the 
protein to the bacterial periplasm. After the pUC-N1-N2-MCS vector construction, the HA-
peptide coding sequence encoding for a 30 amino-acid long peptide, was cloned into the 
MCS of the vector to result in the N1-N2-HA expression vector, the pUC-N1-N2-HA 
(Figure 23). Additionally, the vector pUC-g3p was constructed. This vector contains the wild 
type gene III under the same expression control (pelB, lacP/O) and it could be used as a 
positive control in some SIP experiments or for infective phage production from phages that 
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Figure 21. A) Map of pUC-N1-N2-MCS vector B) In the vector pUC-N1-N2-MCS, the N1-N2 
coding sequence is followed by an MCS (multi-cloning site) for cloning of the peptide ligand coding 
sequence. 
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Figure 22. A) The N1-N2 amino-acid sequence that was chosen to be fused to the ligand peptide is 
shown between the red angles. B) The choice of the N1-N2 domain sequence was based on the pIII 




Figure 23. Map of pUC-N1-N2-HA vector. This vector was used for N1-N2-HA fusion protein 
expression in the E. coli periplasm.  
 
2.2.3.2. Construction of recombinant phages  
In contrast to the previous SIP experimental efforts, where the filamentous phage fd was 
used, the phage that was chosen for SIP in this study was VCSM13. VCSM13 is a helper 
phage designed to be packaged in phage particles with lower efficiency than a phagemid in 
the presence of a phagemid (mutation Met40Ile in gII). However, VCSM13 is able to 
replicate in the absence of phagemid DNA. In addition, VCSM13 contains the origin of 
replication from P15A and the kanamycin resistance gene. VCSM13 was chosen because it 
was the phage vector used for T7RNAP evolution by PACE before (Esvelt et al., 2011), so its 
ability to propagate efficiently and to keep artificially inserted large fragment of DNA intact 
has been proven.  
The VCSM13-ScFv-CT phage vector was constructed for the scFv-CT fusion protein 
expression on the VCSM13 phage surface. The scFv-CT transcription on the phage genome 
is under the control of the wild-type gene III promoter. The scFv coding sequence was cloned 
downstream of the gene III signal peptide according to O’Connell (2002), who cloned a scFv 
library into a phage vector using the gene III signal peptide while adding a signal sequence 
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cleavage site that is commonly used when scFvs are expressed for phage display (QPAMA). 
This cloning step is usually achieved by using the restriction enzyme SfiI which recognizes 
GGCCNNNN^NGGCC sites and allows the insertion of the QPAMA sequence.  
The scFv was cloned in a VL-linker-VH orientation as it was done before (Krebber et al., 
1995). Part of the sequence of the final VCSM13-scFv-CT phage vector is shown in the 
Figure 24. Using a similar cloning strategy a recombinant phage with deleted N1-N2 domain 




Figure 24. The design of the recombinant phage VCSM13-scFv 17/9-CT. The scFv was cloned in a VL-
linker-VH orientation. The vector was designed based on the previously described scFv phage library 
design (O’connell et al., 2002). The scFv-CT fusion protein was directed to the E. coli periplasm using the 
gene III signal peptide and the signal sequence cleavage site QPAMA. The scFv was fused to the N-




The cloning strategy for the VCSM13-ScFv-CT phage construction is described in the 
Methods section. The cloning efficiency using this cloning strategy was low (5x104 cfu/ ug 
for E. coli cells, i.e. with transformation efficiency 1x1010 cfu/µg for pUC19 DNA (2×105-
fold lower than for pUC19). Such efficiency is very low for library construction, so in the 
future another cloning strategy should be cnsidered for construction of a scFvs or DARPin 
library.   
SIP experiments were performed using the E. coli strain S1030 (see Methods for the 
genotype), as this was the strain used in PACE evolution experiments (obtained from the Liu 
group from Harvard University).  
 
2.2.3.3. N1-N2-HA expression in E. coli periplasm  
The E. coli periplasmic fraction was obtained by freeze/thaw treatment of S1030/ pUC-N1-
N2-HA strain cells. The expression of the N1-N2-HA fusion protein was induced by the 
removal of glucose and addition of IPTG in the culture medium. The protein contained in the 
periplasmic fraction were separated by SDS-PAGE and functional expression of the N1-N2-
HA protein was confirmed by Western Blot using an anti-HA primary antibody (Figure 25), 
which binds to the epitope recognized by the scFv 17/9. As a negative control, the periplasmic 
fraction of S1030 cells produced in parallel with the S1030/ pUC-N1-N2-HA periplamic 
fraction was used.  
The size of the protein pIII is around 60 k Da, while that of the pIII CT domain is around 23 
k Da (O’connell et al., 2002). It can be concluded that the size of the N1-N2-HA fusion 
protein was higher than 37 k Da. Since the Western Blot using an anti-HA antibody resulted 
in only one band which has a size similar to the predicted size of the N1-N2-HA fusion 
protein, it can be inferred that the N1-N2-HA protein was functionally expressed in the E. 
coli periplasm.  
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Figure 25. Western Blot of E. coli periplasmic fractions separated by SDS-PAGE. An anti-HA 
antibody was used for detection of the N1-N2-HA fusion protein. Lanes:  
1. Protein ladder 
2-3. S1030/ pUC-N1-N2-HA E. coli periplasmic fraction 
4-5. S1030/ pUC-N1-N2-HA E. coli periplasmic fraction, with 100 mM DTT 
6. Negative Control: S1030 E. coli periplasmic fraction  
 
 
2.2.3.4. VCSM13 titration by plaque assay, infectivity assay and ELISA 
VCSM13 titration by ELISA  
In in vivo SIP, phage particles that contain N1-N2-ligand bound to CT-scFv fusion protein 
are called selectively infective phages. To estimate the percentage of selectively infective 
phage particles, a known number of input phages is used to infect E. coli cells and the 
number of colonies that grow in the presence of the appropriate antibiotic equals the number 
of selectively infective phages. ELISA is a method that could be used for titration of the input 
phage particles. Phage particles can be detected using an HRP-conjugated antibody against 
the major coat protein pVIII, which is present at approximately 2700 copies per phage 
particle and by comparing the signal of the input phages to that of serial dilutions of 
VCSM13 phage particles with known titer. In the Figure 26, VCSM13 was amplified using 
S1030 host cells and serial dilutions of VCSM13 phage particles in the supernatant of 
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unkown titer were detected by ELISA. It seems that it is possible to estimate the 
concentration of phages particles contained in the samples by using this method. 
 
 
Figure 26. VCSM13 phage supernatant titration by ELISA. Starting from unknown phage titer, the 
blue line depicts 2-fold serial dilutions of the phage supernatant. The red line shows 2-fold serial 
dilutions of the same supernatant starting from already 1024-fold diluted sample.  
 
VCSM13 titration by plaque assay 
A plaque assay was performed in order to confirm that the titer estimated by plaque assay, 
ELISA and infectivity is the same. In the Figure 27, an ELISA of phage VCSM13 
supernatant with titer determined by plaque assay is shown (starting from 6×1010 pfu/ ml, 10-
fold serial dilutions). The titer of the same sample was also determined by infectivity assay. 
The estimation of the phage concentration obtained by the plaque assay and the infectivity 
assay was different, 6×1010 pfu/ ml and 2×108 cfu/ ml, respectively.  
The reason why the titer may be underestimated by the infectivity assay is not known. In 
phage display a similar infectivity assay is commonly used for estimation of the phage titers. 
The difference is that in phage display the phagemid (which is a high copy plasmid of around 
4.5 kb) and not the phage genome contains the antibiotic resistance marker gene, which is 
also a different resistance marker (ampicillin instead of kanamycin). This is why as an 
alternative to infectivity assay, a plaque assay for SIP selectively infective phage 
determination was developed as an alternative to infectivity assay. 
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Figure 27. VCSM13 phage supernatant ELISA. Starting from 6×1010 phages/ ml, the blue line shows 
10-fold dilutions of the sample. The titer of the same supernatant was determined by plaque assay. 
 
 
2.2.3.5. Determination of scFv phage surface display levels  
To assess the levels of scFv-CT fusion expression and degradation, a Western Blot of an 
SDS-PAGE gel of the phage supernatant could be performed. However, it was not known 
how many phages are required for successful detection of the scFv-CT fusion and assessment 
of its expression and degradation levels. Additionally, if the detection was sensitive enough, a 
Western Blot of the SIP input phages could be performed for detection and quantification of 
N1-N2-HA protein bound or not bound on the phage-scFv-CT phage.  
After 8 hours of phage production (as described in the Methods section), the supernatant 
containing the phage particles produced by S1030 cells infected with VCSM13 and that of 
cells that had not been infected with VCSM13 were loaded into a SDS-PAGE gel. After 
protein separation by SDS-PAGE gel electrophoresis, the phages were detected using an anti-




Figure 28. Western Blot of phage supernatant separated by SDS-PAGE. An anti-CT (pIII) antibody 
was used for detection of the pIII protein. Lanes: 
1. Protein ladder 
2. VCSM13 phage supernatant (no dilution, 3×109 phage particles) 
3. VCSM13 phage supernatant (5-fold dilution, 6×108 phage particles) 
4. VCSM13 phage supernatant (25-fold dilution, 1.2×108 phage particles) 
5. Negative Control: Supernatant of S1030 culture, non infected with VCSM13 
6. VCSM13 phage supernatant (no dilution), with 100mM DTT 
7. VCSM13 phage supernatant (1/5 dilution), with 100mM DTT 
8. VCSM13 phage supernatant (1/25 dilution), with 100mM DTT 
9. Negative Control: Supernatant of S1030 culture, non infected with VCSM13, with 100 mM 
 
 
The pIII protein size is around 60 k Da, so it was successfully detected. The surface 
expression and degradation levels of an scFv cannot be assessed by loading directly the phage 
supernatant directly onto the SDS-PAGE gel. Instead the phages were concentrated by 
polyethylene glycol (PEG) precipitation.  
 
2.2.3.6. Phage production assay for SIP  
As mentioned above, it is unlikely that the N1-N2-HA fusion protein is still bound to the 
phage- scFv during overnight production of selectively infective phages. In order to reduce 
the selectively infective phage incubation time before execution of the SIP infectivity assay, 
an alternative phage production with shorter incubation time at higher temperatures was 
examined, using the wild-type phage VCSM13 as a positive control.  
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The difference of the protocol that is outlined in the Figure 29 compared to the protocols of 
previous SIP experiments is that starting from a higher OD600 of infected cells, so from a 
higher cell concentration, and growing in higher incubation temperature (37 °C instead of 25 
°C), higher phage concentration in the supernatant is expected in shorter incubation time. In a 
shorter time of incubation more N1-N2-HA fusion protein is expected to be still bound on the 
phage-scFv phage particles and the selectively infective phages can be detected by an 
infectivity assay or plaque assay. 
 
 




The VCSM13 phage titer produced using this protocol was determined by ELISA (Figure 
30). Indeed, high phage titer was achieved using this protocol (either around 5×108 phages/ 
ml after 4 hours or 5×107 phages/ ml after 2.5 hours of incubation). Thus, this protocol could 
be used for selectively infective phage production.  
 
 
Figure 30. VCSM13 titer determination of VCSM13 phage supernatants produced following the SIP 
protocol after 2,5 (purple dot) or 4 hours (light blue dot) of phage production. The titer was 
determined by comparing with known phage titer (dark blue line) (10-fold dilution, starting from 









This chapter described efforts to use SIP technology for continuous evolution by PACE 
(Esvelt et al., 2011). For application of this technology for PACE high efficiency is required. 
Otherwise, in the lagoon, the selectively infective phage population would start to drop and 
the phage encoding the parent protein would not propagate. The work on improving SIP 
technology based on the ideas described in this report was not continued because of the 
difficulties in improving the efficiency of the SIP technology.   
Indeed a system for continuous evolution of protein binding was developed and published in 
Nature (Badran et al., 2016). The basis of this system was not the SIP technology, but a 
bacterial two hybrid system (Dove & Hochschild, 1998). But the two-hybrid system was not 
efficient enough for use in PACE. Thus, before using this system, they optimized the 
transcriptional activation >200-fold by changing several parameters including the DNA-
binding domains in order to increase the protein expression level. Additionally, enhanced 
transcriptional activation was achieved by modifying the distance between the operator and 
the promoter, the DNA-binding domain multivalency state, the reporter gene ribosome-
binding site, the affinity of the interaction between the promoter and the RNA polymerase 








3. Antibody affinity maturation using 
libraries with random indels  
 
 
The chapters III and IV describe my efforts to develop new approaches for construction of 
libraries with in-frame amino acid indels that would enable sampling of random indels of 
different lengths across the entire antibody variable domains and develop methods that could 
















3.1 Introduction  
3.1.1. Transposon-based methods for construction of libraries with random indels  
In Nature, the percentage of indels in affinity matured antibodies seems to be low, probably 
because, as discussed in the Introduction chapter, SHM does not sample random but only 
biased diversity, with insertions occurring only by duplication. Thus, there is the possibility 
that the antibody fold can tolerate higher percentage of indels that could be beneficial in 
terms of affinity, which could be identified by sampling higher diversity of random indels by 
in vitro evolution. Other researchers have not been able to sample random and high diversity 
indels, either because of restrictions in the diversity of indels that can be introduced by their 
method (Bowers et al., 2014) or because they only used rational instead of random 
approaches (Lamminmäki et al., 1999).    
Several attempts to develop methods for construction of libraries with random indels for in 
vitro evolution of proteins other than antibodies have been described in the literature. The 
polymerase pol η has been shown to introduce not only point substitutions but also deletions 
of two or more consecutive bases, while other polymerases, like pol b, generate only single-
base indels (Emond et al., 2008). This method could be used to generate variants combining 
high percentage of point mutations and deletions. Another replication-based approach is 
RAISE (use of TdT) which is based on gene shuffling to introduce not only point mutations 
but also indels in the target gene (Fujii, Kitaoka, & Hayashi, 2006). Using this method to 
mutate TEM β-lactamase some deletions that improved the activity more than point 
mutations were identified. Overall, these approaches can be used to sample short deletions 
combined with point mutations, but do not offer the capability to incorporate high diversity of 
random insertions, as most of these events were single-base additions.  
An approach that allows the generation of variants with insertions of variable lengths in 
random positions by sequence duplication, the so called tandem repeat insertion (TRINS), is 
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based on assembly PCR and rolling circle polymerization (Kipnis, Dellus-Gur, & Tawfik, 
2012). This process is restricted by generation of tandem repeats, instead of high diversity 
insertions. Random insertion/deletion (RID) mutagenesis has been developed to produce 
random insertions of any desired length (Murakami, Hohsaka, & Sisido, 2002). This method 
requires several inter-molecular DNA manipulations and can be difficult to use in generating 
large libraries. Overall, none of these methods allow the generation of libraries with high 
diversity in-frame insertions.  
Another approach to introduce random modifications into a target gene is by using 
engineered transposons. Mutagenesis using in vitro transposition has been used to insert 
penta-peptides in random positions of a target gene (Hallet, Sherratt, & Hayes, 1997; Hayes, 
Hallet, & Cao, 1997). This method is based on insertion of Mu transposons into a target 
sequence at random positions (Haapa, Taira, Heikkinen, & Savilahti, 1999), which is 
followed by removal of the transposon by restriction digestion. Modification of the 
transposon flanking sequences (transposase recognition sites; R sites), which can contain any 
sequence, result is a specific sequence modification at the position of the removed 
transposon.  
The most important innovation has been developed by Jones (2005), who made an 
engineered Mu tranposon with a type IIS restriction endonuclease (MlyI) restriction site at 
the flanking sequences. The design of this transposon leads to removal of a triplet nucleotide 
upon MlyI digestion while the transposon is taken away from the target gene. Subsequently, 
the triplet can also be replaced by an alternative triplet nucleotide (Baldwin, Busse, Simm, & 
Jones, 2008) or the sequence of a whole domain (Edwards, Busse, Allemann, & Jones, 2008), 
which is achieved by using a secondary cassette that contains the desired modification.  
Very recently, Stephane Emond a post-doctoral researcher in Florian Hollfelder’s group, 
based on Jones’s method, created novel cassettes that allow the deletions of double or triple 
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triplets (Emond et al, in preparation; Figure 31). Emond’s major innovation is the 
development of a method which is based on the same principle, but with completely novel 
use of restriction sites and secondary cassettes, allowing the construction of libraries with 
insertion of triplet nucleotides of different lengths (one, two or three triplets) (Emond et al, in 
preparation; Figure 32). These methods have already been applied by Emond to study 
enzyme specificity by in vitro evolution. This chapter describes the use of these methods to 
build antibody libraries with high diversity of random indels which were used for in vitro 






Figure 31. Schematic representation of the transposon-based approach for construction of libraries 
with random 3-nt (D. D. Jones, 2005), 6-nt and 9nt deletions (Emond et al, in preparation). Insertion 
of the transposon TransDel at random positions of the gene of interest is followed by removal of the 
transposon by digestion using the restriction site MlyI at the flanking sequences of the engineered 
transposon. Intramolecular ligation of the library plasmids results in the deletion of a single triplet 
nucleotide, while insertion of a secondary cassette (Del2 or Del3) followed by MlyI digestion leads to 






Figure 32. Schematic representation of the transposon-based approach for construction of libraries 
with random 3-nt, 6-nt and 9nt insertions (Emond et al, in preparation). Insertion of the transposon 
TransIns at random positions of the gene of interest is followed by removal of the transposon by 
digestion using the restriction sites MlyI/NotI at the flanking sequences of the engineered transposon. 
Insertion of secondary cassettes (Ins3, Ins6 or Ins9), which contain NNN triplet insertions followed by 
AcuI digestion leads to addition of single, double or triple triplet nucleotide insertions. Adapted from 





3.1.2. BAK1 as a model antibody for in vitro affinity maturation  
To study the impact of indels on antibody affinity by in vitro evolution, I used as a model the 
anti-IL-13 antibody BAK1. By choosing BAK1 as a model for indel-based affinity 
maturation I hoped to compare and contrast the outcomes of in vitro evolution using either 
indels or point substitutions and to test whether the two strategies might synergise.    
Previously, BAK1 has been affinity-matured by Thom et al. (2006) using substitution-based 
approaches. To achieve higher affinity both random and targeted point mutagenesis 
approaches were used for library construction. Except from the classic approach of 
construction of targeted VH CDR3 libraries, the design of libraries targeting other CDRs was 
guided by scanning the entire BAK1 scFv sequence for mutations that may be related with 
affinity gains (mutational hotspots). The scanning was performed by ribosome display 
combined with ep-PCR mutagenesis between the rounds of selection. Identification of 
mutational hotspots was followed by construction of libraries targeting these hotspots with 
the full diversity of amino acid substitutions. These libraries also contained combinations of 
beneficial mutations in different CDRs to take advantage of additive effects on affinity.  
The majority of beneficial substitutions were not found in the CDR3s but in the VL CDR1, 
underlining the importance of targeting all CDRs to find beneficial point substitutions. 
Furthermore, the majority of the mutation hotspots were located in the CDRs (84%), which is 
in agreement with preferential selection of CDR mutations during SHM of human antibodies 
in Nature. This evolution campaign gave rise to a variant with two point substitutions that 
conferred large improvement in affinity and improved potency, BAK1.1 (Thom et al., 2006), 
which has subsequently entered the clinical trials as a therapeutic candidate for the treatment 
of asthma (May et al., 2012). BAK1.1 has two point substitutions in the loops VH CDR3 
(N99S) and VL CDR1 (N27I) (Figure 33). Hotspots were also identified in other CDRs, the 
VH CDR1 and the VH CDR2. Other variants, with small improvements compared to BAK1.1 
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(≈2-fold), were generated by a CDR walking mutagenesis approach by combining the 
BAK1.1 mutations with mutations in the VH CDR1 or VH CDR2. Although additionally to 
the BAK1.1 mutations, the highest affinity variant (BAK1.45) has several mutations in the 
VH CDR2, the major improvements in affinity were attributed to the BAK1.1 mutations, 
which is the variant that was chosen to proceed in clinical tests.  
Recently, a co-crystal structure of BAK1.1 with human IL-13 was determined (Popovic et al., 
2016), which shows that it is mostly VL regions that are driving paratope interactions; the VL 
CDR2 provides residues that form a network of hydrogen bonds and a salt bridge in the core 
of binding. The paratope is composed of residues of the VL CDR1, VL CDR2, VL CDR3, VL 
FW3 and VH CDR3.  
 
 
Figure 33. BAK1.1 co-crystal structure with IL-13. The BAK1.1 variant has two substitutions (in 
blue) that improve BAK1 affinity. The VH CDR1, VH CDR2 and VH CDR3 loops are coloured in 
wheat, salmon and pale cyan, while the VL CDR1, VL CDR2, VL CDR3 in blue white, pale green and 




3.2. Results  
3.2.1. Library construction   
BAK1 scFv libraries with random indels throughout the entire antibody V-gene were 
constructed using the transposon-mediated approaches developed by Emond (Emond et al., in 
preparation) (Fig. 34 and 35). The BAK1 libraries 3nt-Del, 6nt-Del, 9nt-Del and 3nt-Ins 
contain 3, 6 and 9 nucleotide deletions and 3 nucleotide insertions (triplet NNN), 
respectively. Although it is possible to produce libraries with insertions of different lengths 
(3, 6 and 9nt), only the library with small insertions (3nt-Ins) was constructed, because it was 
considered important to build libraries that cover the diversity of all the possible variants. For 
a scFv coding sequence that is comprised of 750 bp, the number of all possible variants with 
single, double or triple amino acid insertions is 4.8×104, 3×106 and 2×108, respectively. Since 
the library size that can be achieved with this method is 2×106 members, it would be 
difficult to cover the full diversity of a library with insertions longer than a single amino acid. 
It is technically possible to reach a 10-fold larger library size, suggesting that someone could 







Figure 34. Schematic representation of the process of construction of libraries with single, double or 
triple triplet deletions (3nt-Del, 6nt-Del and 9nt-Del) of a target gene of interest. The engineered 
TransDel transposon, which contains type IIS restriction endonuclease (MlyI) flanking sequences, is 
inserted at random positions of the gene of interest by in vitro transposition. The TransDel is designed 
in a way that removal of the transposon by Mly digestion and self-ligation of the library plasmids 
results in deletion of a triplet nucleotide. For construction of the 6nt-Del or 9nt-Del libraries, cloning 
of a secondary cassette (Del2 or Del3) followed by digestion with MlyI is used to remove double or 






Figure 35. Schematic representation of the process of construction of libraries with single, double or 
triple triplet insertions (3nt-Ins, 6nt-Ins and 9nt-Ins) of a target gene of interest. The engineered 
TransIns transposon, which contains MlyI/NotI flanking sequences, is inserted at random positions of 
the gene of interest by in vitro transposition. Removal of the transposon by MlyI/NotI digestion is 
followed by cloning of an MlyI/NotI cassette (Ins1, Ins2 or Ins3) which contains single, double or 
triple NNN triplet insertions, respectively. Following digestion with the type IIS restriction 
endonuclease AcuI, the 3' overhangs are removed by using the Large (Klenow) Fragment of the DNA 
Polymerase I (3’ -> 5’ exonuclease activity). Self-ligation of the plasmids leads to insertion of single, 




The quality of the libraries was assessed by sequencing of 88 variants from each library and 
is shown in Table 1: the 3nt-Del, 6nt-Del, 9nt-Del and 3nt-Ins libraries contained 86.4, 17, 
29 and 35.6 % variants with indels of the desired length, respectively. For each library, the 
functional library size was calculated by multiplying the total percentage of variants with in-
frame indels with the actual library size. The fact that the functional library sizes (1.7×106, 
3.4×105, 5.8×105 and 7.1×105, respectively) were at least 10-fold higher than the theoretical 
library sizes (7.5×102, 7.5×102, 7.5×102 and 4.8×104, respectively) showed that the 
percentages of variants with in-frame indels was high enough to cover the theoretical 
diversity of each library, with actual size 2×106. The percentage of in-frame indel variants 
with extra point mutations across the scFv sequence was negligible (0-1.5%). As a 
consequence, epistatic interactions between indels and random point substitutions should not 
affect the outcome of the selection, as deleterious or beneficial point substitutions would not 
mask the effect of beneficial indels.   
Furthermore, the sequence analysis (Table 1) detected only very few repeats of the same 
sequence, with very high (> 90%) percentage of variants with indels at unique positions, 
demonstrating that indels were randomly distributed across the entire scFv sequence and the 
gene is fully covered. Furthermore, observation of the amino acid residues of the 3nt-Ins 
library did not reveal any amino acid biases (Figure 36): we observed that 100% variants 
possessed unique insertions, with 14/28 insertions of unique amino acid residue.  
Overall, the quality control suggests that libraries with random deletions and high diversity 
insertions across the entire scFv gene without extra point substitutions were successfully 
generated and that this custom-made diversity in sequence space can be explored in library 






Table 1. Sequence analysisa of BAK1 libraries with random indels.  
 
a The analysis was based the sequences of 88 variants from each library. For each library, the 
functional library size was calculated by multiplication of the total percentage of variants with in-






Figure 36. BAK1 library with random single amino acid insertions. Insertions (blue dashes) are 
randomly distributed across the entire (A) VH and (B) VL regions. The amino acid residues of the 






3.2.2. Affinity-based selections of recombined BAK1 indel libraries  
To identify indel variants with improved affinity, panning selections of the BAK1 indel 
libraries were performed by ribosome display (J Hanes & Plückthun, 1997). Figure 37 shows 
an overview of the process that was followed to identify variants with improved affinity from 
the BAK1 libraries with random indels. Ribosome display was the method of choice because 
the PCR step before each selection round enables recombination and sampling of very large 
library sizes (more than 5×1011 variants). By contrast, phage display would have only 
afforded 109 - 1010 variants and compartmentalised droplet selections (e.g. SNAP display) 




Figure 37. Overview of the process that was followed for identification of improved variants, by 
recombination of BAK1 libraries with random indels and selection by ribosome display.    
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To take advantage of potential synergistic effects between indels, variants with more than one 
indel per gene were created before the first round of selection, by recombination of a mix of 
the BAK1 indel libraries (3nt-Del, 6nt-Del, 9-nt Del and 3nt-Ins) using the staggered 
extension process (StEP) in vitro recombination (Zhao, 1998). Based on sequencing analysis 
of 176 variants of the recombined library (Table 2 and Figure 38), the input of the selection 
round 1 was composed of 31.3% parent, 26.9% in-frame single indel variants, 9.2% in-frame 
double indel variants and 32.6% out-of-frame indels variants. Thus, the functional library 
sizes of single (1.4×1011) and double (4.6×1010) indel variants were at least 10-fold higher 
than the theoretical library sizes (5×104 and 1.26×109), which suggests that not only all 
possible single variants, but also high number of all possible double indel variants were 
present in the recombined library. The large diversity of double indel variants in the 
recombined library shows that the recombination step allowed a search for synergistic 
interactions between indels.  
Four rounds of high stringency selections were performed by panning with recombinant 
biotinylated IL-13 concentrations below the KD, using the lowest possible IL-13 
concentration in each round. The concentrations that were used were 100, 20, 20 and 20 pM 
















Table 2. Sequence analysisa of recombined BAK1 indel library mix.  
 
a The analysis was based on the sequences of 176 variants from each library. The number of possible 
single indels variants was the sum of possible variants of each indel library (see Table 1). The 
functional library size was calculated by multiplication of the percentage of in-frame variants with the 







Figure 38. A) Recombination of a mix of the BAK1 indel libraries (3nt-Del, 6nt-Del, 9-nt Del and 
3nt-Ins) created variants with more than one indel per gene. B) The recombined BAK1 indel 
library contained high percentage of single and double indels variants.  
 
 106 
3.2.3. Sequencing analysis of selection outputs   
The highest affinity variants were identified by assessing the enrichment of individual 
variants from the analysis of the sequences of the selection outputs (176 variants from each 
output) from rounds 1 to 4. Between the selection rounds, an alternative PCR protocol was 
followed to keep the mutagenesis rate low and avoid contamination of the selection with high 
affinity variants with point substitutions by using a very high fidelity DNA polymerase 
instead of the low fidelity polymerase which is usually used for ribosome display selections. 
Although the percentage of BAK1 variants with point substitutions in round 4 was low, four 
variants with single point substitutions were enriched (Table 3). Two of these point 
substitutions were found before to improve BAK1 affinity, BAK1.4 (VL CDR1 N27Y) and 
BAK1.0 (VH CDR3 N99S) and the combination of these two point substitutions make up the 
variant BAK1.1, suggesting that the results are in agreement with the previous outcome of 
ribosome display selections of BAK1 (Thom et al., 2006). In addition, two more variants 
with single point substitutions in FWR positions were identified, the VH FWR2 E46K and VH 
FWR3 M80R, which could potentially have a beneficial effect on BAK1 affinity.  
Among the in-frame indel variants, a group of variants with an insertion and a substitution at 
the same position within the VL FWR3 (BAK1-INS variants, Figure 39) were enriched over 
the rounds, reaching 98% of the total indel variants in round 4; a single amino acid insertion 
after residue S67 and a substitution of G68. The other in-frame indel variant that was found 
in round 4 contained a G52a insertion in the VH CDR2, after the residue S52. The amino acid 
types that were enriched were insertion of 67aE, 67aV, 67aD or 67aA combined with 
substitution G68W or G68R. One variant, BAK1-INS1, dominated the selection outcome in 
round 4 (41%) (Figure 40): it has an 67aE insertion and a G68W substitution. Assuming that 
the most enriched variant had the highest affinity, the variant BAK1-INS1 was converted to 
an IgG1 format and was characterized in terms of kinetics.  
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Table 3. Variants with single point substitutions in selection round 4.  
 
 




                B 
 
Figure 39. Selections of the recombined BAK1 indel libraries. A group of variants with different 
amino acid insertion and a substitution at the same position in the VL FWR3 (BAK1-INS variants) 
were enriched, reaching 90% of the total indel clones in round 4.  
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Figure 40. The pie chart shows the predominance of the variant BAK1-INS1 in round 4 (42%), with 
an insertion VL 67aE and a substitution G68W. Sequence numbering according to Kabat (T. T. Wu & 
Kabat, 1970).  
 
3.2.4. Beneficial effect of insertion in the FWR3   
To find out if the insertion of the BAK1-INS1 variant conferred an improvement in affinity, 
the KD values of the BAK1 IgG variants, which were constructed by site-directed 
mutagenesis, were measured by surface plasmon resonance using the Biacore (Table 4). 
14.3-fold higher affinity (KD=140 pM) was observed for the insertion variant compared to the 
parent (KD=2,300 pM). No gain in affinity was observed in variants bearing either 
substitution G68E or G68W (BAK1-E and BAK1-W), suggesting that the G68W was 
beneficial only in the presence of the 67a insertion. This observation supports the conclusion 
that the insertion (67a) was the affinity improving feature of BAK1-INS1. The magnitude of 
improvement was significant, only 2.8-fold lower than that of the variant with two beneficial 
substitutions (BAK1.1; KD = 50 pM).  
Although previously the entire BAK1 scFv was scanned for point mutations that improve 
affinity, no change in affinity was attributed to point substitutions in the VL FWR3. The 
observation of affinity-improving indels in this region suggests that an insertion in FWR3 but 
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no point substitutions enabled large effect on BAK1 affinity. This is the first example of a 
deliberate library strategy in which insertions complement the effect of substitutions on 
antibody affinity.  
 
Table 4. Binding kinetics and thermodynamics of BAK1 variants 
 
 KD values of the human IgG1 variants were determined by surface plasmon resonance using the 
Biacore. The fold improvement in KD is the ratio of koff/kon. ΔΔG was calculated from the equations 
ΔG = - RT In (KD Parent / KD Mutant) and ΔGGAB = ΔGGA + ΔGGB + ΔGG1  
 
 
3.2.5. Specific amino acid substitution enabled the function of the insertion  
The fact that the variant with the highest frequency in round 4 (BAK1-INS1) had a large 
improvement in affinity confirmed that under the panning conditions of the ribosome display 
selections, variants with higher affinity than the parent were enriched. This in turn suggests 
that enrichment of the other BAK1-INS variants was related to affinity improvements. While 
the presence of the variant 67aE/G68 was in the library was confirmed (data not shown), only 
the mutant 67aE/G68W (41%) was enriched, suggesting that the insertion was beneficial only 
in the presence of the 68W substitution. This observation leads to the conclusion that the 
specific amino acid substitution was essential for the improvement in affinity. This idea is 
supported by the fact that other variants with G68W were also enriched, 67aV/G68W and 
67aA/G68W with 27% and 2.3% in round 4, respectively. Our data do not allow the 
comparison of these mutants with the 67aE/G68W that would allow us to determine if the 
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67aE substitution conferred even higher improvement of the variant with 68W substitution, 
as the KD values of all these variants have not been measured individually.  
Taken together, these results demonstrate that the insertion 67a is beneficial only in the 
presence of specific amino acid residue (W) at position 68, indicating that specific point 
substitution of a residue at position flanking the insertion enabled the insertion to exert its 
function (permissive mutation). We speculate that to identify this variant we had to sample 
different variants with each of 20 amino acids at this position (68), which underline the 
importance of sampling a large diversity of insertions and point substitutions around the 
position of the insertion.  
 
3.2.6. Combined effect of beneficial insertions and substitutions on antibody affinity   
To study epistatic interactions of insertions and point substitutions on antibody affinity, we 
determined the combined effect of the beneficial insertion (BAK1-INS1) and two beneficial 
substitutions (BAK1.1) on BAK1 affinity (Figure 41 and Table 4). Combination of both the 
insertion and substitutions resulted in a variant (BAK1-INS1.1; KD = 9 pM) with higher 
affinity than that with either only substitutions (BAK1.1; KD = 50 pM) or only the insertion 
(BAK1-INS1; KD = 142 pM). BAK1-INS1.1 possessed an overall 256-fold improvement in 
affinity compared to the parent, which is 6.3-fold higher than that of the substitution variant 
BAK1.1, with a 6.5-fold lower dissociation constant koff (2.45 × 10-5 s-1). The effect of 
combining insertion and substitutions was synergistic, as the free energy change that resulted 
from combining insertion and substitutions (BAK1-INS1.1; -4.9 kcal/mol) was higher than 
the sum (-4 kcal/mol) of the free energies of the variants with insertion (BAK1-INS1; -1 
kcal/mol) and substitutions (BAK1.1; -3 kcal/mol), while for additive mutations the free 
energy change would be equal to the sum. These results demonstrate that beneficial insertions 
and point substitutions can have additive effects on affinity, thus for engineering purposes 
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insertions could be included in CDR walking mutagenesis approaches, as selections of 
libraries with insertions and point substitutions could be performed in parallel and then 
combined to exploit additive effects on affinity.  
 
 
Figure 41. Comparison of the binding kinetics of a BAK1 variant with insertion in the VL FWR3 
(BAK1-INS1), a variant with two beneficial substitutions (BAK1.1) and a variant combining both the 













3.2.7. Beneficial insertion in the FWR3 loop  
The insertion is lodged within the fourth loop into the third framework region (FWR3) 
(Figure 42), sometimes referred to as CDR4 (Fanning & Horn, 2011). In contrast to the other 
hypervariable loops (CDR1-3), antibodies in Nature show no variation in this loop (Chothia 
& Lesk, 1987). However, it has been shown that this loop is tolerant to variation (Simon & 
Rajewsky, 1992) and some anti-HIV bnAbs have insertions in this loop, including PGT121, 
which originated from the same germline gene (L-Vλ3–21*02) as the BAK1 VL and has a 
three amino acid-insertion in the same position as BAK1-INS1 in the FWR3 (Mouquet et al., 
2012).   
The crystal structure of the variant BAK1.1 in complex with human IL-13 was determined by 
Popovic et al. (2016). BAK1.1 has two point substitutions in the loops VH CDR3 (N99S) and 
VL CDR1 (N27I), improving BAK1 affinity in combination by 46-fold (Table 4, Figure 41), 
located on the periphery of the antigen-binding site (Figure 42b). The position of the single 
amino acid insertion in the VL FWR3 loop (67aE/G68W) is close to the antigen-binding site 
(Figure 42), with residues of this loop (S67 and G68) constituting part of the structural 
paratope (Popovic et al., 2016). Despite the close proximity of these residues to the antigen 
surface, the only residue that possibly forms a hydrogen bond with antigen is the residue 
before the positions of the insertion S67 (side chain oxygen), which is 3.5 Å far from the T20 
(side chain oxygen), while the residue after the positions of the insertion (G68) does not seem 
to form contacts with the antigen, as the side chains of these positions (main chain nitrogen 
from T20 side chain oxygen) are at least 5.4Å far  from atoms of the antigen. These 
observations show that the site of the affinity-enhancing insertion is in close proximity to the 
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Figure 42. Sites of the beneficial insertions and point substitutions on BAK1.1:IL-13 complex 
crystal structure. A) The site of the beneficial insertion in the VL FWR3 loop is in close proximity to 
the antigen-binding site, after the position G68 (shown as red main chain spheres on the cartoon 
representation of the structure). B) Positions of insertions (in red) and point substitutions (in blue) that 
not only conferred a large improvement on BAK1 affinity individually, but also synergized to 
generate a higher affinity antibody are shown on surface representation of the structure. All these 
modifications are located on surface exposed positions on the periphery of the antigen-binding site. 
The VH CDR1, VH CDR2 and VH CDR3 loops are coloured in wheat, salmon and pale cyan, 
respectively, while the VL CDR1, VL CDR2, VL CDR3 in blue white, pale green and yellow orange. 
IL-13 is shown in light orange. 
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3.3. Discussion   
The work described in this chapter reports on the use of new transposon-based approaches to 
build antibody libraries with random indels. Quality control of the BAK1 scFv libraries 
suggested that indels were randomly distributed across the entire scFv and that the single 
amino acid insertion library was comprised of high diversity insertions. Indeed, this type of 
search allowed identification of an insertion that improves affinity away from the CDRs, 
which are the regions usually randomized by targeted approaches, in a non-hypervariable 
region, the FWR3 loop (Chothia & Lesk, 1987). This is the first time that engineering this 
loop using insertion libraries resulted in affinity gain, as previous effort to engineer antibody 
affinity by increasing the length of the FWR3 loop has failed (Young, Watson, Cunningham, 
MacKenzie, & Huston, 2014).  
In Nature, the FWR3 region is not hypervariable and the percentage of insertions in this loop 
in affinity matured antibodies has not been shown to be higher compared to other FWR 
regions (de Wildt, van Venrooij, Winter, Hoet, & Tomlinson, 1999; look Briney, Willis, & 
Crowe, 2012, figure 3A; Bowers et al., 2014). Further evidence that the FWR3 loop is 
amenable to insertions is provided by the presence of insertions in this loop in several anti-
HIV bnAbs which have been subjected to extensive affinity maturation (Klein et al., 2013; 
Kepler et al., 2015); for example 5 of 17 antibodies with broad neutralization activity (29.4%) 
have a FWR3 loop insertion based on Figure 1 by Klein et al. (Cell, 2013). Furthermore, one 
study suggests that the FWR3 loop of an anti-hapten single domain antibody (which lack the 
light chain) confers high improvement in affinity, as grafting the CDR loops on a different 
VHH framework showed that the FWR3 loop (referred to as CDR4) confers a 1000-fold 
improvement in affinity. The data presented in this chapter combined with the presence of 
FWR3 loop insertions in extensively matured antibodies (bnAbs) in Nature paints a 
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consistent picture that FWR3 loop length variation is well tolerated and a potential source of 
affinity enhancement.  
Insertion in the FWR3 (67aE) was beneficial only in the presence of specific amino acid 
residue at position 68 (G68W). These results indicate epistatic interaction between those 
modifications, with specific point substitution of a residue at position flanking the insertion 
enabling the insertion to exert its function (permissive mutation). These results underline the 
importance of sampling not only high amino acid diversity insertions, but also high diversity 
point substitutions of residues flanking the position of the insertion in order to identify an 
insertion variant with improved affinity.  
Epistatic interactions between the FWR3 insertion and two beneficial substitutions (BAK1.1) 
were evaluated by making a BAK1 variant with both FWR3 insertion and BAK1.1 point 
substitutions. Increased affinity of this variant compared to the variant with only point 
substitutions, indicates positive epistatic interaction between affinity-enhancing insertion and 
point substitutions. Insertions have been found to contribute to affinity gains (20 and 40-fold) 
during in vitro affinity maturation of antibodies raised against different antigens by 
mammalian surface display (Bowers et al., 2011). Although collectively insertions and point 
substitutions contributed to the overall affinity improvement, it is not clear if these insertions 
would have had the same effect on affinity if they had been acquired before the occurrence of 
other substitutions. Overall, this is the first time that was shown that insertions and point 
substitutions can have additive effects on affinity. Thus, for engineering purposes insertions 
could be included in CDR walking mutagenesis approaches, as selections of libraries with 
insertions and substitutions could be performed in parallel and then combined to exploit 
additive effects on affinity.  
G68W substitution was beneficial on affinity only in the presence of the insertion (67aE; 
permissive mutation), as the mutant with G68W substitution (BAK1-W) but without insertion 
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at the position 67a did not possess any improvement in affinity. In addition, no point 
substitutions with large effect on BAK1 affinity were identified in this loop either in previous 
or in the current study, indicating that point mutations in the FWR3 loop conferred gain in 
affinity only in the presence of the insertion. These data support the conclusion that insertions 
and substitutions can have complementary mechanisms of function, leading to the 
localization of beneficial insertions in different positions than beneficial point substitutions 
on the same antibody, meaning that insertions offer alternative routes to affinity maturation. 
For engineering purposes, insertions could be used as a type of sequence modification that 
can offer additional pathways to affinity maturation, especially in cases where difficulties are 
encountered with conventional methods using only point substitutions.  
Analysis of the site of the FWR3 loop insertion on the BAK1.1:IL-13 complex structure has 
shown that the position of the insertion constitute part of the structural paratope. The close 
proximity of the insertion site to the antigen-binding site combined with the large effect on 
affinity conferred by the insertion, suggests that it is possible that the insertion induces direct 
interactions of the FWR3 loop with the antigen. Furthermore, the presence of a residue that 
could form intra-molecular hydrogen bonds and even a salt bridge (67aE; glutamic acid 
insertion) combined with a residue with aromatic rings that have multiple interaction 
capabilities with antigen (G68W; tryptophan substitution) (Vindahl, Nielsen, Berg, & Lund, 
2013) in the FWR3 loop supports the hypothesis that increased affinity is caused by the 
insertion due to formation of direct contacts with the antigen. Specifically, the G68W 
substitution could bury additional hydrophobic surface and possibly make some contacts with 
the antigen, but probably not pi stacking interactions because of the absence of aromatic 
residues in close proximity to this residue. Extended hydrophobic surface could also result in 
lowering the dielectric constant that would benefit electrostatic interactions between polar 
residues, like aspartic acid (E67a) and serine (S67), with residues of the antigen, like 
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aspargine (N22) and glutamine (Q21 and Q23) residues that could participate in hydrogen 
bonds.  
The idea that the FWR3 insertion could form new inter-molecular interactions by extending 
the loop is supported by analysis of other FWR3 insertions in natural antibodies from studies 
of crystal structures of antibody fragment complexes with their antigens. For example, a 
FWR3 loop insertion of the anti-HIV bnAb 8ANC195 (Scharf et al., 2014) has been shown to 
exert its effect by extending the loop and forming intra-molecular contacts, which in turn 
enable new contacts of FWR3 loop residues around the position of the insertion with residues 
of the gp120 loops D and V5. The functional effect of the insertion was an extended epitope 
surface that reached a pocket on gp120 surface, resulting in broadened neutralization activity 
of the antibody against various viral strains. Another example is the FWR3 loop of the anti-
MTX VHH which was shown to interacts directly with the hapten, resulting in 1000-fold 
higher affinity than in the absence of the residues that form the inter-molecular contacts 
(Fanning & Horn, 2011). Overall, the FWR3 insertion could form new inter-molecular 
contacts either directly or by enabling other loop residues flanking the position of the 
insertion to interact with the antigen.  
Taken together, although the effect of random indels across the entire scFv on antibody 
affinity was assessed by using libraries with random and high diversity indels, the data 
presented in this chapter indicate that beneficial insertions are located in loops in close 
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4.1. Introduction  
As discussed in introductory sections of previous chapters, Nature appears to sample only 
low diversity insertions, as this type of modification is introduced by SHM in low frequency 
and only by sequence duplication. Consequently, by sampling higher diversity of insertions 
across the variable regions by in vitro evolution, one is likely to identify more insertions that 
confer beneficial effect on antibody affinity. This idea is reinforced by the results presented 
in the previous chapter, underlining the importance of sampling high amino acid diversity 
insertions combined with point substitutions in positions flanking the insertion, which may 
permit the insertion to exert its beneficial effect on affinity.  
In the previous chapter sampling random and high diversity insertions across the entire scFv 
was achieved by using a transposon-based approach to build libraries with single amino acid 
insertions. Although the construction of libraries with even longer insertions is possible using 
this method, this type of library for insertions longer than 2 amino acids would be impossible 
to cover the diversity of all the possible variants (as discussed in chapter II). To overcome 
this limitation, I developed a semi-random approach that allowed sampling of high diversity 
insertions longer than a single amino acid. The capability of this method to enable the 
identification of affinity-enhancing insertions was assessed by searching for beneficial 
insertions in different loops of the same model antibody, BAK1.  
Identification of a beneficial insertion in the VL FWR3 loop combined with the frequent 
presence of insertions in that loop of bnAbs to HIV-1, suggest that FWR3 loop insertions can 
be tolerated and confer improvements in affinity. Random sampling of indels across the 
entire scFv sequence led to the identification of a beneficial insertion in a loop close to the 
antigen-binding site, suggesting that beneficial insertions are more likely to be found in loops 
close to the antigen-binding site. This conclusion is supported by data of affinity matured 
antibodies in Nature showing beneficial indels mainly occurring in the CDRs 1 and 2 and in 
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close proximity to the CDRs (de Wildt, van Venrooij, Winter, Hoet, & Tomlinson, 1999; 
Briney, Willis, & Crowe, 2012; Bowers et al., 2014). It is unclear whether or not the CDR3 
loops can accommodate beneficial indels as the analysis of these loops is impossible, because 
indels in the VH CDR3 and at the end of the VL CDR3 cannot be identified due to length 
variation that is introduced at these positions (junctions) during the initial V(D)J 
rearrangement. In addition, extensively somatically mutated bnAbs accumulate insertions 
both in the FWR3 and in the CDR loops (Diskin et al., 2011; F. Klein et al., 2013). Taken 
together, these data suggest that insertions not only in the FWR3 loop but also in other CDRs 
could potentially confer significant improvements in affinity.  
Assuming that insertions not only in the FWR3 loop but also in other CDRs can confer 
significant improvements in affinity, I decided to sample different lengths of high diversity 
insertions in the CDRs of the same antibody (BAK1), in order to find more beneficial 
insertions on the same antibody. Additionally, according to the findings presented in the 
previous chapter, it would be desirable to include point substitutions in positions around the 
insertion, because these could enable the functional effect of the insertion. To find out which 
CDR positions could be randomized, I followed a semi-random approach, dubbed insertional-
scanning mutagenesis (Figure 43). This method is based on the notion that positions that can 
tolerate single amino acid insertions are more likely to tolerate longer insertions as well.  
Identification of the positions of the BAK1 gene that can tolerate single amino acid insertions 
without losing binding to IL-13 was used to inform the construction of libraries with length 
variation at targeted positions. CDR positions that were found to tolerate insertions were 
randomized with different lengths of insertions (up to five amino acids), with the full 
diversity of amino acids, by construction of separate libraries using classic methods of 
targeted mutagenesis. In contrast to previous methods of insertional mutagenesis 
(Lamminmäki et al., 1999), knowledge of the structure is not required as the design of 
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libraries with insertions is not based on natural length variation or structural information, but 
on screening for binding to the antigen of a library with single amino acid insertions either 
random or only in the CDRs loops, including the FWR3 loops.  
 
 A                                                      B                                                     C  
 
Figure 43. Insertional-scanning mutagenesis. A) The BAK1 library with random single amino acid 
insertions (see chapter II) (different X colours indicate different amino acid residues), B) was used to 
identify the BAK1 variants that are still functional and consequently, can tolerate single amino acid 
insertions (Figure 45). Assuming that the variants that tolerate single amino acid insertions might also 
tolerate longer insertions, these positions were chosen for randomization with full diversity insertions 
of different lengths. C) The libraries with insertions of different lengths at chosen positions were built 















4.2. Results  
4.2.1. Positions that tolerate insertions across the BAK1 scFv  
Positions that tolerate insertions were identified by using the library containing random single 
amino acid insertions across the BAK1 gene (see chapter III). By screening a subset (5,632 
variants) of this library for binding to human IL-13 using an HTRF assay, BAK1 insertion 
variants that were still functional were picked and their sequences were determined. The 
positions that can tolerate insertion across the scFv gene and the frequency of each variant 
with insertion in specific position (even of different amino acid residue) in the screen are 
shown in Figure 44.  
11 positions were confirmed to tolerate single amino acid insertions in the CDR loops, 
including the FWR3 loop, specifically insertions were found in four different loops, the VH 
FWR3, VH CDR2, VL CDR3 and VL FWR3. In the VL FWR3 loop, the position before the 
G68 can tolerate single amino acid insertion (5 hits), which is in agreement with the findings 
presented in the previous chapter, that the BAK1-INS1 variant has a beneficial insertion at 
this position. A cluster of four positions with high frequency was found in the VL CDR3 
before the D92, T93, G94 and S95 with 4, 16, 18 and 1 hits, respectively. Only one position 
with high frequency (before A53) was observed in the VH CDR2. Except from the N-
terminus of the VH, which may tolerate insertions because it is a free terminus with little 
involvement in binding but with structural plasticity, high frequency of hits was not observed 
in other regions out of the CDRs. These results indicate that BAK1 can tolerate single amino 










Figure 44. Identification of positions that tolerate single amino acid insertions across the BAK1 scFv 
were found by screening the BAK1 library for retention of IL-13 binding following single amino acid 
insertion at different positions. The columns represent a position that tolerate insertion before the 
indicated residue. The frequency shows the number of hits at a given position (even if the inserted 
amino acid differs). The loop with the highest frequency, the VL CDR3, was chosen as the target for 
insertional mutagenesis.  
 
4.2.2. Design of libraries with different lengths of insertions in the VL CDR3 
Assuming that the variants that tolerate single amino acid insertions might also tolerate 
longer insertions that could also be beneficial on affinity, some of the CDR positions that 
tolerated insertions were chosen for randomization with full diversity insertions of different 
lengths. Length variation was considered important to investigate if different insertion 
lengths would have different effect on affinity and increase the chances of identifying a 
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beneficial insertion by sampling large diversity of insertions in terms of both length and 
amino acid composition in each position.  
The loop with the highest frequency of insertions in our binding assay, the VL CDR3, was 
chosen as the target for insertional mutagenesis. Five libraries with different lengths of 
insertions, from 0 to 5 amino acids, after the residue W91 were constructed by classic 
methods of phage library construction by site-directed mutagenesis (Table 5). Each library 
contained 109-1010 variants with variation in blocks of 5-6 residues (NNS randomization), 
targeting not only the insertion residues, but also the residues around the insertions with the 
full amino acid diversity.  
 




4.2.3. Affinity-based selections and screening of the VL CDR3 insertion libraries  
An overview of the design of libraries with different lengths of insertions in the VL CDR3 by 
Insertional-scanning mutagenesis and the phage display selections and screening of these 





Figure 45. Insertional-scanning mutagenesis (Figure 43) of the BAK1 antibody. Scanning of the 
BAK1 library with random insertions was used to guide the design of libraries with different lengths 
of insertions in the VL CDR3. Subsequently, selections of these libraries by phage display were 
followed by screening for improved variants.   
 
Four rounds of phage display KD-based selections were performed by panning with a starting 
recombinant biotinylated IL-13 concentration in the KD range in the first round, followed by 
10-fold lower IL-13 concentration in each round (from 10nM to 0.01 nM). For all the 
libraries enrichment of specific variants over the rounds was confirmed by sequencing of 44 
variants from the outputs of selection rounds 2, 3 and 4 (Figure 46). Enrichment of unique 
variants (40 - 76.5% unique variants in round 4), suggesting that specific variants were 




Figure 46. Enrichment of specific variants during phage display selections of VL CDR3 libraries. 
Enrichment of unique variants was observed for all libraries, especially the libraries with 1-5 amino 
acid insertions.  
 
From the round 4 selection output of each library, 384 His6-tagged scFv periplasmic fractions 
were screened for binding to human IL-13 using an HTRF competition assay. The sequences 
of all the screening hits were determined (Figure 47) and a few variants from each library 
were selected for further affinity-based screening. Around half of the variants tested from the 
libraries with 2-5 amino acids were still binding to IL-13, while from the library with 0/1 
amino acid insertions only ¼ of the variants were hits, suggesting that it is more likely to 
identify variants with improved either expression or affinity from the libraries with 2-5 amino 
acids. Additionally, the library with 0/1 amino acid insertions presented higher percentage of 
unique variants (43%), showing higher diversity compared to the other libraries (4.8 - 27.3% 
unique variants), suggesting that the hits of this library probably contained lower number of 
improved variants. The library with the lowest diversity of unique hits (5%) was the library 
with the longest insertions of 5 amino acids, suggesting either a lower number of variants 
with improved expression for longer insertions or that some variants predominated the 
selection due to much higher affinity than the other variants.  
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Figure 47. Screening round 4 output of phage display selections of the libraries with insertions in the 
VL CDR3 for binding to IL-13. A) The percentage of hits in a screen of 384 scFv variants per library. 




The criteria for selecting the variants from each library for further affinity-based screening 
were the frequency of each unique hit and their signal value in the competition assay. The 
results of the affinity-based screening are presented in Table 6. To identify the variants with 
improved affinity, an initial HTRF competition affinity screen of purified His6-tagged scFvs, 
was followed by picking the variants which seemed to have improvement in affinity rather 
than in expression. To confirm that these variants were indeed improved, 29 variants were 
converted to human IgG1 format and tested using a competition ELISA assay. IgG variants 




























4.2.4. Beneficial insertions in the VL CDR3     
KD measurements of 10 IgG variants (Table 7) showed that 8 of those had improvement in 
affinity, but only variants with two-amino acid insertions or longer had large improvements 
(> 5-fold), indicating that only insertions of more than one amino acid exert large effects on 
affinity. All the variants with large improvements, INS2.1, INS3.4, INS4.3, INS4.4 and 
INS5.3 (13.5, 7.7, 25.5, 67.6 and 48-fold improvement in KD, respectively), had different 
lengths of insertions from 2 to 5 amino acids and a motif, 93aW or 93aF combined with 
93bD, suggesting that insertion longer than two amino acids combined with this specific 
motif were required for the insertion to confer a large beneficial effect on affinity. From the 
library with zero and single amino acid insertions only one variant with single amino acid 
insertion seemed to hold a small improvement in affinity (INS1.6; 2.9-fold), indicating that 
variants without insertion in the VL CDR3 were not improved, which is in agreement with 
previous data (Thom et al., 2006). These results demonstrate that insertions in the VL CDR3 
have complementary effects with point substitutions on affinity.  
Although the variants with long insertions in the VL CDR3 had even larger improvements in 
affinity (INS4.4; 67.6-fold) than the variant with a single amino acid insertion in the VL 
FWR3 (BAK1-INS1; 14-fold) (Chapter III) and compared to variants with shorter insertions 
in the VL CDR3, there is not enough data to support the idea that longer insertions result in 
larger improvements in affinity. Compared to the variant with two point substitutions 
(BAK1.1, 46-fold), the variants with 4 and 5 amino acid insertions (INS4.3, INS4.4 and 
INS5.3) had similar improvement in affinity, thus one long insertion had the same effect as 











 KD values of the human IgG1 variants were determined by surface plasmon resonance using the 
Biacore. The fold improvement in KD is the ratio KD 
Variant




4.2.5. Effect of beneficial insertions on thermal stability   
Mutations that improve protein function often have negative effect on stability, indicating a 
trade-off between function and stability of enzymes (Wang, Minasov, & Shoichet, 2002; 
Gong, Suchard, & Bloom, 2013) and antibodies (Julian et al., 2015; Julian, Li, Garde, Wilen, 
& Tessier, 2017). To study the effect of beneficial insertions on stability and compare them 
with that of beneficial point substitutions, I performed thermal stability measurements of the 
improved IgG variants by differential scanning fluorimetry (DSF) (Niesen, Berglund, & 
Vedadi, 2007) (Figure 48 and Table 7). IgGs have two unfolding transitions, the CH2 
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domain unfolding is followed by that of the Fab and the CH3 domain (Tavakoli-Keshe, 
Phillips, Turner, & Bracewell, 2014; McConnell et al., 2014). DSF does not resolve both 
peaks, but for the IgG1 variants with the lowest Tm values two peaks were observed. The 
first peak shows how the Tm of the IgG variants is affected by changes in the variable 
regions of the Fab.  
Most variants with small improvements in affinity (INS2.1, INS3.4, INS4.2) were as stable as 
the parent IgG (BAK1; Tm=62), thus the insertions did not have a negative impact on 
antibody stability. Most variants with large improvements in affinity had a loss in stability 
(INS4.3; Tm=57.5, INS4.4; Tm=60), and the same loss was observed for the variant with two 
point substitutions (BAK1.1; Tm=57) (Figure 49), indicating that the trade-off between 
affinity and stability was observed for both the insertion and the substation variants with 
large improvements in affinity. The only exception was the variant with a five-amino acid 
insertion (INS5.3) which besides conferring large gain in affinity, it also possessed higher 
stability than the parent (Tm=64.5). This improvement in stability could be attributed to the 
insertion of two cysteines residues that likely form a disulphide bond that could stabilize the 
loop. Intra-loop disulphide bond in the VL CDR3 has not been observed in natural antibodies, 
suggesting that despite the large beneficial effect on both affinity and stability, this type of 
modification does not occur in Nature. These data support the conclusion that by engineering 
this loop with long insertions and high diversity of amino acids we generated an antibody that 
would not be found in Nature, probably due to sampling of low diversity insertions.  
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Figure 48. Thermal stability measurements of the IgG variants. The normalized melting curves are 
shown as measured by DSF. Measurements were repeated twice for all mutants. 
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Figure 49. Correlation between melting temperatures and KD values of IgG variants with large 
improvements in affinity.  
 
Overall, these results show that insertions that result in gains in affinity can have the same 
effect as point substitutions on antibody stability, can be neutral, deleterious or beneficial 
(Julian, Li, Garde, Wilen, & Tessier, 2017b). Insertions induce the same affinity/stability 
trade-off as has been observed for point substitutions. All these different effects were 
observed for insertions of different amino acids in the same position in the VL CDR3, 
suggesting that specific amino acid substitutions and lengths of insertion in the same position 








4.2.6. Structural interpretation of the beneficial VL CDR3 insertions   
The crystal structure of the variant BAK1.1 in complex with human IL-13 was determined by 
Popovic et al. (Popovic et al., 2016). BAK1.1 has two point substitutions in the loops VH 
CDR3 (N99S) and VL CDR1 (N27I), improving BAK1 affinity in combination by 46-fold 
(Table 4), located on the periphery of the binding site (Figure 50b). Affinity-enhancing 
insertions with different lengths, from two to five amino acids were identified in the VL 
CDR3 loop (following W91). Some of the residues that were chosen for randomization by 
insertional mutagenesis, W91 and T93, constitute part of the structural paratope (Popovic et 
al., 2016) (Figure 50a), suggesting close proximity of these residues to the antigen surface. 
The side chains of these positions have a distance of at least 6.6 Å (T93 oxygen from R7 
nitrogen) from atoms of the antigen which means that none of these residues form direct 
contacts with the antigen. All the positions of the insertions are completely surface exposed 
(D92 – S95), indicating that the site of beneficial insertions is surface exposed on the 
periphery of the antigen-binding site.  
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Figure 50.  Sites of the beneficial insertions and point substitutions on BAK1.1:IL-13 complex crystal 
structure. A) The site of the beneficial insertions in the VL CDR3 loop is in close proximity to the 
antigen-binding site, after the position W91, the positions D92 - S95 (shown as red main chain 
spheres on the cartoon representation of the structure). B) Positions of insertions (in red) and point 
substitutions (in blue) that conferred large improvements on BAK1 affinity. All these modifications 
are located on surface exposed positions on the periphery of the antigen-binding site. The VH CDR1, 
VH CDR2 and VH CDR3 loops are coloured in wheat, salmon and pale cyan, respectively, while the 
VL CDR1, VL CDR2, VL CDR3 in blue white, pale green and yellow orange. IL-13 is shown in light 
orange. 
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4.3. Discussion     
The work described in this chapter reports on the use of a new semi-random approach to 
build antibody libraries with different lengths of insertions, up to six amino acids. Sampling 
high diversity insertions longer than a single amino acid was considered important because, 
as discussed in previous sections of this thesis, in Nature only low diversity of insertions is 
sampled by SHM, therefore, it is likely that sampling high diversity insertions could lead to 
the discovery of more insertions that confer beneficial effect on antibody affinity. In the 
previous chapter, sampling insertions no longer than a single amino acid resulted in the 
identification of an affinity-enhancing insertion in the FWR3 loop of the BAK1 antibody. In 
this chapter, the method that was developed allowed the discovery of more beneficial 
insertions in a different loop (VL CDR3) of the same antibody, suggesting that sampling high 
diversity insertions of different lengths is important in order to identify beneficial insertions. 
This idea is also supported by the fact that out of all these high diversity sequences of 
insertions in the VL CDR3 that were sampled, only a few variants with a specific motif 
(positions 93a and 93b; WD or FD) were selected for significantly improved affinity.  
The utility of this method was also demonstrated by the fact that the position of the beneficial 
insertion in the VL FWR3 (67a) was also identified as one of the positions that can tolerate 
insertions thus could be randomized by insertional mutagenesis, indicating that this method 
could have predicted that it is possible to generate variants with improved affinity by 
randomizing this position. Additionally, the identification of the position that could tolerate 
insertions in the VL CDR3 would be difficult to predict without scanning, that allows 
prediction of the positions that tolerate insertions even without any structural information. 
However, in another study the same position of an anti-hapten antibody was chosen for 
randomization by insertional mutagenesis based on the crystal structure to identify variants 
with modified specificity (Krykbaev et al., 2002).  
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Furthermore, scanning allows prediction of positions that tolerate insertions even if these do 
not have length variation in Nature. The first example is the FWR3 loop, which is not 
hypervariable in Nature, as described in previous chapters. The same conclusion is supported 
by the identification of insertions longer than those normally found in Nature in the VL 
CDR3. BAK1 has a λ-type light chain (IGLV3 family, germline gene; L-Vλ3–21*02). In 
Nature, the λ-chain VL CDR3 adopts a wide range of lengths and conformations, composed 
of 7-13 residues, thus it is possible that this loop can tolerate length variation. Only insertions 
from two to five amino acids in the 11-amino-acid VL CDR3 of the parent antibody conferred 
large improvements in affinity, resulting in 13-15 amino-acid loop, which is longer than 
normally found in Nature. Thus, although the VL CDR3 loop can tolerate length variation in 
Nature, the fact that only longer than single amino-acid insertions would result in 
improvements in affinity would be difficult to predict.  
To compare the outcome of affinity maturation by insertional mutagenesis with that of point 
mutagenesis in the same loop, VL CDR3 libraries both with and without insertions in the 
same positions were constructed. The fact that mutations in the VL CDR3 loop conferred 
large gain in affinity only in the presence of two amino acid insertion or longer, suggests 
complementary mechanisms of function of insertions and point substitutions on antibody 
affinity. Complementarity is important for engineering purposes, as it means that insertions 
could be used as a complementary type of sequence modification that could offer alternative 
routes to affinity maturation.  
Taken together, using insertional-scanning mutagenesis to guide the design of libraries with 
insertions, we were able to sample high diversity insertions of different lengths, which 
resulted in the discovery of more beneficial insertions on the same antibody, with even higher 
improvements in affinity, demonstrating that this method can guide the design of libraries 
with long insertions and could be widely applied in affinity maturation campaigns.  
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The position of VL CDR3 loop insertion on the BAK1.1:IL-13 complex structure was shown 
to be surface exposed on the periphery of the antigen-binding site. The close proximity of the 
position of the insertion to the antigen combined with the large effect of the insertion on 
affinity, suggests that it is possible that the insertion makes new contacts with the antigen. 
Additionally, the presence of a motif (positions 93a and 93b; WD or FD) in all the improved 
variants with insertions longer than two amino acids suggests that important interactions of 
these residues can occur only in the presence of an insertion longer than two amino acids, 
which could be explained by a longer insertion enabling these or other residues to reach and 
interact with residues on the antigen surface. Specifically, aromatic rings (F106) on the 
surface of the antigen could achieve pi stacking interactions with 93aW or 93bF and 93bD 
could form hydrogen bonds or even a salt bridge with residues on the antigen surface (S3, T4, 
R7).  
Furthermore, the idea that the CDR3 insertion could form new contacts with the antigen is 
supported by studies of the mechanism of function of insertions in affinity matured bnAbs in 
Nature. Crystal structures of antibody complexes with their antigens have revealed that 
insertions in both the FWR3 loop (as discussed in section 2.3) and the VH CDR3 enabled 
direct interactions with the antigen by extending these loops. The four-residue insertion in the 
VH CDR3 of the bnAb NIH45-46, which belongs to the VRC01 clonal lineage (Bjorkman, 
2012), introduced not only intra-molecular interactions but also new hydrogen bonds and 
electrostatic interactions of the insertion residues with the antigen by extending the CDR3 
loop and consequently, increasing the buried interface area (Diskin et al., 2011).  
Overall, the VL CDR3 insertion could improve BAK1 affinity by forming new inter-
molecular contacts either directly or indirectly by enabling other residues around the position 





5. Conclusions  
 
 
This thesis aimed at studying the effect of random and high diversity indels on antibody 
affinity by in vitro evolution. Insertions that have a beneficial effect on function were found in 
different locations of the same antibody and structural analysis of these insertions gave 
insight into the mechanism by which insertions exert their beneficial effect, by extending 
loops enabling new contacts with the antigen. This thesis demonstrates that insertions besides 
offering alternative routes to affinity maturation can also be combined with point 
substitutions to take advantage of additive effects on function. This knowledge improves our 














5.1. Insertions in the CDR and FWR3 loops can confer significant improvements in 
affinity 
Sampling of random indels across the entire variable region of the BAK1 antibody revealed 
that insertions that confer large affinity improvements can be found not only in the CDR 
loops, as was expected based on studies of affinity matured antibodies in Nature, but also in a 
non-hypervariable loop, the FWR3 loop. The fact that the FWR3 loop can accommodate 
insertions is further supported by the frequent presence of insertions in this loop in 
extensively affinity matured antibodies (anti-HIV-1 bnAbs), which have been shown to 
confer broad neutralization activity of the 8ANC195 and 3BNC60 bnAbs (Scharf et al. 2014; 
Klein et al. 2013). It was expected that affinity-enhancing insertions would be found mainly 
in the CDRs 1 and 2, as in Nature a low percentage of affinity matured antibodies acquire 
indels in these loops. The CDR3 loops can tolerate high length variation, thus it is likely that 
further length diversification of these loops through SHM could contribute to antibody 
affinity maturation, but the occurrence of indels in these loops cannot be estimated. In this 
study, insertions in the VL CDR3 that improve the affinity of the BAK1 antibody were 
identified, suggesting that length diversification of the VL CDR3 might also represent a 
mechanism of affinity maturation in Nature.  
 
5.2. Sampling high diversity insertions enables the discovery of beneficial insertions  
In Nature, the low rate of in-frame indels occurring by SHM combined with introduction of 
only low diversity insertions, as these occur only by sequence duplication, suggests that the 
diversity generated by SHM is probably not enough to sample high diversity insertions across 
the entire variable region. Thus, it is likely that the antibody fold can accommodate higher 
diversity of beneficial insertions. To overcome this limitation, this thesis focused on the 
development of methods that allowed sampling of high diversity insertions, by using either 
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an entirely random approach to test short (single) amino acid insertions or a semi-random 
approach, called insertional-scanning mutagenesis, that uses scanning of random insertions to 
guide the design of libraries with high diversity longer insertions, up to six amino acids. 
Indeed, these methods were proven capable of delivering beneficial insertions in more than 
one loop of the same antibody. In contrast to previous methods of insertional mutagenesis 
(Lamminmäki et al., 1999), the design of libraries with insertions is not based on natural 
length variation or structural information, thus knowledge of the structure, which is often not 
available, is not a prerequisite. Wide application of the methods that were used in this thesis 
only require scanning for binding to the antigen of a library with single amino acid insertions 
either at random positions or only in the CDR loops, including the FWR3 loop, as these are 
the loops that is more like to identify beneficial insertions.  
 
5.3. Enabling point substitutions in positions flanking the insertion  
Epistatic interactions between point substitutions is a common factor affecting the functional 
effect of individual mutations. For example, one mutation may be context dependent, which 
means that it would be beneficial only in the presence of other, enabling mutations, which 
could be located far from the mutation. Whether the acquisition of beneficial insertions 
would depend on the presence of other point substitutions across the antibody variable region 
was not known before designing the insertion libraries. The discovery of insertions that 
improved BAK1 affinity in two different loops, independently of the presence of other point 
substitutions across the scFv gene, points out that the effect of insertions does not necessarily 
depend on the presence of other mutations. This fact has important engineering implications, 
as makes possible the identification of beneficial insertions without sampling the 
combinations of insertions with point substitutions, which would make the search for 
beneficial insertions impossible because of the magnitude of the libraries that would have to 
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be constructed or additional epPCR steps. Although the effect of insertions did not depend on 
point substitutions far from the positions of the insertions, positive epistasis was observed 
with positions around the insertions, indicating the importance of sampling high diversity of 
point substitutions in positions flanking the insertion.  
 
5.4. Beneficial insertions and point substitutions can synergize to generate even higher 
affinity antibodies  
Epistatic interactions between indels and point substitutions in Nature are still unclear. 
Combination of a beneficial insertion (in FWR3 loop) with beneficial point substitutions 
(BAK1.1 point substitutions) increased the affinity of the variant containing both 
modifications compared to the variant with only point substitutions, suggesting that insertions 
and point substitutions can have positive epistatic interactions. These results demonstrate that 
for engineering purposes, beneficial insertions could be selected separately and then 
combined with substitutions to exploit additive effects on affinity, thus these could be 
included in CDR walking mutagenesis approaches. Overall, this is the first time that it was 
shown that insertions could be included in a parallel CDR walking approach, where affinity 
maturation using either point substitutions or insertions could be performed separately and 
then combined to take advantage of additive effects on function.  
 
5.5. Insertions possibly improve affinity by enabling new inter-molecular interactions 
Both beneficial insertions in different loops (VL FWR3 and VL CDR3) of the BAK1 antibody 
were located on surface exposed positions on the periphery of the antigen-binding site, 
suggesting that beneficial insertions are more likely to be found in loops close to the antigen-
binding site. The same has been shown for beneficial point substitutions; while the diversity 
in the primary repertoire is concentrated in the centre of the combining site, point mutations 
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introduced by SHM are located on the periphery of the binding site (Tomlinson et al., 1996), 
indicating that these modifications improve affinity while keeping stable the topology that 
defines specificity. These observations suggest that insertions improve binding by acting in a 
similar mechanism as point substitutions, without affecting the residues that form direct 
contacts with the antigen, but residues adjacent to those residues.  
Insertions could be involved in making new contacts, like new hydrogen bonds, salt bridges, 
hydrophobic interactions, intra-molecular interactions with other loops, additional 
hydrophobic surface and potential pi stacking interactions. Aromatic residues combined with 
short-chain hydrophilic residues are often found on antibody functional paratopes (Peng, Lee, 
Jian, & Yang, 2014). This is because aromatic residues (Tyr, Trp, Phe) have multiple 
interaction capabilities with antigen (Vindahl et al., 2013). The close proximity of the 
positions of the insertions to the antigen combined with the large effect of the insertions on 
affinity and the enrichment of specific residues that are frequently found on antibody 
paratopes (WD or FD motifs) support the idea that the large effect of insertions on BAK1 
affinity in both loops (VL CDR3 and VL FWR3) could be the result of new contacts with the 
antigen that was enabled by extended loops.  
Furthermore, the idea that insertions may exert their effects by making new contacts with the 
antigen is supported by studies of the mechanism of function of insertions in affinity matured 
anti-HIV bnAbs in Nature, which have shown that insertions extend loops and make new 
contacts with the antigen, either directly or indirectly by enabling other residues around the 
position of the insertion to reach the antigen surface and interact with the antigen. Another 
mechanism by which insertions can change antibody affinity is by changing the 
conformations of adjacent loops, like the 2D1 anti-HA antibody insertion (Krause et al., 
2011) at the junction of CDR2 and FWR3, which altered the conformation of the CDR1 loop 
resulting 35-fold higher affinity. Overall, the mechanisms by which insertions could exert 
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their function are either by extending loops and making new contacts with the antigen or by 
altering the conformation of adjacent loops.    
Increased affinity by SHM has been shown to involve improvement of the shape and 
molecular complementarity (additional inter-molecular hydrogen bonds, van der Waals 
contacts) of the antigen combining site to the epitope (Cauerhff et al., 2004). Additionally, 
improved binding has been shown to be achieved by increasing the area buried at 
the interface, which is the result of subtle structural rearrangements on the periphery of the 
interface with the antigen (Sundberg et al., 2000; Li, Li, Yang, Smith-Gill, & Mariuzza, 
2003). The fact that BAK1 beneficial insertions are likely to have gained improved affinity 
by making new contacts with the antigen on the periphery of the interface, suggests that the 
improvements in affinity could be attributed to increased buried surface area.  
 
5.6. Complementary effect of insertions to point substitutions on antibody affinity  
We found insertions that improve BAK1 affinity in the VL FWR3 and the VL CDR3, while 
beneficial substitutions were found in different loops, the VH CDR3 and VL CDR1. The 
observation that the location of insertions and substitutions that improve BAK1 affinity are in 
different loops combined with the identification of beneficial insertions in positions where 
point substitutions did not confer any improvement in affinity, suggests complementary 
mechanisms of function of insertions and point substitutions on affinity. Thus, insertions 
have a different mechanism of function than point substitutions, which is in agreement with 
the observation that insertions exert their effect by extending loops which would not be able 
to reach the antigen in the absence of the insertion, allowing new inter-molecular interactions. 
This observation is in contrast to the suggestion that most indels share the same hotspots with 
point mutations because indel duplications or deletions involve AGY motifs (de Wildt et al., 
1999), suggesting same localization of beneficial insertion and point substitutions.  
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The engineering implications of complementarity are significant. The fact that insertions lead 
to alternative pathways of evolution of antibody affinity suggests that additional beneficial 
modifications can be identified by using insertions for affinity maturation. Additionally, the 
location of insertions and substitutions in different loops point out absence of interaction 
between those modification, which is in agreement with our finding that their combination 
can have additive effect on affinity. Overall, for affinity maturation purposes libraries with 
insertions could be constructed in parallel with libraries with point substitutions and then 
combine the modifications that improved affinity to take advantage of possible additive 
effects on function or offer alternatives in cases that it is difficult to identify beneficial point 
substitutions.   
 
5.7. Why is the percentage of affinity-enhancing insertions in natural antibodies low?  
The work reported here provides a greater understanding of the principles governing affinity 
maturation in Nature. Beneficial insertions were found only on surface exposed positions on 
the periphery of the binding site area, which is in agreement with the conclusion that affinity-
improving insertions introduce only subtle structural rearrangements on the periphery of the 
interface without affecting the already defined topology of the combining site. Thus, 
insertions and point substitutions impact affinity by similar mechanisms, by introducing only 
subtle structural rearrangements on the periphery of the interface area.  
Based on studies of the percentage of indels in affinity matured antibodies in Nature, affinity-
improving indels were expected to be rare. Thus, the identification of beneficial insertions in 
two different positions of the same antibody was an unexpected result, indicating that the 
antibody fold may be able to accommodate higher percentage of indels compared to that 
observed in natural antibodies. Low occurrence of beneficial insertions in natural antibodies 
could be attributed to the low rate of incorporation of in-frame insertions during the 
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diversification process, sampling of only biased diversity of insertions which occur by 
sequence duplication and the restriction of including the CDR3 regions in the search.  
 
5.8. Outlook   
This is the first time that random and high diversity indels across the entire antibody variable 
region of an antibody were sampled for affinity maturation by in vitro evolution. Other 
researchers have not been able to sample high diversity indels at random positions, either 
because of restrictions in the diversity of indels that can be introduced by their method 
(Bowers et al., 2014) or because they only used rational instead of random approaches 
(Lamminmäki et al., 1999). The methods that I used allowed sampling of random deletions 
and insertions of different lengths. Although sampling high diversity insertions longer than a 
single amino acid was not possible by using the entirely random approach (chapter III), I 
developed an approach that allows the construction of libraries with different lengths of 
insertions, which could be widely applied in future in vitro affinity maturation projects.   
As discussed in the introduction, there are two main approaches that have been widely 
applied for affinity maturation. Parallel or sequential CDR walking mutagenesis (Barbas et 
al., 1994; W. P. Yang et al., 1995) and scanning by epPCR to guide the design of libraries 
targeting the CDRs (Thom et al., 2006). The parallel approach involves randomization of 
different CDRs in different libraries, parallel affinity-based selections and subsequent 
combination of the most beneficial mutations from each CDR in one library. As described in 
this thesis, beneficial insertions and point substitutions can have synergistic effects on 
antibody affinity, suggesting that insertions could be included in parallel CDR walking, as 
affinity maturation using either point substitutions or insertions could be performed 
separately and then combined to take advantage of additive effects on function.  
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Furthermore, an important information gained by this thesis is that insertions and point 
substitutions can have complementary mechanisms of function, leading to localization of 
beneficial insertions in different positions than beneficial point substitutions on the same 
antibody, meaning that insertions offer alternative routes to affinity maturation. For 
engineering purposes, the fact that insertions lead to alternative pathways of evolution of 
antibody affinity suggests that insertions can offer an alternative in cases where the 
identification of beneficial point substitutions has proven difficult. Taken together, including 
insertions in parallel CDR walking approaches could not only lead to identification of even 
higher affinity antibodies by taking advantage of additive effects of insertions and point 
substitutions on function, but can also increase the chances of identifying a beneficial 
modification.  
By insertional-scanning mutagenesis, it is possible to find the positions that could be 
randomized in length in targeted libraries. This approach requires construction of libraries 
with single amino acid insertions either by the transposon-based approach (random 
insertions) or by targeting only the CDRs and the FWR3; for example by construction of a 
library with single amino acid insertions using the method for construction of single-site 
saturated mutagenesis library (Koenig et al., 2017). To take advantage of both point 
substitutions and insertions starting by scanning libraries with either single amino acid 
insertions or single-site saturated point substitutions in parallel to identify the loops that can 
possibly improve affinity could be used as a guide for the construction of insertions and point 
substitution libraries by targeted approaches. The search could even be restricted in the 
CDR3 loops.  
Overall, the approaches for construction of libraries with insertions and deletions that were 
described in this thesis could be applied in future antibody affinity maturation campaigns to 
complement and synergize with the classic point substitutions approaches.  
 149 
6. Materials and Methods  
 
6.1. Continuous In Vitro Evolution of Protein Binding  
6.1.1. Media  
NZY Broth (per Liter): 5g of NaCl, 5 g yeast extract, 10 g NZ amine (casein hydrolysate), 
Add deionized H2O to a final volume of 1 Liter. Adjust the pH to 7.5 with NaOH, Autoclave 
NZY Top Agar (per Liter): Prepare 1 liter of NZY broth, Add 0.7% (w/v) agarose, Autoclave 
2xTY: 10 g/L bacto-yeast extract, 16 g/L bacto-tryptone, 5 g/L NaCl, pH adjusted to 7.0.  
Antibiotic concentrations: 100 μg/ml of Ampicillin and 50 μg/ml of Kanamycin, 12.5 μg/ml 














Table 8. Primers 
 
 
6.1.3. SIP vector construction 
For pUC-N1-N2-MCS, pUC-g3p and pUC-N1-N2-HA vector construction, synthetic gene 
fragments of the pelB-N1-N2-MCS, pelB-MCS-gene III and HA peptide coding sequences 
flanked by appropriate restriction sites for cloning into the pUC19 vector were ordered from 
GenScript. Electrocompetent DH10B cells were used for cloning. Colony PCRs were 
performed using BIOTAQ DNA Polymerase (BIOLINE). The inserted sequences of positive 
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clones were sequenced with appropriate primers. Strains S1030/pUC-g3p and S1030/pUC-
N1-N2-HA were made by transformation of electrocompetent S1030 cells. 
 
6.1.4. Recombinant phage construction 
VCSM13 phage particles were obtained from Stratagene and were used to infect S1030 cells, 
which were then used for VCSM13 RF DNA (replicative form, ds DNA) purification using 
the protocol for low copy plasmid DNA purification of the Thermo Scientific GeneJET 
Plasmid Miniprep Kit. 
For VCSM13-ScFv-CT phage construction, the phage genome sequence lacking the N1-N2 
domains sequence (8 kb fragment) was amplified by PCR with the primers Fw-SfiI-VCSM13 
and Rev-SfiI-VCSM13. These primers allowed the insertion of the restriction enzyme SfiI 
sites for cloning of the scFv fragment using the same sites. The scFv synthetic gene fragment 
was ordered from GenScript and the ScFv coding sequence was amplified by PCR with 
primers that introduced the SfiI sites. A similar approach was followed for cloning of the 
VCSM13-CT phage genome, which lacks the N1-N2 domains sequence. PfuUltra II Fusion 
HS DNA Polymerase was used for amplification of the SfiI-VCSM13-SfiI (8053 bp) and 




After PCR product cleanup from the 0.8% agarose gel, the PCR product was digested with 
DpnI to degrade template DNA followed by SfiI overnight (≈ 14 hours) digestion reaction 
using the Fast Digest enzymes (Thermo Scientific). Then, an overnight 20 μL volume 
ligation reaction was performed using 100 ng vector and 1: 3 molar ratio vector: insert. 25 ng 
of the ligation reaction was used for transformation of NEB Turbo Electrocompetent E. coli 
cells with transformation efficiency 1x1010 cfu/µg for pUC19 DNA. The transformation 
efficiency of the ligated VCSM13-ScFv-CT DNA was low (5x104 cfu/ug, i.e. 2×105-fold 
lower than pUC19). The scFv-CT sequence of VCSM13-scFv DNA isolated from positive 
NEB turbo/VCSM13-scFv clones was obtained by sequencing with primers Fw-VCSM13-
seq and Fw-VCSM13-seq2.   
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6.1.5. pUC-N1-N2-HA fusion protein expression  
A single colony of S1030/pUC-N1-N2-HA strain was picked and grown overnight at 37 °C 
in 5 ml 2TY containing 2 % glucose with AMP. The overnight culture was diluted in 300 mL 
TG1 in 2TY with AMP (1: 900) with 0.09% glucose (1.35 mL 20 % glucose, final glucose 
concentration is ~ 0.12 % glucose) and grown at 37 °C until an OD600 between 1.0 and 1.5 
was reached. 100 mL of 2TY containing AMP (no glucose) and 400 μL IPTG (1 mM final) 
was then added to the culture (glucose concentration drops below the 0.1% glucose) and 
grown overnight at 26 oC with very slow shaking. 
The periplasmic fraction was prepared by spinning the culture (20 min at 4500 rpm). The 
supernatant was discarded and pellet was frozen for 90 min at - 80 °C. The pellet was then 
defrosted (30 min RT) and re-suspended in PBS (25 mL per 400 mL culture) by incubating 1-
2 hours on head-over-head at 4 °C. The periplasmic fraction (supernatant) was obtained by 
centrifugation for 20 min at 4700 rpm (max speed).  
 
6.1.6. Western Blots 
The samples were boiled in denaturing SDS buffer, subjected to SDS-PAGE (NuPAGE  10% 
gel) and electroblotted onto InvitrolonTM PVDF membranes (0.45 μm pore size). The PVDF 
membrane and SDS-PAGE gel was dipped in 100 % methanol before transfer (50 mL 10× 
Transfer Buffer containing 250 mM Tris-HCl, 1917 mM glycine and 100 mL methanol in 
500 mL total volume. The transfer was performed for 1 hour at 10 V. The membrane was 
blocked for 45 min in 5% milk/PBS/0.1% Tween 20 and washed three times with PBS.  
The membrane was incubated with mouse anti-HA antibody, clone HA-7 SIGMA (1: 1160 
dilution in PBS-0.1 % Tween 20) for N1-N2-HA fusion protein detection for 1 hour and 
washed three times with PBS/0.1 % Tween 20. For phage detection, membranes were 
incubated with a 1: 3000 dilution of pIII antibody (Mo Bi Tec) in 3% milk/PBS/0.1 % Tween 
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20. The blot was then incubated with secondary antibody (anti-mouse Antibody-HRP 
Conjugated, ABCAM) (1: 2000 dilution in PBS-3 % milk, 0.01 % Tween 20) and washed 
three times with PBS/0.1 % Tween 20. HRP conjugate was detected using the Amersham 
ECL Prime Western Blotting Detection Reagent.  
 
6.1.7. Phage amplification 
An overnight culture of S1030 was diluted in 2TY containing tetracycline and grown until an 
OD600 of 0.5 was reached (mid-log phase). 2 ml of this culture was infected with VCSM13 
particles (Stratagene) at a multiplicity of infection of 20:1 (phage-to-cell-ratio), by incubating 
at 37 °C for 30 minutes (slow shaking). The culture was centrifuged at 2.200 rpm and re-
suspended in 20 mL 2TY with kanamycin (final concentration 50 μg/mL). Phages were 
amplified by culturing the infected cells at 37 °C for 8 hours. The phage supernatant was 
obtained by centrifuging the culture at maximal speed. Residual cells were killed by heating 
to 65 °C for 15 minutes. The phage concentration in the supernatant was measured by plaque 
assay, infectivity assay and ELISA and stored at - 80°C (1 mL phage supernatant containing 
0.5 ml aqueous glycerol, 60 % w/w). 
 
6.1.8. Plaque assay 
An overnight culture of S1030 was diluted in 2TY containing tetracycline and grown until 
OD600 of 0.5 (mid-log phase). While cells were growing, before reaching the mid-log phase, 
Top Agar was melted in microwave and 3 mL were dispensed into sterile culture tubes (one 
per expected phage dilution) and maintained at 47 °C. LB plates (15 mL medium per plate) 
were pre-warmed at 37 °C. 107–1011-fold dilutions of phage supernatant were prepared. 
Aerosol-resistant pipette tips were used to prevent cross-contamination. When the S1030 
culture reached the mid-log phase (OD = 0.5), 200 μL into microfuge tubes were dispensed, 
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one for each phage dilution. To carry out infection, 10 μL of each phage dilution was added 
to each tube, vortexed quickly, and incubated at room temperature for 1– 5 minutes. Infected 
cells were transferred to culture tubes containing 47 °C Top Agar. After brief vortexing the 
culture was immediately poured onto a pre-warmed LB plate and the plate was gently tilted 
and rotated to spread top agar evenly. The plates were allowed to cool for 5 minutes, and 
incubated overnight at 37 °C. Plaques were counted on plates that have approximately 100 
plaques. Each number was multiplied by the dilution factor for that plate to get phage titer in 
plaque forming units (pfu) per 10 μL.   
 
6.1.9. Infectivity assay 
An overnight culture of S1030 was diluted in 2TY containing tetracycline and grown at 37 
°C with shaking (300 rpm) until OD600 of 0.5 (mid-log phase). Diluted phage supernatants 
were mixed with appropriate volumes of S1030 (OD=0.5) and were slowly shaken (150 rpm) 
at 37 °C for 1 hour. The phage supernatant was serially diluted as described in the Table 9.  
 
Table 9. Phage dilutions 
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After infection the cultures were plate on LB agar plates containing 50 μg/mL kanamycin and 
colonies were grown overnight at 37 °C. The phage titer was calculated based on the dilution 
factor. Colonies were counted on each plate and the titer was calculate using the following 
formula: [No. of colonies] multiplied by [Dilution factor in plate] = cfu/mL 
 
6.1.10. Phage titration ELISA 
Microtiter plate was coated with serial dilutions of phage supernatant in PBS (50 μL per well) 
and incubate overnight at 4 °C. The next day the plate was washed with PBS 0,05 % Tween 
20 and wells were blocked with 300μl PBS with 3% milk for 1 hour at RT (no shacking). 
Anti-M13 [B62-FE2] HRP conjugated antibody (ab50370, Abcam) was added to the wells 
(50 μL) after three times washing with PBS-0.05 %Tween 20. The plate was Incubated 1 
hour at RT (shaking) and washed 5 times with PBS-0.05 % Tween 20. The signal was 
detected by adding 50 μL TMB per well and measure OD at 620 nm. 
 
6.1.11. Phage production assay 
An overnight culture of S1030/VCSM13-CT-ScFv/pUC-N1-N1-HA or S1030/VCSM13 
strain was diluted (1/50) in 2TY containing ampicillin and kanamycin with 2% glucose or 
2TY containing kanamycin with 2% glucose, respectively, and grown at 37 °C with shaking 
(300 rpm) until OD600 of 0.5 (mid-log phase). The culture was then centrifuged at 2.200 rpm 
and re-suspended in 2TY containing ampicillin and kanamycin without glucose, so that the 
OD600 was 0.5. The phage production was done by incubating at 37 °C with shaking (300 
rpm) the culture for 2.5 or 4 hours. The phage supernatant was obtained by centrifuged the 
culture at max speed. Residual cells were killed by heating to 65 °C for 15 minutes.   
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6.1.12. E. coli strain genotypes 
NEB turbo: F' proA+B+ lacIq ∆lacZM15 / fhuA2  ∆(lac-proAB)  glnV galK16 galE15  R(zgb-
210::Tn10)TetS  endA1 thi-1 ∆(hsdS-mcrB)5.  
DH10B strain: F- endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 araD139 
Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ- 
S1030 strain (Carlson, Badran, Guggiana-Nilo, & Liu, 2014): F’proA+B+ Δ(lacIZY) 
zzf<Tn10(TetR) lacIQ1PN25-tetR luxCDE/endA1 recA1 galE15 galK16 nupG rpsL(StrR) 
ΔlacIZYA araD139 Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) proBA<pir116 araE201 


















6.2. Molecular Biology  
6.2.1. Primers  
Table 10: List of primers used in this thesis.   
Name Use Sequence 
 






















Fw-VH99S: VH CDR3 
(N99S) 
GAGATTCCAGCAGCAGCTGGGCCCGCTGG 
Rev-VH99S VH CDR3 
(N99S) 
CCAGCGGGCCCAGCTGCTGCTGGAATCTC 




Rev-VL27I VL CDR1 
(N27I) 
GTTTACTTCCAATGATGTTTCCCCCACAGG 
Fw-VL68W VL FWR3 
(G68W) 
CTGGCTCCAACTCTTGGAACACGGCCACCC 
Rev-VL68W VL FWR3 
(G68W) 
GGGTGGCCGTGTTCCAAGAGTTGGAGCCAG 
Fw-VL68E VL FWR3 
(G68E) 
CTGGCTCCAACTCTGAGAACACGGCCACCC 






L3-no INS NNS  
in VL CDR3 
CCTCCGCCGAATACCACGGGSNNSNNSNNSNNSNN
CCACACCTGACAATAATAGTCGGCC 
L3-1INS 1xNNS insertion 
in VL CDR3 
CCGCCGAATACCACGGGATCSNNSNNSNNSNNSNN
CCACACCTGACAATAATAGTCGGCC 
L3-2INS 2xNNS insertion 
in VL CDR3 
CCGCCGAATACCACGGGATCSNNSNNSNNSNNSNN
SNNCCACACCTGACAATAATAGTCGGCC 
L3-3INS 3xNNS insertion 
in VL CDR3 
CCGCCGAATACCACGGGATCACTSNNSNNSNNSNN
SNNSNNCCACACCTGACAATAATAGTCGGCC 
L3-4INSI 4xNNS insertion 
in VL CDR3 
CCGCCGAATACCACGGGATCACTACCSNNSNNSNN
SNNSNNSNNCCACACCTGACAATAATAGTCGGCC 
L3-5INSI 5xNNS insertion 




FwL3stop Stop template CTATTATTGTCAGGTGTGGGATTAATGA 
AGTGATCCCGTGGTATTCGG 




6.2.2. Construction of BAK1 indel libraries using engineered transposons 
To build BAK1 libraries with random indels using engineered transposons (D. Jones, 2005, 
Emond et al, in preparation), the BAK1 coding sequence was cloned into the vector pIDR9 
while removing the restriction sites that were used in the following digestion steps (MlyI, 
NotI and AcuI). For the series of digestion and ligation steps that followed (section 2.2.1), 
plasmids were treated with Fast Digest restriction enzymes (Thermo Scientific) according to 
the manufacturer’s instructions, digestion products were analysed on agarose gels and 
purified using the Zymo research, DNA Clean & Concentrator TM-5. The transposition 
reactions of pIDR9-BAK1 were performed using the TransDel or TransIns transposon and 
the enzyme MuA Transposase (Finnzymes). The conditions of the reaction were as follows: 
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A 20 μL reaction containing 300 ng pIDR9-BAK1, 50 ng TransDel or TransIns, MuA 
Transposase (Finnzymes), reaction buffer (5x) and nuclease-free water. The transposition 
reaction was incubated for 1 hour at 30 °C followed by heat inactivation at 75 °C for 10 min. 
The cassettes Ins1, Del1, Del2 and Del3 were extracted from pUC57 plasmids. To remove 
the 3’ overhangs 1U DNA Polymerase I Large (Klenow) Fragment (NEB) was used per 1 μg 
DNA. A 20 μL reaction containing 500 ng DNA, 2 μL ligase buffer (10x), 3.5 μL dNTP’s 
(200 uM) and Klenow fragment (0.5 U/μL, diluted in NEB buffer 2) was incubated for 15 
min at 25 °C, stopped by adding 10 mM EDTA (0.4 μL of EDTA, 0.5 M, pH8), incubated 20 
min at 75 °C and purified using a Zymo research column. For 20 μL ligation reactions the T4 
ligase (Fermentas) was used in a 1:3 molar ratio of vector: insert. Ligations reactions were 
concentrated using the Zymo research, DNA Clean & Concentrator TM-5 and then 
transformed into ≈30 μL of E. cloni® 10G Electrocompetent Cells (Lucigen) (> 5 x 109
 
cfu/μg). After electroporation, 300 μL of recovery medium were added and all the cells were 
plated in LB medium containing appropriate antibiotics after 45 min incubation at 37 °C 
(slow shaking). After overnight incubation at 37 °C, cells were scraped and collected by 
centrifugation and plasmid DNA was extracted using a Qiagen plasmid purification kit. The 
transformation efficiency was higher than 2 x 106 colonies in each step.   
 
6.2.3. Subcloning BAK1 indels libraries and quality control  
To subclone the BAK1 indel libraries from pIDR9 to pUC_RD (ribosome display vector; 
Figure 51), NEB restriction enzymes were used according to the manufacturer’s instructions. 
Digestion products were analysed on agarose gels and purified using a Qiagen purification 
kit. 30 μL ligation reactions including vector to insert DNA ratio of 1:3, T4 DNA ligase 
(NEB) and reaction buffer were incubated at RT for 2 hours and concentrated using the Zymo 
Research, DNA Clean & Concentrator TM-5 before electroporation of E. cloni® 10G 
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Electrocompetent Cells (Lucigen) as described above.  The same procedure was followed to 
subclone the BAK1 3nt-Ins library from pUC_RD to pCANTAB6 (phage display vector) 
before screening of the library.  
 
 
Figure 51. pUC_RD vector  
 
6.2.4. Recombination of BAK1 indels libraries by Step PCR 
A protocol for DNA recombination of the BAK1 indel libraries was developed based on the 
SteP method (Staggered Extension Process In-Vitro DNA Recombination) (Zhao, 1998). The 
Phusion DNA polymerase (Thermo Scientific, F-531) was chosen instead of the Taq DNA 
poymerase in order to keep the mutagenesis rate as low as possible. Although different 
extension times were tested, PCR extension time of 1 sec was chosen because it combined 
high recombination rate and good quality PCR product. The 50 μL SteP PCR reaction 
contained a plasmid DNA mix of all the BAK1 indel libraries in pUC_RD, 25 μL of the 2x 
Phusion master mix, 10uM pUC-Fw and 10uM pUC-Rev. The PCR conditions were as 
follows: initial denaturation at 95 °C for 30 sec followed by 29 more cycles of denaturation at 
95 °C for 10 seconds, annealing at 55 °C for 10 seconds and extension at 72 °C for 1 second 
and 5 min extra extension at 72 °C in the end. SteP PCR products were purified and 
concentrated using the DNA Clean & Concentrator TM-5, Zymo Research. This concentrated 
PCR product was used for in vitro transcription for the first round of RD selections. The 
products of the SteP PCR were also cloned into the pUC_RD vector, individual colonies were 
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picked in 2 x 96-well plates and sequenced using the same primers (pUC-For/pUC-Rev) to 
assess the quality of the ribosome display selection input.  
 
6.2.5. Subcloning RD selection outputs into pCANTAB6 for sequencing 
To sequence outputs of the ribosome display selections, each output was cloned into 
pCANTAB6 (phage display vector). Each output was amplified by PCR (with primers T7B/ 
T6te) and the products were purified from agarose gels using a Qiagen purification kit. 20 μL 
ligation reactions including vector to insert ratio of 1:3, T4 DNA ligase (NEB) and reaction 
buffer were incubated at room temperature (RT) for 2 hours, purified and used to transform 
competent TG1 cells. Individual colonies from each output of rounds 1, 2, 3 and 4 were 
picked in 2 x 96-well plates per output containing 2 x TYAG medium (2 x TY with 100 g 
ml-1 ampicillin and 2% glucose) for sequencing, which was performed by the DNA chemistry 
team at Medimmune.  
 
6.2.6. Site-directed mutagenesis of BAK1 variants  
Site-directed mutagenesis of BAK1 scFv gene into the pCANTAB6 vector was performed 
using non-overlapping oligonucleotides that contained the desired mutation during whole 
plasmid PCR. Using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) 
following the according to the manufacturer’s instructions. The primers that were used are 




Figure 52. The alignment presents the amino acid sequences of BAK1 IgG variants. The residues are 
numbered by Kabat numbering system. The CDR residues are highlighted in blue, and introduced 
point substitutions are marked in pink.  
 
6.2.7. Construction of libraries with insertions in the VL CDR3 by Kunkel mutagenesis 
Kunkel mutagenesis method widely used for the introduction of mutations into phagemids, 
like pCANTAB6. Kunkel mutagenesis (Sidhu, 1990) was employed to fully randomise 
blocks of 5 or 6 consecutive amino acid residues per library in the VL CDR3. To generate the 
template for saturation mutagenesis a stop codon was introduced into the BAK1 scFv by site-
directed mutagenesis (as in section 5.1.6) using the primers FwL3stop and RevL3stop. The 
BAK1-L3 stop variant was then subcloned into pCantab6 and transformed an E. coli dut-
/ung- strain called CJ236. Uracil-containing ssDNA (dU-ssDNA) encoding the BAK1-L3 
stop variant was purified from M13 phage. Production of dU-ssDNA template was performed 
by growing CJ236 transformed with stop template DNA into 2 x 5 ml of 2 x TYGAC (2 % 
glucose, 100 µg/ml ampicillin, 10 µg/ml chloramphenicol) at 37 ˚C (300 rpm) until OD600 = 
0.8 to 1 (assuming that OD600 of 1= 5 x 108 cells/ml). Wild-type helper phage was added in 
multiplicity of infection (MOI) = 10 and allowed the infection by incubating at 37 C (no 
shaking) for 10 min. The 1 ml culture was transferred to 30 ml 2 x TYA supplemented with 
50 µg/ml kanamycin (to select M13KO7) and 0.25 µg/ml uridine (to enable synthesis of 
uracil-containing template) which was incubate overnight at 37 C and 300 rpm. The 
supernatant was collected after centrifugation and the phage particles were precipitated by 
adding 1/5 volume of 20% PEG8000/2.5 M NaCl followed by 10 min incubation at room 
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temperature and centrifugation until the white phage pellet was visible. The pellet was 
resuspended in PBS and the dU-ssDNA template was purified using a Qiagen Qiaprep Spin 
M13 kit. Mutagenic oligonucleotides (Table 10) encoding the desired mutations (NNS codon 
insertions) were annealed to the dU-ssDNA template, extended and ligated to form covalently 
closed circular DNA (ccc-DNA). Annealing was carried out by incubating at 90 C for 2 min, 
50 C for 3 min and 20 C for 5 min. The mutagenesis reaction contained 10 mM ATP, 25 
mM dNTPs, 100 mM DTT, 30 Weiss units of T4 DNA ligase (6 U/µl) and 30 units T7 DNA 
polymerase (10 U/µl), which was incubated at 20 ˚C for 3 h. The DNA was purified using a 
Roche DNA purification kit following the manufacturer’s recommendation. Libraries with 
large number of variants (109-1010) were constructed by transforming fresh electrocompetent 
E. coli TG1 cells with the DNA of each reaction.  
 
6.2.8. Preparation of fresh electrocompetent E. coli TG1 cells 
60 mL of TG1 culture was grown overnight in 2 x TY media at 30 ˚C and 300 rpm. The next 
day, flasks containing 400 mL medium were inoculated with overnight culture such that the 
OD600 was ~0.1 and were grown at 30 ˚C and 300 rpm until OD600 ~0.5-0.6. Once optimum 
OD600 was reached, the cells were chilled for 30 min on ice and 300 mL volumes of culture 
were divided in centrifugation pots. Following centrifugation for 15 min at 2 ˚C, the 
supernatant was discarded and the cells were resuspended in 300 mL of ice-cold autoclaved 
Milli-Q water per pot. The same process was repeated once more and finally the pellet was 
resuspended in the remaining liquid and transferred into 50 mL Falcon tubes which were 
filled with cold Milli-Q water. After 10 min of slow speed centrifugation the supernatant was 
discarded and the cells were resuspended in the remaining liquid. 4 x 400 µl of these cells per 
library were used for electroporation. Immediately after electroporation 1 mL of 2 x TYG 
was added to each cuvette and incubated at 37 ˚C and 150 rpm for 1 hour to recover before 
 165 
plating in large 2 x TYAG bioassay plates (one plate per library), which were incubated 
overnight at 30 ˚C. In addition, dilution series of each library were plated in 2 x TYAG plates 
to determine the number of transformed cells, which was used to calculate the size of each 
library by counting the number of colonies after overnight incubation.      
 
6.2.9. Conversion of BAK1 scFvs to IgGs  
To measure the affinities of the variants with insertions in VL FWR3 or VL CDR3 by 
competition ELISA and Biacore, scFv variants were converted to IgG1 format. The BAK1 
VH and VL sequences were subcloned into the heavy chain vector (pEU1.3) and the light 
chain vector (pEU4.4), respectively.  
 
6.3. Selections  
6.3.1. Ribosome Display selections of recombined BAK1 indel libraries  
Isolation of affinity matured antibody fragments (scFv) from the recombined BAK1 indels 
libraries was done by ribosome display (Jozef Hanes et al., 1998). Selections were performed 
in solution using biotinylated human IL-13 to allow capture using streptavidin-coated 
magnetic beads. To isolate fragments with improved affinity over parent a variety of 
biotinylated IL-13 concentrations below the KD were used in each round, but only the 
selection output of the lowest IL-13 concentration which gave a positive outcome was chosen 
to proceed to the next round. Four rounds of high stringency selections were performed and 
the concentrations that were finally used were 100, 20, 20 and 20 pM for rounds 1, 2, 3 and 4, 
respectively.  
In vitro transcription of either concentrated PCR product (section 6.1.4) that was the input of 
the first round of RD selection or amplified selection output between the rounds of selection 
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was done using the Ribomax Large Scale RNA production system (T7) (Promega), by setting 
up 50 μL transcription reaction with the following composition: 20 μL linear DNA template 
(with concentration higher than 50 ng/ μL), 10 μL transcription Buffer (5x), 100 mM rNTP 
mix and 5 μL T7 enzyme mix. Following incubation of the reaction at 37 ˚C for 2 h, 5 µl of 
RQ1 RNAse-free DNAse was added and incubated at 37˚C for a further 15 minutes. The 
mRNA was purified using a ProbeQuant G50 micro column (Amersham Biosciences) 
according to manufacturer’s instructions. The mRNA was quantified by measuring the OD 
A260 of a diluted sample in a spectrophotometer. The mRNA concentrations were determined 
to be 2.5-3 µg/ mL.  
Cell-free translation and stabilisation of scFv-ribosome-mRNA complexes was performed 
using an S30 extract prepared in-house (Medimmune). The 330 l translation reactions 
contained 30 µl mRNA (approximately 6 x 1013 molecules), 38.5 μL potassium glutamate (2 
M), 26.6. μL magnesium acetate (0.1 M), 5 mg/ mL anti-Protein Disulfide Isomerase (PDI, 
Sigma), 140 μL S30 translation system and 77 μL Premix X (prepared in-house). The Premix 
X was contained 250 mM Tris-acetate pH 7.5, 1.75 mM of each amino acid, 10 mM ATP, 2.5 
mM GTP, 5 mM cAMP, 150 mM acetylphosphate, 2.5 mg/ mL E. coli tRNA, 0.1 mg/ mL 
folinic acid and 7.5 % PEG 8000. The translation reaction was stopped by adding 1250 µl 
chilled HB buffer on ice to stabilise scFv-ribosome-mRNA complexes. 50 mL heparin-block 
(HB) buffer was prepared by mixing 5 mL 10x E. coli wash buffer, 625 μL heparin (200 mg/ 
mL) and 45 mL sterile-filtered milliQ cold water.  
Selection and capture of specifically bound scFv-ribosome-mRNA complexes was performed 
by mixing 500 µl of stabilised scFv-ribosome-mRNA complexes with 50 µl of de-
biotinylated sterile milk to each tube and 30 µl biotinylated antigen at the required 
concentration. The selections were incubated at 4 ˚C for 2 hours with gentle end-over-end 
rotation. The complexes were captured by addition 50 µl HB-washed M280 streptavidin-
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coated magnetic beads for each selection. KingFisher mL was used to wash the selections in 
order to remove non-specifically bound complexes. The mRNA was eluted in 220 μL EB20 
containing 50 mM Tris-acetate pH 7.5, 150 mM NaCl, 20 mM EDTA, which was then 
transferred into 400 µl of lysis buffer from the High Pure RNA Isolation kit (Roche) that was 
used to purify the enriched mRNA following the manufacturer’s instructions.    
The mRNA was amplified by RT-PCR. The RT reaction contained 4 μL 5x first strand buffer 
(Invitrogen), 2 μL DTT (100 mM), Reverse (RT) primer, 0.25 μL T8te (100 µM), 0.5 μL 
dNTP mix (25 mM each), 0.5 μL RNasin (40 U/µl) (Promega) and 0.5 μL Superscript II 
Reverse Transcriptase (200 U/µl) (Invitrogen). 7.75 µl of this RT Mastermix was mixed with 
12.25 µl eluted mRNA. The reactions were incubated in a PCR block at 50 ˚C for 30 min. A 
PCR reaction was then carried out to amplify the cDNA by mixing 10 µl cDNA with 90 μL 
of master mix containing 50 μL PCR master mix (2x) (Thermo), 2.5 μL primer SDCAT-BAK1 
(10 µM) and 2.5 μL primer T7te (10 µM) and 5 μL DMSO (Sigma). The thermocycling 
conditions were: denaturation at 95 °C for 30 sec followed by 29 more cycles of denaturation 
at 95 °C for 10 sec, annealing at 62 °C for 30 sec and extension at 72 °C for 1.45 minutes.  
 
6.3.2. Phage Display selections of BAK1 VL CDR3 insertion libraries  
Phage display selections were used to select the variants with improved affinity from the 
BAK1 VL CDR3 insertion libraries. Enrichment of improved variants was achieved by 
equilibrium selections by reducing the concentration of the antigen by 10-fold after each 
selection round  (Hawkins, Russell, & Winter, 1992; Schier et al., 1996; Groves & Nickson, 
2012).  These selections were performed in solution using a biotinylated IL-13, which was 
allowed to reach a binding equilibrium with the library of different phage antibodies. The 
incubation was followed by capturing on streptavidin-coated magnetic beads, washing and 
eluting the phages which were bound to the soluble biotinylated IL-13.  
 168 
In order to carry out phage display selections the bacteriophage particles expressing the scFv 
were produced. Phage particles from the large libraries containing more than 109 variants 
were generated by large-scale (400 mL) growth and helper phage rescue of the scFv library 
followed by concentration and crude purification of the bacteriophage particles using PEG. 
400 mL volume of 2TY media containing 100 µg/ mL ampicillin and 2% glucose were 
inoculated with frozen library glycerol stock, so that at least a 10-fold excess of the 
transformed library size was inoculated and grown at 37 ˚C and 280 rpm to OD600 = 0.5-1.0 
(mid-log phase). Superinfection with helper phage in order to rescue infective phagemid 
particles was done by adding 80 µl of 3x1013 / mL M13KO7trp (multiplicity of infection 
(MOI) = 10). After infection, 1 hour incubation at 37 ˚C (slow shaking) and centrifugation, 
the cell pellet was resuspended in 400 mL of 2 x TY medium with 100 µg/ mL ampicillin and 
50 µg/ mL kanamycin (no glucose). The removal of glucose allows for expression of scFv-
g3p fusion from the phagemid throughout the course of overnight incubation with rapid 
shaking (280 rpm) at 25 ˚C.  
The next day, phage particles were precipitated using polyethylene glycol (PEG). Briefly, this 
was achieved by centrifugation of the cultures and collection of the supernatant. 3/10 volume 
of chilled 20% PEG8000/2.5 M NaCl was added and incubated on ice for 1 hour for phage 
precipitation. The phage pellet was concentrated by spinning, that was repeated to collect all 
the phages, which were resuspended in 10 mL TE pH 8.0. After addition of 3/10 volume of 
chilled 20% PEG8000/ 2.5 M NaCl and 1 hour precipitation on ice each phage pellet was 
centrifugated and resuspended in a small volume 2-5 mL TE pH 8.0. The phage titre was at 
least 1013 cfu/ mL and was used for the first selection round.  
For selection, the phage particles were pre-blocked by adding 50 µl phage aliquot to 450 µl 
of 3% (w/v) skimmed milk powder in PBS (MPBS), which was incubated at room 
temperature for 1 hour. Magnetic streptavidin-coated beads (Dynabeads) were also pre-
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washed with PBS and resuspended in 1 mL of 3% MPBS. The phage library was de-selected 
against streptavidin beads by adding 50 l of the blocked beads to the blocked library 
followed by 1 hour incubation at RT and removal of the beads from the blocked library with 
a magnetic separator. 500 µl aliquots of each phage library were then incubated with the 
required concentration of biotinylated antigen, which was rotated end-over-end on a rotor for 
1 hour. Bound phage particles were captured by adding 50 µl blocked streptavidin magnetic 
beads to each selection and the beads were washed (with PBS-Tween) to remove unbound 
phage by using the Kingfisher 96. Elution of the bound phage was achieved by adding 200 l 
freshly made trypsin solution (10 µg/ mL trypsin in 0.1 M sodium phosphate buffer) and 
incubation for 30 min at 37 ˚C while shaking at 600 rpm. The beads were pelleted with a 
magnetic separator and the supernatant was used to infect 1 mL of mid-log E. coli TG1 cells, 
which were incubated for 1 hour at 37 °C with slow shaking. The cells of each selection 
output were plated onto 2 x TYAG agar bioassay plates.  
 
6.4. Protein Expression, Purification and Biotinylation  
The VH and VL coding sequences were cloned into appropriate vectors which were given to 
the Medimmune expression team who implemented the scFv and IgG expression and 
purification. The protocols that they followed are described below.  
 
6.4.1 Periplasmic Extraction of scFv from E. coli 
The production of periplasmic extracts containing his-tagged scFv from E. coli (TG1 strain) 
was implemented as follows: Initially 96 deep well plates filled with 1000 μL medium/well 
grow-up media (2xTYA, 0.1% glucose and 100 mg/mL ampicillin) were inoculated with 
culture from a freshly grown plate or frozen glycerol plate. These cultures were incubated at 
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37 °C for approximately 5 hours shaking at 250 rpm and the scFv expression was induced by 
adding 1 mM IPTG. After overnight (16 hours) incubation at 30 °C shaking at 250 rpm the 
cells were pelleted by high speed centrifugation at 4 °C for 15 min. The pellet was 
resuspended in 400 l of osmotic shock buffer (MES) containing MOPS (pH 7.4), EDTA and 
sorbitol (final pH 7.4) and incubated at 4 C for 30 minutes to lyse the cells. The periplasmic 
extracts were collected by centrifugation at high speed in chilled centrifuge for 15 min.  
 
6.4.2. His-tagged scFv affinity purification   
His-tagged scFvs cloned into the pCantab6 vector were expressed in an E.coli (TG1 strain). 
Overnight cultures (10 mL) were used to inoculate 400 mL of 2 xTY medium (100 μg/mL 
ampicillin and 0.1% glucose). When the bacteria reached OD600 of 0.6 (30 °C, 300 rpm, ~2.5 
hours) the scFv expression was induced by adding 1 mM IPTG and incubation for 3 hours at 
30 °C. After centrifugation of the cultures (high speed, 10 min at 4 °C) the cell pellet was 
resuspended in 10 mL of osmotic buffer (TES) containing 200 mM Tris-HCl, 0.5 mM EDTA, 
0.5 M sucrose, pH 8.0. Cold 1:5 TES was added (15 mL) and incubated on ice for 30 min. 
Finally, the cell debris were pelleted by centrifugation in a benchtop centrifuge (high speed, 
30 min at 4 °C) and the periplasmic extract was purified on nickel sepharose (GE Healthcare) 
packed columns followed by buffer exchanged to PBS (NAP-10 columns; GE Healthcare).  
 
6.4.3. Transient transfection of mammalian cells for IgG production 
Co-transfection of the heavy chain vector pEU1.3 and lambda light chain vector pEU4.4 into 
HEK EBNA-293 allowed whole IgG to be expressed and purified by protein A affinity 
chromatography (GE Healthcare, Little Chalfont, UK). HEK-EBNA cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% foetal bovine serum, 250 g 
mL-1 geneticin (to select for the EBNA marker gene) and 1% non-essential amino acids. Prior 
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to transfection the medium (20 mL) was replaced with fresh DMEM containing 2% foetal 
bovine serum and 1x penicillin/streptomycin.  
The calcium phosphate transfection method was used to introduce the plasmid DNA into the 
mammalian cells. 100 μL of CaCl2 (2.5 M) were added in a mixture containing 50 μg of each 
plasmid DNA in 100 μL pre-warmed filter sterilised distilled water. The pre-warmed DNA 
mixture was added to 2 x HBS buffer (50 mM Hepes, 280 mM NaCl and 1.5 mM Na2HPO4) 
dropwise whilst mixing on a vortex mixer and incubated for 2-5 min at 37 °C. The HBS/ 
DNA solution was added to HEK-EBNA cells, which were incubated overnight at 37 °C in 
5% CO2 concentration with humidification.  
After overnight incubation the medium was removed and replaced with an appropriate 
volume of fresh CD-CHO medium containing 8 mM glutamine, 1 x penicillin/streptomycin 
supplement, 1 x hypoxanthine/thymidine supplement and 1 x OptiMab supplements A and B 
(25 mL for T150, 60 mL for triple T150 flasks). This was carried out on the first day after 
transfection has taken place while the harvest was taken 8 days post-transfection, filter 
sterilised using 0.22 μm steriflips and stored at 4 °C until purification.   
 
6.5. Binding assays and measurements  
6.5.1. IL-13 biotinylation  
Biotinylation of recombinant human IL-13 (PeproTech) was performed by biotinylating 
surface lysine residues using EZ link NHS-LC-Biotin according to the manufacturer’s 
instructions (Pierce protein research products, Thermo Fisher Scientific) and confirmed by 
MALDIN TOF mass spectrometry (Medimmune), which was carried out by Alan 
Sandercock. Biotinylated IL-13 was stored in -80°C in PBS/0.1% BSA after showing that 
biotinylation did not affect its activity by ELISA, which was done by coating with the same 
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concentration of IL-13 either biotinylated or not, titration of BAK1-IgG1 (human) and 
detection using anti-human IgG-HRP antibody.  
 
6.5.2. Homogenous Time Resolved Fluorescence Assays  
The 3nt-Ins BAK1 library with random single amino acid insertions was tested by an HTRF 
binding assay (Figure 53), which was performed in 384-well shallow well plates 
(Corning/Costar). The assay buffer was composed of 0.1% bovine serum albumen, 0.4 M 
potassium fluoride, 1 x PBS. Each well contained the following reagents diluted in assay 
buffer (final concentration): streptavidin cryptate (CisBio) (1 nM), biotinylated IL-13 (5 nM), 
9-fold dilution of periplasmic fraction (his-tagged scFv), anti-his-XL665 (CISBIO) (20 nM) 
to give a total assay volume of 20 μL/well.  
Screening of the phage display selection outputs of the BAK1 VL CDR3 insertion libraries 
for improved affinity was done using an HTRF competition assay (Figure 53), which was 
performed in shallow 384-well plates (Corning/Costar). Each well contained the following 
reagents diluted in assay buffer: (Eu-labelled) streptavidin cryptate (CisBio) (1 nM), 
biotinylated IL-13 (1.25 nM), 3-fold dilution of periplasmic fraction (his-tagged scFv), 
Dylight 650-labelled BAK1-IgG1 (1 nM) to give a total assay volume of 20 μL/well. For 
further screening for improved affinity, the same assay was used to determine the IC50s of 
purified his-tagged scFv variants by titration of the scFv with 2-fold dilutions, starting from 
100 nM as the highest concentration.  
For both assays the reaction mixture was incubated at RT for 4 hours to reach equilibrium 
binding and then read on a Perkin Elmer Envision plate reader using the following settings: 
100 flashes, delay 70 μs, cycle 2000, Excitation UV2 (TRF) 320 nm, Emission APC 665 
(Bandwidth 7.5nm), Emission Rhodamine 590 (Bandwidth 20 nm), mirror D400/630. The 
HTRF ratio was calculated by (665 nm emission/620 nm emission) x 10,000. Non-specific 
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binding (NSB) was determined by calculation of the HTRF ratio in control wells. Specific 
binding was calculated by (% delta Fluorescence-NSB)/(Total-NSB) x 100. All data was 
analysed in Graphpad Prism.  
 
   A                                                                          B 
             
Figure 53. A) HTRF binding assay FRET signal was generated upon binding of biotinylated IL-13 to 
his-tagged scFv using Eu-labelled streptavidin (donor) and XL665-labbeled anti-his-tag antibody 
(acceptor). B) Using an HTRF competition assay, his-tagged scFv binding to biotinylated IL-13 
competed binding of the Dylight 650-labelled BAK1-IgG (acceptor) resulting in reduced FRET 
signal, which was detected using Eu-labelled streptavidin (donor).  
 
6.5.3. Competition ELISA  
A competition ELISA was carried out to identify improved BAK1 IgG1 variants from the VL 
CDR3 insertion libraries. Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated with 
BAK1-IgG in PBS (10 μg/mL) and incubated overnight at 4 ˚C. The wells were blocked with 
PBS/3% milk for 1 hour at RT and washed with PBS. 50 μL of the mix of a 2-fold serial 
dilution of the BAK1-IgG (30 μL, starting from 10 μg/mL, final 5 μg/mL) with IL-13-bio (30 
μL, 0.2 μg/mL, final 0.1 μg/mL) in PBS-3% milk was incubated at RT (shaking) for 1 hour. 
After washing with PBS/0.01% Tween binding was detected using a streptavidin conjugated 
to HRP antibody. Colorimetric detection was done by the addition of 50 μL of the substrate, 
3,3′,5,5′-Tetramethylbenzidine (Sigma) and the reaction was stopped with 50 μL 0.5 M 
H2SO4.  
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6.5.4. Surface Plasmon Resonance affinity measurements  
KD measurements of the IgG variants were performed using the Biacore T200 (Cambridge 
University, Biochemistry Department). Biosensor affinity measurements were performed 
using protein G′-mediated capture immobilisation of the human antibodies by flowing the 
recombinant human IL-13 (PeproTech) (analyte). A sensor surface pre-immobilized with a 
recombinant Protein G variant (Sensor Chip Protein G, GE Helthcare) was used for binding 
of the human IgG1 variants. The buffer (HBS-EP+) contained 0.01 M HEPES pH 7.4, 0.15 
M NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20. IgG analysis was performed by first 
capturing ~100 resonance units (RUs) of the antibody on the protein G sensor chip (60 s 
capture at 5 μl/min) and running a 2-fold serial dilution, starting from 6.25 nM IL-13 as 
analyte at 50 μL/min flow rate with an association time of 5 min. Depending on the strength 
of the interaction, dissociation was followed for 300 -1800 sec. Regeneration of protein G′ 
surfaces was performed with two consecutive 20 sec injections of 6 M guanidinium 
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Figure 54. Sensorgram of the A) BAK1 B) INS4.4 and C) INS5.3 IgG1 variants. The data were fitted 




6.5.5. Thermal stability measurements   
Thermal stability measurements of the BAK1 IgG variants were performed to measure 
unfolding by monitoring unfolding using SYPRO Orange fluorescence. Purified IgGs were 
diluted to 5 μM in a Tris buffer (TrisNHCl 50 nM and NaCl 150 nM). SYPRO Orange dye 
(Invitrogen) was used at a final concentration of 20x. Melting curves were recorded over a 
temperature range of 25 °C to 99 °C in duplicate 20 μL reaction volumes using a real-time 
PCR machine (Rotor-Gene 6000; Corbett Research) with filters to excite at 460 nm and 
measure emission at 510 nm as the temperature continually increased (ramp rate of 0.5 
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